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“Success is stumbling from failure to failure with no loss of enthusiasm.”  
Winston S. Churchill 
  
Abstract 
Pseudomonas aeruginosa is the cause of nosocomial infections and recurrent pneumonia in 
cystic fibrosis patients. Antibiotic treatment becomes increasingly difficult due to the spreading 
of multi-drug resistant strains and its ability to grow in a biofilm. The virulence of this pathogen is 
mainly controlled by quorum sensing (QS) systems. This process enables bacteria to coordinate 
the expression of virulence factors and biofilm formation as a function of cell density. For this 
purpose, P. aeruginosa utilize among others the pqs (Pseudomonas Quinolone Signal) system. 
In this study anti-virulence agents were developed interfering with the pqs system. During a 
fragment-based drug discovery campaign antagonists of the Pseudomonas Quinolone Signal 
Receptor (PqsR) were synthesized. Based on hits identified in a surface plasmon resonance 
(SPR) screening, novel lead structures were generated. This development process involved 
selective synthetic modifications of the hit structures and structure-based design methods. 
Fragments were successfully merged with moieties of an alternative compound class. The 
optimized structures displayed potent reduction of virulence factors and signaling molecules in 
P. aeruginosa. 
During another fragment screening the first synthetic PqsE ligands were identified. The binding 
mode of these fragments was elucidated. Furthermore, it was shown that the inhibition of the 
enzymatic activity did not translate into an effect on its virulence regulatory role. 
 
 
  
Zusammenfassung 
Pseudomonas aeruginsa ist ein Erreger nosokomialer Infektionen sowie von Pneumonien bei 
Patienten mit zystischer Fibrose. Die Antibiotikatherapie wird durch das vermehrte Auftreten 
von multiresistenten Stämmen und die Ausbildung von Biofilmen erschwert. Die Virulenz des 
Erregers wird hauptsächlich durch Quorum Sensing reguliert. Dies ermöglicht es dem 
Bakterium die Bildung von Virulenzfaktoren und Biofilmen in Abhängigkeit von der Zelldichte zu 
koordinieren. P. aeruginosa nutzt hierfür unter anderem das pqs (Pseudomonas Quinolone 
Signal) System. 
In dieser Arbeit wurden Substanzen entwickelt, die in dieses System eingreifen. Zunächst 
wurden in einem Fragment-basiertem Ansatz PqsR Antagonisten synthetisiert. Ausgehend von 
Fragmenten, die einem Surface Plasmon Resonance (SPR) Screening gefunden wurden, 
konnten neue Leitstrukturen generiert werden. Dies gelang durch gezielte synthetische 
Modifikation der Ausgangsverbindungen und dem Einsatz Struktur-basierter Methoden. 
Weiterhin konnten Fragmente mit Motiven aus einer anderen Strukturklasse erfolgreich 
kombiniert werden. Die optimierten Strukturen zeigten eine potente Absenkung der Virulenz und 
der Produktion von Signalmolekülen in P. aeruginosa. 
In einem weiteren Fragment Screening wurden die ersten synthetischen PqsE Liganden 
identifiziert und ihr Bindungsmodus aufgeklärt. Weiterhin konnte gezeigt werden, dass eine 
Inhibition der enzymatischen Funktion keinen Einfluss auf die Virulenz Regulation durch PqsE 
hat. 
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1 Introduction 
1.1 Rational Drug Design 
In the beginning of pharmaceutical research, the development of therapeutic drugs was mainly 
characterized by serendipity or the isolation of the active principles from biological samples and 
their subsequent chemical modification.(Drews, 2000; Klebe, 2009) The outcomes of these 
efforts still represent the groundwork of our present pharmaceutical portfolio. An impressive 
example of such an approach is the discovery of acetyl salicylic acid 1897 by the German 
chemist Felix Hoffmann.(Dreser, 1899) Another milestone of this era is the isolation of the 
antibiotic agent penicillin 1929 by Alexander Fleming.(Fleming, 1929) Paul Ehrlich’s visionary 
concept of ‘the magic bullet’ laid the foundation for modern rational drug discovery 
approaches.(Strebhardt and Ullrich, 2008) He proclaimed that ‘chemoreceptors’ can be 
selectively targeted by chemically optimized therapeutic agents.(Ehrlich, 1909) From 1880 to 
the 1980, lead molecules were mainly developed without knowing the exact molecular mode of 
action mainly based on the ‘trial and error’ methodology.(Klebe, 2009) Over the last 30 years, 
after the rise of molecular biology, it was possible to gain novel insights into biochemical and 
pathophysiological processes on a molecular level.(Henderson et al., 1999) This provided 
researchers with the ability to identify suitable targets for the subsequent development of highly 
specific therapeutic agents.(Hopkins and Groom, 2002) Moreover, these new genetic 
techniques enabled cloning and expression of target proteins as well as the development of 
tailored in vitro assays to assess the potency of drug candidates. In course of this genetic 
revolution new disciplines joined the field. The implementation of computational methods, 
automatization and robotics as well as modern biophysical techniques to drug discovery 
approaches enabled to advance and to rationalize the development of novel lead 
compounds.(Henderson et al., 1999) These changes transformed drug discovery into a 
multidisciplinary endeavor.(Drews, 2000)  
1.2 Fragment-based Drug Discovery  
In 1894, Emil Fischer recognized that different glycosides were hydrolyzed by particular 
enzymes while others were not affected. From these observations he drew a pioneering 
conclusion: substrate and enzyme fit together like lock and key.(Fischer, 1894) For the first 
time, it was noticed that the complementary shape of a small molecule (substrate) and its 
molecular target (enzyme) leads to the formation of a ligand-receptor complex. Fischer’s theory 
was extended by taking into account protein flexibility; the induced-fit model describes the 
complex formation as dynamic process where a small molecule induces a conformational 
change in the protein structure.(Koshland, 1958) These concepts have a sustained influence on 
modern drug discovery. 
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The discovery of a suitable ligand for a pharmaceutical target protein is a fundamental step in 
every drug development program. These ligands are also called hits or actives and generate a 
response above a defined threshold in a screening assay.(Proudfoot et al., 2011) A compound 
or compound class which met more predefined criteria such as target associated cellular 
activity, selectivity and metabolic stability is called a lead.(Proudfoot et al., 2011) Hit or lead 
molecules can originate from different strategies. Until nowadays, natural products have been a 
valuable source for biological active molecules, especially in the field of anti-infectives and 
anticancer therapeutics.(Harvey, 2008) In ligand-based approaches, the endogenous ligand of a 
given drug target has been used as framework for the design of active lead molecules.(Kubas 
and Stark, 2007) Additionally, known drugs and inhibitors were used as role models for the 
development of lead molecules in so called me-too approaches.(Wermuth, 2006) During the last 
decades large compound libraries were established in pharmaceutical companies and 
academic research institutes. Modern screening technologies allow screening for active 
molecules in a high-throughput format (HTS, high throughput screening) accounting for 10,000 
to 100,000 compounds per day.(Inglese et al., 2007) HTS-derived lead compounds tend to have 
a higher molecular weight and lipophilicity than those discovered by other techniques.(Lipinski 
et al., 1997) These poor physicochemical properties are associated with insufficient 
pharmacokinetic properties (Lipinski et al., 1997; Leeson and Springthorpe, 2007) and 
increased risk for off-target toxicity issues (Price et al., 2009), overall leading to higher attrition 
rates during the drug development process.(Leeson and Springthorpe, 2007) Hence, Lipinski 
established ‘the rule of five’ as guideline for the successful development of orally bioavailable 
drugs.(Lipinski et al., 1997) Notably, natural products like antibiotics and cardiac glycosides 
form exceptions from these rules.(Lipinski et al., 1997) 
Besides these more traditional approaches, fragment-based drug discovery (FBDD) evolved as 
a valuable alternative.(Murray and Rees, 2009) During such an approach significantly smaller 
libraries usually containing 500 to 2000 low molecular weight compounds were mostly screened 
by biophysical methods. Most of the fragment libraries are ‘rule of three’-compliant which 
demands the following criteria: a molecular weight < 300 Da, only three or less H-bond donators 
and acceptors as well as clogP ≤ 3. Additionally the number of rotatable bonds should be ≤ 3 
and the polar surface area (PSA) ≤ 60.(Congreve et al., 2003) These guidelines emphasize the 
need for sufficient physicochemical properties from early beginning in FBDD campaign. Hits 
identified by a fragment screening usually show low affinities (ranging from µM to mM) but in 
relation to their small molecular size, they form high quality interactions with their target 
protein.(Murray and Verdonk, 2002) This can also be embodied in the ligand efficiency (LE) of a 
particular hit compound.(Hopkins et al., 2004) This metric allows comparison between ligands of 
different sizes and shapes. LE refers to the average contribution of a single heavy atom (N) to 
the Gibbs free energy (∆G) upon compound binding (LE = ∆G/N). It has been reported that the 
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hit rates observed in fragment screenings are higher compared to a conventional HTS 
campaign.(Schuffenhauer et al., 2005) This observation is explained by simple theoretical 
ligand-receptor model which shows that less complex structures (fragments) are more likely to 
match the molecular requirements for binding to a receptor. The probability of a mismatch rises 
drastically with increasing complexity of the ligand.(Hann et al., 2001) The fragment-sized 
chemical space (< 12 heavy atoms) is calculated to consist of 145 million drug-like structures, 
whereas the Lipinski compliant lead-sized space (<25 heavy atoms) contains 1025 
structures.(Fink et al., 2005) Therefore, a typical fragment-library (about 1000 entities) can 
cover the relevant chemical space more efficiently than a large HTS collection.(Fink et al., 2005; 
Leach et al., 2006) 
A typical FBDD approach usually starts with a biophysical screening technique which can detect 
low affinity protein-ligand interactions and enables a sufficient throughput. For primary 
screening surface plasmon resonance (SPR) biosensors, thermal shift assays (TSA) and 
biomolecular nuclear magnetic resonance (NMR) methods are most widely used. Several 
methods are described in more detail below. The identified primary actives are further validated 
by another orthogonal technique to eliminate false-positives and screening artifacts. The hit 
validation phase ideally includes the elucidation of compound binding mode using x-ray 
crystallography (Figure 1) or protein NMR methods to facilitate the synthetic optimization.(Ciulli 
and Abell, 2007)  
 
Figure 1: Structural biology workflow: proteincrystals, diffraction pattern, electron density map, 
protein model (from left to right; with friendly permission by Florian Witzgall) 
The optimization of a low affinity fragment hit into a highly active lead molecule is a challenging 
process. The determination of a protein-ligand complex structure enables the implementation of 
structure-based design methods into the drug discovery process leading to tremendously 
increased success rates.(Hajduk and Greer, 2007) During the optimization process potency is 
gained by enlargement of the initial hit compound. Different strategies were applied depending 
on the discovered hit compounds (Figure 2). If the screening affords two fragments which bind 
non-competitively into two adjacent regions of a binding pocket, the design of a suitable linker 
which connects both compounds was successfully employed to generate highly active leads  
(Fragment-linking; Figure 2A).(Hajduk et al., 1997) In most of the FBDD approaches, one 
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validated hit is nominated as starting point for fragment-growing (Figure 2B). Thereby, the 
fragment is enlarged iteratively by the use of gathered structural information and new areas 
within the binding pocket are occupied to enhance the potency (Fragment-growing; Figure 
2B).(Shipe et al., 2015) In case the hit compounds occupy overlapping regions within the 
protein pocket, features of both compounds can be merged to advance compound development 
(Fragment-merging; Figure 2C).(Hudson et al., 2012) All these strategies are interconnected 
and can be combined depending on the situation and the specific requirements of a project.  
 
Figure 2: Schematic depiction of different fragment optimization strategies A) fragment-linking 
B) fragment-growing C) fragment-merging (adapted and modified Murray and Rees, 2009) 
FBDD is the latest technology that was added to the arsenal of medicinal chemists. In 2011, the 
first fragment-derived drug got approval by the FDA.(Bollag et al., 2012) A recent analysis of 
clinical candidates proved that fragment-derived molecules show superior physicochemical 
properties.(Keserü and Makara, 2009)  
1.3 Biophysical Methods in Fragment-based Approaches 
A fragment screening requires highly sensitive techniques to identify the expected weak 
interactions to a particular target protein. Usually, a combination of different biophysical 
methods is applied to detect and characterize fragment-protein interactions.(Holdgate et al., 
2010; Silvestre et al., 2013) Surface plasmon resonance (SPR) screening, thermal shift assays 
(TSA, also known as differential scanning fluorimetry DSF) and isothermal titration calorimetry 
(ITC) have been mostly applied in the course of this thesis and will be outlined in more detail 
below. Notably, there are some other well established methods like biomolecular nuclear 
magnetic resonance (NMR) and mass spectroscopy (MS) available.(Holdgate et al., 2010) 
1.3.1 Surface Plasmon Resonance  
An SPR optical biosensor allows monitoring protein-ligand interactions in real time and 
subsequent evaluation of binding affinities and kinetics. In a usual setup, the target protein, also 
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called ‘receptor’, is attached to a gold surface and the analyte, e.g. a small molecule, flows in 
solution above the surface. In case of a complex formation between ligand and the immobilized 
protein, the refractive index of the medium close to gold surface is changed. This change is 
detected by use of polarized light, which is totally reflected at the interface of an optical prism 
and a gold surface (Figure 1A). Thereby, a surface plasmon wave (SPW) is generated at the 
outer boundary of the gold layer (biosensor surface). When the parameters of the incident light 
(wavelength, angle) and the propagation constants of the SPW fit together, resonance occurs 
leading to attenuation of total reflection at these specific parameters of the light beam. The 
propagation constants of the SPW are highly sensitive to the refractory index of the surrounding 
medium. Hence, a change in this medium can be monitored by tuning the angle or wavelength 
(depending on the instrument) of the incident light until resonance and attenuation of total 
reflection are achieved again. Therefore, a change in the refractory index, for example due to an 
interaction of a small molecule with a surface-attached protein directly correlates with the 
change in one of these characteristics which can be measured over time. (Homola, 2003; 
Cooper and Mayr, 2011)  
A typical SPR experiment is outlined in Figure 1B. At time points before 0 buffer flows over the 
sensor surface and a baseline signal is monitored. At time point 0 to 60s, a small molecule is 
injected and interacts with the protein leading at first to an increasing response in the 
association phase (0 to 20s) and then to a plateau in the steady state phase (20 to 60s). After 
60s buffer flows over the sensor surface and the molecule dissociates from the immobilized 
protein. (Cooper, 2002)  
 
Equation 1: Simple 1:1 binding model with analyte A and immobilized protein B forming a 
complex AB. This process can be described by the association rate constant kass and 
dissociation rate constant kdiss 
These processes can be described as a simple bimolecular interaction as illustrated in 
Equation 1. Mathematical analyses of the association and dissociation phase allow 
determination of the association rate constant (kass) and the dissociation rate constant (kdiss), 
respectively, which in turn enable to estimate the dissociation constant KD  of the biomolecular 
complex (Equation 2). (Cooper, 2002; Mol and Fischer, 2008)  
    
 
  
 
     
    
 
Equation 2: Estimation of the dissociation constant KD from association rate constant kass and 
dissociation rate constant kdiss 
The amount of complex AB is proportional to the measured SPR response. Hence, the affinity 
can also be determined by plotting the measured response under steady-state conditions 
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against the compound concentration, respectively, and performing a non-linear regression 
analysis (Figure 3C). (Mol and Fischer, 2008; Cooper and Mayr, 2011) 
Due to the low amount of protein and the high throughput of SPR biosensors, this technique is 
widely applied in various phases of a drug discovery process.(Cooper, 2002) 
 
Figure 3: SPR binding experiment. A) Schematic representation of an SPR biosensor setup B) 
Overlay of SPR sensorgrams showing the particular phases of binding events as indicated and 
schematically depicted above. C) Derived dose-response plot for affinity estimation; SPR 
measured response at steady-state against the compound concentration, respectively. (adapted 
and modified from Copper 2002 and Homola 2003) 
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1.3.2 Thermal Shift Assay 
Thermal shift assays (TSA), also known as differential scanning fluorometry (DSF), is a 
technique which allows measuring the effect of a ligand on the thermal stability of a protein 
target. A protein is incubated with a putative ligand in the presence of an environment-sensitive 
fluorescent dye while applying a temperature ramp. For most proteins, the concentration of 
unfolded protein increases with rising temperatures. Hydrophobic regions of the protein 
structure are exposed to the surface during unfolding; the used dye displays an increase of 
fluorescence signal in such hydrophobic environments whereas its fluorescence is quenched in 
the polar aqueous buffer. Hence, the fluorescence signal correlates with the amount of unfolded 
protein. At the melting point, the concentrations of native and unfolded protein are equal. The 
fluorescence intensity is plotted over the applied temperature range and the inflection point of 
the resulting sigmoid curve represents the melting point (Tm) of the protein. (Niesen et al., 2007) 
Ligands binding reversibly to the native state of a protein usually enhance the melting point 
compared to a ligand free control. This shift in the melting temperature (ΔTm = Tm(ligand)-Tm(control)) 
is proportional to the ligand concentration and affinity.(Matulis et al., 2005) Compounds which 
decrease the melting temperature are assumed to bind preferably to the unfolded 
protein.(Cimmperman et al., 2008)  
Compounds stabilizing the target protein are described to gain access for protein structure 
determination (Vedadi et al., 2006) what facilitates the application of structure-based methods in 
a follow-up drug discovery program. TSAs are applicable for a broad range of different proteins, 
require low amounts of protein and can be performed in high throughput format (Pantoliano et 
al., 2001; Lo et al., 2004) Hence, this technique is widely used as primary screening tool.(Ciulli 
and Abell, 2007) 
1.3.3 Isothermal Titration Calorimetry 
Isothermal titration calorimetry (ITC) provides detailed thermodynamic insights into the 
formation of macromolecular complexes. A typical setup for an ITC experiment is shown in 
Figure 2A. A binding partner (normally a small molecule) is added via successive injections into 
the sample cell containing the target protein. ITC measures the release (exothermic reaction) or 
the absorption (endothermic reaction) of heat associated with a biomolecular interaction. The 
rate of heat transfer to regain a thermal equilibrium between the sample cell and reference cell 
(containing water or buffer) is detected over time (Figure 2B).The association constant (KA  or 
ΔG), the enthalpic (ΔH) contribution and the stoichiometry N of the interaction can be estimated 
by fitting the integrated heats to an appropriate binding model as shown in Figure 2C. The 
entropic contribution (ΔS) is calculated from the Gibbs-Helmholtz equation.(Freyer and Lewis, 
2008) 
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Figure 4: ITC experiment A) Schematic representation of an ITC experiment B) ITC raw data; 
differential heat for successive injections of a ligand to a binding partner C) Integrated heat of 
every injection against the molar ratio of the reaction. (adapted and modified from Malvern 
Instruments Ltd., 2015) 
ITC is a powerful tool that allows differentiating between ΔH and ΔS as the main driving forces 
of a binding event. The enthalpic contribution (ΔH) is regarded as the sum of non-covalent 
interaction which were broken and formed upon formation of a protein-ligand complex. In detail, 
a ligand in solution is surrounded by a hydrate-shell. During the switch from the free to the 
bound state, the interactions between ligand and water molecules are detached. Subsequently, 
new interactions between protein and ligand are formed. Hence, for a beneficial enthalpic 
contribution these protein-ligand interactions have to overcompensate the energy spent for 
desolvation. Accordingly, polar moieties not forming beneficial interactions with the protein 
result in an enthalpic penalty.(Freire, 2004; Ladbury et al., 2010)  
The entropic term consists of the favorable entropy associated with water that is displaced from 
the protein binding pocket upon ligand binding and the entropic penalty associated with the loss 
of conformational and translational freedom in the bound state.(Freire, 2004)  
Given, that it is much easier to increase the affinity of hit compounds by the addition of space-
filling hydrophobic moieties than by the introduction of polar groups forming directed interactions 
compounds tend to become more lipophilic during lead optimization. Therefore, Ladbury 
introduced the enthalpic efficiency (EE) metric which normalizes ΔH for the number of non-
hydrogen atoms (N; EE = ΔH/N). This metric allows to rank hit compounds according to their 
strength of non-covalent interactions and it provides an alternative guidepost during lead 
optimization.(Ladbury et al., 2010) 
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ITC is valuable tool during the drug discovery process facilitating the investigastion of multiple 
characteristics of a binding event in a single experiment. Despite the huge amount of protein 
and time consuming measurements, ITC is considered as the ‘gold standard’ for the validation 
and characterization of identified hit compounds. (Ciulli and Abell, 2007) 
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1.4 Targeting the Virulence of Pseudomonas aeruginosa  
1.4.1 The Opportunistic Pathogen Pseudomonas aeruginosa 
Pseudomonas aeruginosa is a ubiquitous Gram-negative opportunistic pathogen. It is highly 
adaptable to different environmental conditions and able to infect a broad spectrum of host 
organisms ranging from plants, nematodes to humans (Silby et al., 2011). Most human 
infections are associated with an impaired immune response for example found in HIV 
(Franzetti et al., 1992) or are acquired in a hospital setting (Gaynes and Edwards, 2005). P. 
aeruginosa is able to grow on almost all human tissues thereby causing severe acute and 
chronic infections. Hence, the pathogen can be found prevalently in all kinds of nosocomial 
infection sites for example urinary tract (16%), surgical wounds (9%) and pneumonia (18%) 
(Gaynes and Edwards, 2005). Moreover, P. aeruginosa represents a serious threat for burned 
patients (Pruitt and McManus, 1984). 
This opportunistic pathogen is the major cause of death for patients suffering from cystic fibrosis 
(CF).(Emerson et al., 2002) CF is caused by various genetic disorders leading to malfunction of 
the CFTR chloride channel expressed in the lung epithelium.(Riordan et al., 1989; Dean et al., 
1990) The microenvironment within CF lungs enables P. aeruginosa to establish chronic 
infections. Several hypotheses are discussing the mechanism promoting bacterial colonization 
of CF lungs: reduced mucocilary clearance due to viscous airway surface liquid or impaired 
function of antibacterial peptides due to high salt concentrations in the liquid.(Davies, 2002) 
The high genetic mutability of P. aeruginosa (Smith et al., 2006) as well as its ability to regulate 
gene expression in response to changing environmental conditions (Bragonzi et al., 2005) allow 
for rapid phenotypic adaption. These processes provide the bacterium with the ability to switch 
from a planctonic to a sessile biofilm lifestyle. Biofilms are bacterial communities embedded in 
hydrated extracellular matrix attached to a surface (Costerton et al., 1999). The composition of 
the matrix is highly variable depending on the present nutrients and conditions. Major structural 
components are polysaccharides, extracellular DNA (eDNA) and proteins.(Sutherland, 2001) 
Biofilm development is described as a multi-stage process: initially, free floating bacteria adhere 
to an inert or living surface; these bacteria proliferate and form microcolonies; from these 
colonies matured biofilms emerge.(Costerton et al., 1999) Chronic infections like pneumonia in 
the CF airways are associated with P. aeruginosa growing in a sessile biofilm mode.(Lam et al., 
1980; Singh et al., 2000) This lifestyle leads to increased tolerance against host defense 
mechanisms and intensive antibiotic treatment.(Stewart and William Costerton, 2001) The 
biofilm forms a diffusion barrier slowing down the penetration of xenobiotics (Gordon et al., 
1988) and antimicrobial peptides (Mulcahy et al., 2008) into lower compartments by capturing 
positively charged molecules on negatively charged matrix components or by enzymatic 
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degradation (Dibdin et al., 1996) of therapeutic agents. Furthermore, within a biofilm different 
microenviroments can be found. In such areas where nutrients and oxygen are limited, bacterial 
cells show low metabolic activity and slow growth rates leading to low antibiotic 
susceptibility.(Walters et al., 2003) Another reason for relapsing P. aeruginosa infections is the 
occurrence of persister cells. This small subpopulation of dormant cells possesses high 
tolerance to antibiotics and represents the basis for infection recurrence.(Lewis, 2010) 
Another characteristic of P. aeruginosa is the expression and secretion of various virulence 
factors during the course of an infection.(Lyczak et al., 2000) Pili and flagella promote adhesion 
to the initial infection site as well as motility for the dissemination of the infection.(Sato et al., 
1988) The adherence process is further supported by lectin A and B which bind to specific 
carbohydrates on the surface of host cells.(Chemani et al., 2009) The production of bacterial 
surfactants, especially rhamnolipids (RhlAB), increases the permeability of host epithelia 
thereby facilitating bacterial invasion.(Zulianello et al., 2006) Furthermore, the secretions of 
different cytotoxic extracellular products like, hydrogen cyanid (HCN) and the redoxactive blue 
pigment pyocyanin induce damage to host cells and impair the growth of competing 
pathogens.(Lau et al., 2004; Anderson et al., 2010) Additionally, the bacterium secretes various 
enzymes like elastase (LasB) degrading host proteins (Bejarano et al., 1989), phospholipases 
damaging cell membranes (Ostroff et al., 1990) and exotoxin A (Foley et al., 1995) impairing 
protein biosynthesis in eukaryotic cells. Overall, all these virulence determinates contribute to 
the establishment and maintenance of the infection process. 
The release of virulence factors as well as the establishment and maturation of a biofilm are 
processes which would remain ineffective if they were carried out by single organisms. Hence, 
these activities need to be coordinated on a population-wide scale. Therefore, the regulation of 
such behaviors mostly involves bacterial cell-to-cell communication systems which are 
described in the following section. (Waters and Bassler, 2005)  
1.4.2 The Quorum Sensing Networks of Pseudomonas aeruginosa 
During the last decades our view on bacterial lifestyle changed drastically. Bacteria were 
previously regarded as unicellular planktonic organisms; nowadays it becomes more and more 
evident that bacterial colonies build organized communities. The synchronization of phenotypic 
actions on a colony-wide scale relies on the release and detection of small signaling molecules 
also known as autoinducers. The concentrations of these molecules increase as a function of 
cell density allowing the bacterium to sense its environment for the neighboring cells. If a critical 
concentration is reached gene expression is altered collectively.(Waters and Bassler, 2005) 
This bacterial cell-to-cell communication is called quorum sensing (QS) and was first discovered 
in the marine bacterium Vibrio fischeri.(Nealson and Hastings, 1979) In this bacterium the QS 
LuxR-LuxI regulatory circuitry controls characteristic bioluminescence and provides a prime 
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example for QS systems in other Gram-negative bacteria. In detail, the synthase LuxI generates 
an N-acyl-homoserine lactone (AHL) derivative as signaling molecule (Figure 5).(Eberhard et 
al., 1981; Engebrecht and Silverman, 1984) While the population density increases the signal 
accumulates in the medium.(Kaplan and Greenberg, 1985) When a certain threshold is 
reached, the molecule binds to transcriptional regulator LuxR,(Adar and Ulitzur, 1993) which in 
turn activates the expression of an operon encoding for luciferase enzymes responsible for 
bioluminescence and the AHL synthase LuxI.(Engebrecht and Silverman, 1984) The enhanced 
expression of the enzyme LuxI leads to increased biosynthesis of the autoinducer generating to 
a positive feedback loop. 
 
Figure 5: Quorum sensing autoinducer molecules found in Vibrio fischeri (upper part) and 
P. aeruginosa (lower part) 
P. aeruginosa possesses four distinct QS systems (Figure 5 and 6).(Lee and Zhang, 2015) The 
las (Gambello and Iglewski, 1991; Passador et al., 1993) and the rhl (Ochsner et al., 1994; 
Ochsner and Reiser, 1995) systems use AHLs as autoinducers and belong to the LuxR-LuxI 
regulator family. The LuxI homologues LasI and RhlI catalyze the synthesis of 3-oxo-C12-HSL 
(Pearson et al., 1994) and C4-HSL (Pearson et al., 1995), respectively (Figure 5). 3-oxo-C12-
HSL activates the corresponding regulator LasR while C4-HSL acts as an agonist on RhlR. 
Transcriptomic analysis revealed that over 6% of the P. aeruginosa genome are regulated via 
these QS systems including genes required for basic metabolic pathways as well as for the 
expression for virulence determinates.(Schuster and Greenberg, 2006) Examples for key 
virulence factors controlled by the las and the rhl system are shown in Figure 6. These include 
the LasA protease, LasB elastase, ArpA alkaline protease, rhamnolipids, pyocyanin and 
hydrogen cyanid. (Lee and Zhang, 2015)  
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Figure 6: The interplay of the four quorum sensing networks and their contribution to 
P. aeruginosa virulence factor expression. (adapted and modified from Lee and Zhang, 2015)  
In contrast to the widespread use of AHL derivatives by Gram-negative bacteria, P. aeruginosa 
uses two structurally unrelated scaffolds for QS cell-to-cell communication (Figure 5). The third 
QS network is called the Pseudomonas Quinolone Signal short pqs (Pesci et al., 1999) and 
employs the 4-hydroxy-2-akylquinolones (HAQs) as messenger molecules. The HAQ signaling 
was found only in Pseudomnas and Burkholderia strains.(Diggle et al., 2006a) Over 50 HAQ 
congeners have been identified (Lepine et al., 2004) among them 2-heptyl-3-hydroxy-4-
quinolone (PQS) and its precursor 2-heptyl-4-quinolone (HHQ) are the most prominent 
autoinducer molecules. HAQs were originally isolated from P. aeruginosa cultures and their 
structures were elucidated due to the antibacterial properties of some derivatives. (Hays et al., 
1945; Cornforth and James, 1956) In 1999, Pesci and coworkers recognized the role of PQS as 
an intercellular signaling molecule.(Pesci et al., 1999)  
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Figure 7: The pqs system and the biosynthesis of HHQ and PQS. (Drees and Fetzner, 2015) 
The biosynthesis of HHQ and PQS is outlined in Figure 7 and involves the expression of the 
biosynthesis operon pqsABCDE and pqsH.(Gallagher et al., 2002) The coenzyme A ligase 
PqsA activates anthranilate to anthraniloyl-CoA.(Coleman et al., 2008) PqsD catalyses a 
Claisen-type condensation reaction using anthraniloyl-CoA and malonyl-CoA to yield 2-
aminobenzoylacetyl-CoA (2-ABA-CoA).(Zhang et al., 2008; Dulcey et al., 2013) The thioester of 
2-ABA-CoA is cleaved by PqsE to obtain the free carboxylic acid 2-aminobenzoylacetate (2-
ABA).(Drees and Fetzner, 2015) The heterodimer PqsBC directs the ring-closing reaction of 2-
ABA and octanoyl-CoA to afford HHQ.(Dulcey et al., 2013) HHQ is hydroxylated in the 3-
position by PqsH to form PQS.(Gallagher et al., 2002; Schertzer et al., 2010) Notably, this 
biosynthesis process furnishes two major degradation products: 2-ABA-CoA is highly instable 
and spontaneously decomposes to 2,4-dihydroxyquinoline (DHQ).(Zhang et al., 2008) Similarly, 
2-ABA either undergoes spontaneous cyclization to form also DHQ or decarboxylates to 2-AA. 
(Dulcey et al., 2013; Drees and Fetzner, 2015) So far, a function of DHQ in QS signaling has 
not been reported. However, 2-AA is supposed to promote the switch to chronic infection 
phenotypes and the formation of persister cells. (Kesarwani et al., 2011; Que et al., 2013)  
Both molecules, HHQ and PQS, bind to the Pseudomonas quinolone signal receptor (PqsR), 
also known as multiple virulence factor regulator (MvfR).(Xiao et al., 2006) PqsR is a LysR-type 
transcriptional regulator (LTTR) which controls directly the expression of the pqsABCDE and 
phnAB operons.(Cao et al., 2001; Wade et al., 2005) The phnAB operon encodes for 
anthranilate synthase catalyzing the conversion of chorismate to anthranilate.(Gallagher et al., 
2002) The interaction of PQS and HHQ with PqsR results in an enhanced expression of these 
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operons.(Wade et al., 2005; Xiao et al., 2006) Overall this leads to an autoinductive loop 
comparable to the ones found in AHL-based QS systems. The pqs system is essential for the 
full pathogenicity of P. aeruginosa.(Deziel et al., 2005) Accordingly, it takes part in the 
regulation of various virulence determinates such as pyocyanin, elastase and hydrogen 
cyanide.(Cao et al., 2001; Diggle et al., 2003; Deziel et al., 2005) The contribution of PqsE to 
these regulatory processes will be discussed in section 1.4.5. The pqs system clearly 
contributes to the establishment and maturation of biofilms by triggering the release of eDNA 
(Allesen-Holm et al., 2006) and the expression of lectins (Diggle et al., 2006b). Notably, the 
HHQ and PQS molecules possess immune suppressive properties.(Kim et al., 2010)  
A recently discovered fourth QS circuitry is called iqs (Lee et al., 2013) and employs 2-(2-
hydroxyphenyl)-thiazole-4-carbaldehyde also known as IQS (Figure 5) as signaling molecule. 
The biosynthetic gene cluster ambBCDE directs the biosynthesis of IQS. Though the 
transcriptional regulator has not been identified so far, ambBCDE knock-out studies clearly 
demonstrated the role of IQS in cell-to-cell communication.(Lee et al., 2013)  
All four QS regulatory circuits are intertwined (Figure 6) and hierarchically organized, wherein 
the las system possesses a superordinate role. Activated LasR positively regulates the 
expression of rhlR (Latifi et al., 1996; Pesci et al., 1997) and pqsR (Wade et al., 2005) as well 
as pqsH (Gallagher et al., 2002). Furthermore, the autoinducer IQS is not detectable in lasI or 
lasR negative mutant strains when grown in rich medium.(Lee et al., 2013) Despite the central 
role of the LasR, loss-of-function mutations are frequently observed during the course of chronic 
infections.(Hoffman et al., 2009; Ciofu et al., 2010) It has been clearly shown that in a lasR 
mutant, the pqs and rhl systems are able overcome the las dependency and restore virulent 
phenotypes.(Diggle et al., 2003; Dekimpe and Déziel, 2009) The same phenomenon was 
observed for the iqs system. When encountering low phosphate levels IQS is produced in the 
absence of LasR. Under these conditions, iqs supersedes the position of the las system and 
drives the expression of the rhl and pqs systems.(Lee et al., 2013)  
This complex regulatory network allows P. aeruginosa to collectively adapt to changing 
environmental conditions and represents the social intelligence of bacterial colonies.(Ben Jacob 
et al., 2004) The discovery of this bacterial cross talk opens the door for the development of 
anti-infectives with novel mode-of-action. 
 
1.4.3 Interference with the pqs System as Antivirulence Strategy 
Classical antibiotics target structures are essential for bacterial viability (bactericidal) or impair 
bacterial replication (bacteriostatic). The use of antibiotics provides organisms, which are 
resistant to this substance, with a growth advantage over bacteria which are susceptible. 
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Therefore antibiotics select for resistant mutants, thereby limiting their own efficacy and 
lifetime.(Walsh, 2003) Regardless of their underlying mechanisms or origin, bacteria developed 
resistance mechanisms against all established antibiotics.(Walsh, 2003; Alanis, 2005) 
“Resistance, then, has proven not to be a matter of if, but a matter of when.” Christopher Walsh 
Most of the antibiotic classes, which are in use today, have been discovered between 1940 to 
1960.(Fischbach and Walsh, 2009) These discoveries enabled the successful treatment of 
former life-threatening bacterial infections like pneumonia or tuberculosis and, hence, 
significantly contributed to an increase of life expectancy.(Centers for Disease Control and 
Prevention, 1999) After this golden age, most antibiotics introduced to the clinic represent 
synthetically modified derivatives of former identified scaffolds.(Fischbach and Walsh, 2009) 
This lack of innovation was accompanied by decreasing research efforts within the antibiotic 
field.(Projan, 2003) The popular belief that the “war against pestilence” (Spellberg and Taylor-
Blake, 2013) is won was rapidly disproved by the spreading of resistant bacterial strains.(Alanis, 
2005) Nowadays, highly resistant bacteria so called “superbugs” represent a serious and 
prevalent threat to public health while the development of novel treatment options 
stagnates.(Boucher et al., 2009) Alarmingly, the first plasmid-mediated resistance mechanism 
against the last resort antibiotic colistin emerged recently.(Liu et al., 2015)  
The development of anti-virulence drugs which prevent the expression of highly virulent 
phenotypes without affecting bacterial viability possesses an attractive and innovative escape 
strategy from the antibiotic crisis.(Rasko and Sperandio, 2010) In contrast to conventional 
antibiotics, this strategy does not exert selective pressure on bacterial populations and, 
therefore, it is assumed to be less prone to rapid development and spreading of 
resistance.(Clatworthy et al., 2007) Notably, this claim is controversially discussed in the 
scientific community and has to be proven or falsified in future studies.(Allen et al., 2014) 
In P. aeruginosa the expression of most virulence factors is tightly regulated by QS cell-to-cell 
communication.(Lee and Zhang, 2015) Hence, the interference with such superordinate 
regulatory processes provides a way to inhibit multiple virulence determinates with a single 
compound.(Rasko and Sperandio, 2010) Consequently, this strategy has been successfully 
applied and selected compounds interfering with QS regulated virulence in P. aeruginosa are 
shown in Figure 8.  
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Figure 8: Selected QS inhibitors targeting P. aeruginosa virulence 
The brominated furanon C30 (1) is a close synthetic analog of secondary metabolites isolated 
from the marine macroalga Delisea pulchra.(Nys et al., 1993; Manny et al., 1997) Compound 1 
displayed potent inhibition of QS-regulated phenotypes by destabilizing LasR and in vivo 
efficacy in a mouse lung infection model.(Manefield et al., 2002; Hentzer et al., 2003) Various 
libraries of AHL analogs were synthesized.(Geske et al., 2005; Ishida et al., 2007; Amara et al., 
2009) Compound 2 is one of the first analogs which showed antagonistic activity on LasR and 
RhlR resulting in reduction of pyocyanin, elastase and biofilm volume.(Smith et al., 2003)  
A loss of las activity was frequently observed during chronic infections (Hoffman et al., 2009) 
which would render a las-targeting antivirulence therapy ineffective. Therefore, we and other 
groups focused on the development of compounds interfering with pqs system. Remarkably, the 
pqs system only occurs in Pseudomonas and Burkholderia strains.(Diggle et al., 2006a) Hence, 
this strategy allows targeting specifically these strains without affecting the residual human 
microbiota.  
Lesic et al. aimed at the discovery of PqsA inhibitors based on the natural substrate anthranilic 
acid (3).(Lesic et al., 2007) Compound 3 was applied to a mouse thermal injury infection model 
leading to increased survival rates and limited dissemination through host tissues.(Lesic et al., 
2007) This study afforded the first in vivo proof of principle for a pqs targeting antivirulence 
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therapy. Following a ligand-based approach our group was able to obtain the first PqsD inhibitor 
(4) which inhibited HHQ biosynthesis and affected biofilm formation.(Storz et al., 2012) The 
benzamidobenzoic acid derivative 5 was derived from published inhibitor of FabH, an enzyme 
sharing structural similarities with PqsD.(Hinsberger et al., 2014) In a comparable approach, 
inhibitors containing a catechol scaffold were identified.(Allegretta et al., 2015) Sahner et al. 
established the 5-aryl-ureidothiophene-2-carboxylic acid derivatives (6) as PqsD 
blockers.(Sahner et al., 2013) Notably, the high in vitro activities of PqsD inhibitors 5 and 6 did 
not translate into potent antivirulence activities in P. aeruginosa.(Sahner et al., 2013; Hinsberger 
et al., 2014)  
In a parallel project, our group successfully worked on the development of the PqsR antagonists 
(7) by chemical modification of the natural ligand HHQ. Compound 7 displayed nanomolar 
antagonistic activity in a heterologous E. coli reporter gene strain but suffered from lacking 
antivirulence activity in P. aeruginosa.(Lu et al., 2012) A subsequent MS analysis elucidated 
that 7 undergoes enzymatic hydroxylation catalyzed by PqsH which transforms the antagonist 7 
into a potent agonist. A blockade of the metabolically labile position by a carboxamide moiety 
led to the potent antagonist 8 which showed the expected antivirulence activities and was able 
to protect Galleria mellonella from lethal P. aeruginosa infections.(Lu et al., 2014) In a similar 
study quinazolinone derivative 9 was developed and its effect on biofilms described. Moreover, 
the crystal structures of the ligand binding domain (LBD) of PqsR (apo form), in complex with 
antagonist 9 and the native agonist NHQ (2-nonyl-4-quinolone) were resolved.(Ilangovan et al., 
2013) During a phenotypic HTS campaign, over 280,000 compounds were evaluated for their 
effects on the PqsR regulon. Thereby, the benzamido-benzimidazole scaffold was discovered 
and optimized to afford PqsR antagonist 10. Beyond its impressive antivirulence activities, this 
compound affected persister cell formation and showed efficacy in acute and chronic mice 
infection models as stand-alone or combination therapy with conventional antibiotics.(Starkey et 
al., 2014) All described antagonists possess a poor physico-chemical profile. In order to 
address these drawbacks, our group conducted a fragment-based screening initially leading to 
compounds containing a carboxamide moiety. A straightforward optimization approach resulted 
in the hydroxamic acid 11 which showed remarkable potency in P. aeruginosa with respect to its 
small molecular size.(Klein et al., 2012)  
Overall, there is a high need for novel anti-infectives especially against Gram-negative 
pathogens like P. aeruginosa. Therefore, the development of compounds targeting pqs 
mediated virulence is a compelling strategy which led to first promising in vivo results.(Lesic et 
al., 2007; Lu et al., 2014; Starkey et al., 2014) Nevertheless, more research efforts are 
necessary to generate lead-like molecules. 
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1.4.4 The Transcriptional Regulator PqsR as Antivirulence Target 
PqsR belongs to LTTR receptor family and consists of a N-terminal helix-turn-helix DNA binding 
motif and a C-terminal LBD.(Cao et al., 2001) In general, LTTRs form homodimeric complexes 
which bind to specific DNA regions in proximity to the regulated gene. Two dimers form a 
tetrameric complex leading to bending of DNA strand. The binding of autoinducer molecules 
results in an alteration of this bending which in turn facilitates the interaction of the RNA 
polymerase with the promoter region leading to enhanced transcription of the target 
genes.(Maddocks and Oyston, 2008) Notably, this working model has been proven for similar 
LTTRs but not in detail for PqsR. However, PqsR shows several characteristic features 
indicating that it works in a similar fashion: specific DNA binding (Cao et al., 2001), enhanced 
expression of pqsABCDE and phnAB operons in the presence of autoinducer molecules (Wade 
et al., 2005; Xiao et al., 2006) and its LBD crystallizes as homodimeric complex (Ilangovan et 
al., 2013). 
 
Figure 9: Crystal structure of the PqsR LBD in complex with NHQ (4JVD). Lipophilicity is plotted 
on the Van-der-Waals surface of the receptor as follows green: lipophilic, purple: hydrophilic. A) 
View from the dimer interface to alkyl chain pocket (in the front) B) Side view; quinolone pocket 
in the front 
The crystal structure of the LBD of PqsR with the autoinducer NHQ (PDB code: 4JVD; Figure 9) 
revealed a L-shaped binding pocket.(Ilangovan et al., 2013) This pocket possesses a highly 
lipophilic environment and is divided in two subpockets: the alkyl side chain pocket (Figure 9A) 
located at the dimer interface and the narrow quinolone pocket (Figure 9B) pointing deeper into 
the protein structure. 
PqsR is a key player for the expression of various P. aeruginosa virulence factors (Deziel et al., 
2005) and pqsR-negative strains displayed reduced pathogenicity in several host infection 
models. (Rahme et al., 1997; Cao et al., 2001; Gallagher et al., 2002; Xiao et al., 2006) 
Furthermore, first antagonists showed efficacy in different in vivo models (Lu et al., 2014; 
Starkey et al., 2014) what underlines the potential of PqsR as drug target for the development of 
future anti-infectives.  
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1.4.5 The Enigmatic Role of PqsE  
The presence of PqsE is essential for the full expression of virulence determinants like 
pyoyanin, elastase and rhamnolipids.(Gallagher et al., 2002; Diggle et al., 2003; Farrow et al., 
2008) Knock-out complementation studies clearly demonstrated that PqsE can restore virulent 
phenotypes even in the absence of a functional pqs system.(Farrow et al., 2008; Hazan et al., 
2010) Similar experiments confirmed these findings also in different in vivo infection 
models.(Rampioni et al., 2010)  
Transcriptomic analysis revealed that the PqsE stimulon comprises a subset of pqs controlled 
and additional genes.(Rampioni et al., 2010) Different studies disclosed that the regulatory 
function of PqsE is at least partially mediated via RhlR.(Farrow et al., 2008; Hazan et al., 2010) 
Furthermore, PqsE down regulates the expression of its own operon leading to negative 
regulatory loop.(Hazan et al., 2010; Rampioni et al., 2010) 
For many years, it was assumed PqsE would not take part in the HHQ biosynthesis but Drees 
and Fetzner showed recently that PqsE can act as pathway-specific thioesterase (Figure 7). 
Notably, this biosynthetic function can be bypassed by other housekeeping 
thioesterases.(Drees and Fetzner, 2015) 
Yu et al. resolved the crystal structure of PqsE which revealed a beta-lactamase fold containing 
a dinuclear Fe(II)/Fe(III) metal center at the active site. The crystals contained a ‘benzoic acid 
shaped ligand’ in the active center (Figure 10). Subsequently, the binding of benzoic acid and 
anthranilate was confirmed by ITC.(Yu et al., 2009)  
 
Figure 10: The crystal structure of PqsE in complex with benzoic acid depicted in green (2Q0J). 
View into the active site with the Fe(II)/Fe(III) metal center 
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Despite many research efforts, the exact molecular mechanism of PqsE for the regulation of 
virulence remains a mystery. However, its central role for the pathogenicity of P. aeruginosa 
makes PqsE a potentially attractive antivirulence target.  
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2 Objectives  
There is an increasing need for novel and innovative treatment options for bacterial infections. 
Especially infections with Gram-negative pathogens like P. aeruginosa have become more and 
more difficult to treat due to rapid development and spreading of resistances against 
conventional antibiotics. Anti-infectives which block the expression of virulent phenotypes 
without exerting selective pressure on the bacteria might overcome these drawbacks. Following 
this idea, the present work aims at the development of compounds interfering with the pqs QS 
system in P. aeruginosa. 
Antagonizing the transcriptional regulator PqsR by synthetic ligands (8 and 10, Figure 8) 
resulted in increased survival rates in different infection models.(Lu et al., 2014; Starkey et al., 
2014) Hence, the ‘proof-of-principle’ for PqsR as an antivirulence target has been achieved. 
However, both compounds showed poor physicochemical properties which might hamper the 
further development. 
The first part of this thesis deals with the development of drug-like PqsR antagonists. In doing 
so, fragment-based drug discovery methods are applied. Starting points for further synthesis 
programs are selected from the hits of an SPR fragment screening based on their 
thermodynamic profiles and their antagonistic activities in a heterologous E. coli reporter gene 
system. Structure-based methods as well as literature-known SAR should be incorporated into 
the drug design process. Subsequently, a robust synthetic route has to be developed allowing 
access to numerous derivatives. Selected hit scaffolds should be optimized regarding their 
antagonistic potencies and anti-virulence activities in P. aeruginosa without affecting the 
bacterial viability. The development process is guided by suitable efficiency metrics in order to 
put a special emphasis on physicochemical properties of the designed antagonists. 
The fundamental role of PqsE for virulence regulation (Farrow et al., 2008) as well as the 
reduced pathogenicity of pqsE negative strains (Rampioni et al., 2010) in different infection 
models makes this mysterious protein attractive for future drug discovery approaches. 
Therefore, the second objective of this work is the discovery of synthetic PqsE ligands allowing 
to gain novel insights into the different protein functions. Achieving this goal involves the 
screening of a fragment library and the elucidation of the binding mode of the obtained hit 
compounds. The effects of these compounds on the PqsE enzymatic activity are evaluated in 
different in vitro assays. Subsequently, the ligands are profiled for their effect on the expression 
of virulence factors and signaling molecules in P. aeruginosa.  
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3 Results 
3.1 Chapter A: 
Discovery and Biophysical Characterization of 2-Amino-
oxadiazoles as Novel Antagonists of PqsR, an Important 
Regulator of Pseudomonas aeruginosa Virulence 
Michael Zender, Tobias Klein, Claudia Henn, Benjamin Kirsch, Christine K. Maurer, 
Dagmar Kail, Christiane Ritter, Olan Dolezal, Anke Steinbach, Rolf W. Hartmann 
 Reprinted (adapted) with permission from J. Med. Chem. 2013, 56, 6761–6774 
 Copyright (2013) American Chemical Society. 
 
ABSTRACT 
The human pathogen Pseudomonas aeruginosa employs alkyl quinolones for cell-to-cell 
communication. The Pseudomonas Quinolone Signal (PQS) regulates various virulence factors 
via interaction with the transcriptional regulator PqsR. Therefore, we consider the development 
of PqsR antagonists a novel strategy to limit the pathogenicity of P. aeruginosa. A fragment 
identification approach using surface plasmon resonance screening led to the discovery of 
chemically diverse PqsR ligands. The optimization of the most promising hit (5) resulted in the 
oxadiazole-2-amine 37 showing pure antagonistic activity in E. coli (EC50 7.5 µM) and P. 
aeruginosa (38.5 µM) reporter gene assays. 37 was able to diminish the production of the PQS 
precursor HHQ in a PqsH deficient P. aeruginosa mutant. The level of the major virulence factor 
pyocyanin was significantly reduced in wild-type P. aeruginosa. In addition, site-directed 
mutagenesis in combination with isothermal titration calorimetry and NMR INPHARMA 
experiments revealed that the identified ligands bind to the same site of PqsR by adopting 
different binding modes. These findings will be utilized in a future fragment growing approach 
aiming at novel therapeutic options for the treatment of P. aeruginosa infections. 
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INTRODUCTION 
Our view of bacterial lifestyle has changed drastically in the last few years. In the past, bacteria 
were deemed to be autonomous unicellular organisms. Nowadays, it is increasingly recognized 
that they have the ability to communicate with each other. A particular form of bacterial 
communication is referred to as quorum sensing (QS). QS functions via the release of signaling 
molecules. The concentration of these molecules increases as a function of cell density. After a 
threshold concentration has been reached they regulate gene expression in bacteria by 
activation of corresponding transcriptional regulators. QS cell-to-cell communication enables 
bacteria to monitor population density and to orchestrate their behavior on a population-wide 
scale.1,2 
Pseudomonas aeruginosa, a Gram-negative opportunistic pathogenic bacterium is an important 
causative agent of nosocomial infections3,4 and is involved in several acute and chronic 
infections. It is one of the major pathogens causing pneumonia e.g. in people suffering from 
cystic fibrosis.5 The ability of P. aeruginosa to form biofilms contributes to its low antibiotic 
susceptibility mainly due to lowered metabolic activity and decreased growth rate of biofilm 
bacteria.6 Moreover, during the last decades, P. aeruginosa strains resistant against nearly all 
established antibiotics have emerged, necessitating alternative therapeutic options.7,8 
P. aeruginosa coordinates group behaviours via three interconnected QS circuitries. The 
las9,10and rhl11,12 communication systems operate via N-acylated homoserine lactones (AHLs), 
which are prevalent signaling molecules in Gram-negative bacteria. In contrast, the pqs 
system
13,14
 is restricted to particular Pseudomonas and Burkholderia strains.
15
 It functions via 
the 2-alkyl-4(1H)-quinolones (HAQ) signal molecules PQS (Pseudomonas Quinolone Signal; 2-
heptyl-3-hydroxy-4(1H)-quinolone) and its precursor HHQ (2-heptyl-4(1H)-quinolone; Figure 1).  
 
Figure 1: Structure of the P. aeruginosa signaling molecules PQS and HHQ as well as recently 
published PqsR ligands 
 
Both interact with their receptor PqsR16,17 to control many genes involved in the production of 
various virulence factors like elastase, pyocyanin and lectins.18 Moreover, PQS enhances its 
own biosynthetic pathway by positively regulating the pqsABCD(E)16,19,20 and phnAB14 operons 
Chapter A 34 
 
 
as well as it influences biofilm formation.
18,21
 The discovery of QS systems in pathogenic 
bacteria provides novel options for inhibiting the virulence without interfering with bacterial 
viability.22  The interference with QS systems by synthetic inhibitors23 and the reduction of 
virulence factors by flucytosine24 resulted in diminished P. aeruginosa pathogenicity in mouse 
pulmonary infection models demonstrating the in-vivo relevance of these anti-virulence 
strategies. Regarding P. aeruginosa, we consider PqsR - a key player for its pathogenicity - an 
attractive drug target. PqsR, also known as multiple virulence factor regulator (MvfR), belongs 
to the family of LysR-type transcriptional regulators (LTTR).17 The N-terminal region contains a 
helix-turn-helix DNA binding motif and the C-terminus between amino acids 92-298 encodes for 
a predicted ligand binding domain (LBD).17 
Recently, we have reported on the discovery of two different classes of antagonists which target 
PqsR (Figure 1). The HHQ derivative 1
25
 is a potent PqsR antagonist, but shows insufficient 
drug-like properties such as low aqueous solubility. Given that it is very difficult to strongly 
improve the physico-chemical profile of lead compounds with high logP values without losing 
activity,
26
 a fragment screening was initiated as an alternative
27,28
 initially leading to the 
benzamide 2.29 2 showed mixed agonistic-antagonistic properties. The introduction of a 
hydroxamic acid motif (3) provided a pure antagonistic profile.29 It is noteworthy that hydroxamic 
acids are reported as chelating agents30 and accordingly have been used as inhibitors of 
various metalloproteins.31 Furthermore, aromatic hydroxamic acids are described as potential 
mutagenic agents.32 In order to overcome these shortcomings and to gain chemical diversity, it 
was of major interest to discover PqsR antagonist with alternative scaffolds. 
In this work, we present the discovery of structurally diverse, low molecular weight PqsR ligands 
employing surface plasmon resonance (SPR) biosensor experiments. Selected hits displaying 
sufficient affinity were functionally and thermodynamically characterized. Furthermore, the most 
promising hit compound 5 was structurally optimized and transformed into the potent PqsR 
antagonist 37 which was able to reduce the production of HHQ in a PqsH deficient mutant and 
the major virulence factor pyocyanin in wild-type P. aeruginosa.  
RESULTS AND DISCUSSION 
Chemistry. The top screening hits 4-9 (Figure 2) were commercially available. The synthesis of 
the thiadiazole and oxadiazole derivatives was achieved by the use of different synthetic routes 
as described in the following.  
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Scheme 1. Synthesis of Oxadiazole-2-amine and Thiadiazole-2-amine Derivatives
a
 
 
a Reagents and Conditions: (a) oxalyl chloride, DMF cat, DCM, reflux; (b) thiosemicarbazide, 
THF, 0 °C to RT; (c) thiosemicarbazide, POCl3, 80°C; (d) H2SO4, RT; (e) 1,3-Dibromo-5,5-
dimethylhydantoin, KI, NaOH, 2-propanol, 4 °C.  
 
The synthesis of 1,3,4-oxadiazole-2-amine and 1,3,4-thiadiazole-2-amine derivatives is shown 
in Scheme 1. Thiadiazoles 5 and 33 were synthesized in a one-step procedure from 
commercially available benzoic acid derivatives and hydrazinecarbothioamide in POCl3.
33 A 
classic coupling reaction of benzoic acid chlorides and hydrazinecarbothioamide afforded the 
benzoylthiosemicarbazides 23-30.
34
 31 was obtained by treating the respective 
benzoylthiosemicarbazide 23 with concentrated sulfuric acid as dehydrating agent.35 The ring 
closure which gives the respective 2-amino-1,3,4-oxadiazoles 32 and 35-42 was achieved 
under mild oxidative conditions using compounds 23-30 and employing 1,3-dibromo-5,5-
dimethylhydantoin as primary oxidant in the presence of catalytic amounts of potassium 
iodide.34 
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Scheme 2. Synthesis of 2-Substituted Oxadiazoles
a
 
 
aReagents and Conditions: (a) methanol, Et3N, RT, then hydrazine hydrate, water, 120 °C; (b) 
methyl chloroformate, NaHCO3, water, dioxane, 0 °C; (c) trifluoroacetic anhydride, Et3N, DCM, 
RT; (d) R1C(OEt)3, 150 °C; (e) ethyl oxalyl monochloride, Et3N, DCM, 0 °C then tosyl chloride, 
RT; (f) N-methylhydrazinecarbothioamide, DCM, RT then EDC, 40 °C; (g) carbonyldiimidazole, 
Et3N, DCM, RT; (h) Burgess reagent, THF, MW radiation, 100 W, 150 °C; (i) ammonia in 
methanol, RT.  
The synthesis of compounds containing variations in the 2-position of the oxadiazole 
heterocycle (47-53) is summarized in Scheme 2. The precursor 3-
(trifluoromethyl)benzohydrazide (43) was obtained from the corresponding benzoyl chloride 17 
in a two-step procedure. Coupling of 43 with methyl chloroformate and trifluoroacetic anhydride 
afforded 44 and 45. Ring-closure was carried out under microwave radiation using Burgess 
reagent as selective dehydrating agent yielding compounds 49 and 50.
36
 Heating of 43 in triethyl 
orthoformate or triethyl orthoacetate provided the oxadiazoles 47 and 48, respectively.37 46 was 
synthesized in a one-pot two-step procedure, following the coupling of 43 with ethyl oxalyl 
monochloride and ring closure with tosyl chloride.38  46 was treated with ammonia in methanol 
to directly transform the ethyl ester in the corresponding carboxamide 52.39 The N-methylated 
analog 51 was obtained in a one-pot two-step protocol: the benzoylchloride was coupled with N-
methylhydrazinecarbothioamide and ring closure was carried out by employing EDC.40 
Oxadiazol-2-one 53 was prepared by conversion of 43 with carbonyldiimidazole.41  
Chapter A 37 
 
 
Identification of PqsR Ligands by Fragment Screening. The detection and analysis of 
biomolecular interactions is one of the key issues in the hit identification phase of a drug 
discovery project. Surface plasmon resonance spectroscopy represents a powerful tool to 
monitor and characterize binding events in real-time.42 We have applied this technology to 
screen a library containing 720 compounds with a molecular weight ranging from 100 to 350 
g/mol (for details see SI; Table S2). PqsR was immobilized on the sensor chip surface via 
biotin-streptavidin specific interaction and compounds were initially screened at a single 
concentration of 100 µM. Approximately 40 binding compounds were selected based on affinity 
and selectivity against negative control (bovine carbonic anhydrase II). Compounds showing 
undesirable SPR binding characteristics as described by Giannetti et al.43 were not taken into 
consideration. These included fragments displaying binding irregularities, fragments with non-
typical slow dissociation and compounds producing super-stoichiometric binding responses. 
The obtained hit rate of 5-6% can be regarded as excellent compared to the screening of more 
complex structures.28 The best fragments were further subjected to SPR dose-ranging 
experiments to accurately determine dissociation constants (KD values). The five top candidates 
displayed KD values below 11 µM (4-8, Figure 2 and Table 1). To further evaluate binding of the 
best screening hits we performed SPR competition experiments similar to those described 
previously.44 Dose binding experiments with mixtures consisting of various concentrations of 
either compound 4 or 5 and constant concentrations of PQS showed no overall additivity in the 
SPR response (SI, Figure S2). Increasing the PQS concentration did not exceed the maximal 
binding capacity of the chip surface (Rmax; experimentally determined for the different 
fragments). These results show that both fragments compete with PQS for binding to PqsR. 
 
Figure 2: Chemical structures of highest affinity compounds 4-8 and compound 9 
As evaluation of the KD values alone gives no clear indication of which ligands to select for 
further progression,45 the thermodynamic parameters, which allow a more detailed 
understanding of biomolecular interactions,46 were determined (Table 1) using isothermal 
titration calorimetry (ITC). 
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Table 1: Biophysical characterization of PqsR ligands.
a
 
Comp. KD (SPR) 
[µM]
b
 
KD (ITC) 
[µM] 
ΔG 
[kcal mol
-1
] 
ΔH 
[kcal mol
-1
] 
-TΔS 
[kcal mol
-1
] 
LE 
[kcal mol
-1
] 
2 - 0.9±0.0 -8.3±0.0 -9.7±0.3 1.5±0.3 0.63 
4 0.8±0.2 1.8±0.2 -7.9±0.1 -8.6±0.2 0.7±0.2 0.60 
5 4.5±0.0 3.7±0.1 -7,4±0.0 -8.2±0.9 0.7±0.9 0.57 
6 6.8±3.5 7.6±0.7 -7.0±0.1 -6.9±0.1 0.1±0.1 0.70 
7 6.8±3.8 10.0±1.3 -6.8±0.1 -9.3±0.4 2.5±0.4 0.85 
8 10.7±6.5 8.5±0.7 -6.9±0.0 -8.6±0.0 1.6±0.1 0.49 
9 200-500  - - - - - 
37 - 1.3±0.3 -8.0±0.1 -8.5±0.5 0.4±0.5 0.50 
41 - 12.4±1.0 -6.7±0.0 -4.0±0.1 -2.6±0.1 0.51 
42 - 3.1±0.6 -7.5±0.1 -7.6±0.0 0.0±0.1 0.47 
47 - 6.5±0.5 -7.1±0.0 -9.0±0.5 1.9±0.3 0.47 
48 - 12.9±2.4 -6.7±0.1 -3.8±0.2 -2.8±0.3 0.42 
aSPR measurements and ITC titrations were performed at 20 °C and 25 °C, respectively. Data 
represent mean ± SD from at least two independent experiments. bKD (SPR), PQS: 0.21±0.0 µM 
 
The ITC derived KD values were in good accordance with the ones determined by SPR 
experiments. The naphthalene-2-carboxamide 4 and the thiadiazole derivative 5 displayed the 
highest affinities (Table 1). Analysis of the thermodynamic signatures revealed that 4-8 are 
enthalpy-driven binders (Table 1) indicating a good non-covalent bond complementarity 
between the protein site and the compounds.45 Given that it is harder to improve the ΔH 
contribution than to improve the ΔS contribution, enthalpy driven binders are usually preferred 
for further optimization.45 Moreover, we determined the ratio of Gibb’s free binding energy to the 
number of non-hydrogen atoms termed ligand efficiency (LE) that enables a better comparison 
of hits with widely differing structures and activities.47 Compounds 4-8 showed LEs ranging from 
0.49 to 0.85 kcal/mol and are above the threshold value of 0.33 kcal/mol, which should be 
exceeded for an efficient optimization.47 In order to evaluate the agonistic and antagonistic 
activities of 4-8, we examined the PqsR-mediated transcriptional effect in a reporter gene assay 
by measuring the β-galactosidase activity in E. coli  the pEAL08-2 plasmid containing the tacP-
pqsR and pqsAP-lacZ fusion genes (Table 2).
48 E. coli was used, as it provides a system to 
characterize the functionality of PqsR ligands independent of the entire pqs system and the low 
outer membrane permeability49 characteristic for P. aeruginosa. While 6-8 showed no or only 
weak antagonistic activity, compounds 4 and 5 exhibited marked antagonistic properties. In 
contrast to compound 4, compound 5 provided only moderate agonistic activity. Overall, the 
screening process afforded thiadiazole 5 which combines a remarkably high affinity with regard 
to its low molecular weight with superior functional properties in the E. coli reporter gene assay 
and was therefore selected for further optimization. 
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Fragment Optimization. Another hit compound sharing a high degree of similarity with 5, 
compound 9 (Figure 2), which had shown lower affinity in the SPR screen, but pure antagonistic 
activity (Table 2) was included in the optimization strategy (Figure 3). 
 
Figure 3: Fragment modification strategy 
In the first modification step the position of the Cl substituent was shifted into the meta and 
ortho position (Table 2), as we had observed that the antagonistic properties in the quinolone 
class of PqsR antagonists strongly depended on the position of the aromatic substituents.25 The 
compounds with Cl in meta position showed an opposed functional profile in case of both 
heterocycles: the thiadiazole 31 displayed pure agonistic properties, while the oxadiazole 32 
turned out to be a pure antagonist. The Cl substituent in ortho position (33, 34) led to a 
moderate agonistic activity without antagonistic properties for both heterocycles. 
Compound 32 was used for further optimization. The Cl group was exchanged for substituents 
providing different electronic properties (35-42, Table 2). Omitting the Cl substituent (35) led to 
a moderate agonistic activity. The bioisosteric exchange of Cl for electron-withdrawing moieties 
in meta position (36-39) resulted in pure antagonists with the Br compound 36 and the CF3 
derivative 37 as the most potent ones (EC50 7.5 µM). Interestingly, in the class of HHQ derived 
antagonist a CF3 substituted quinolone also showed the strongest antagonistic properties.
25 The 
introduction of a methoxy group (40) was accompanied by a complete loss of activity. In 
contrast, the introduction of a methyl substituent resulted in a partial antagonist (41, SI, Figure 
S5). In the case of the benzamide scaffold reported by Klein et al. (2, Figure 1) the exchange of 
Cl for tert-butyl resulted in an increased affinity due to an enthalpic gain.29 Assuming a similar 
binding mode of 2 and 37 (discussed in detail below) this structural modification was deemed to 
have a similar effect in the oxadiazole class. Compound 42, however, showed a slightly reduced 
affinity according to ITC analysis (Table 1) and more importantly a diminished antagonistic 
activity. Overall, 37 showing a favorable logP of 2.12 (ACD Perspecta 14.0.0 consenus logP) 
and a better aqueous solubility compared to 36 emerged as the most promising compound. 
Accordingly, 37 was tested in the P. aeruginosa reporter gene assay. As the outer membrane is 
much less permeable in P. aeruginosa49 the observed antagonistic activity being only 5-fold 
reduced (EC50s: 7.5 µM in E. coli, 38.5 µM in P. aeruginosa; SI Figure S6) was remarkably high. 
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 Table 2: Agonistic and antagonistic activities of PqsR ligands
a
 
 
Compd. Pos X R1 R2 Agonistic 
activity  
[%] 
Antagonistic 
activity 
[%] 
EC50
b
 
[µM] 
4 - - - NH2 52±12 41±12 - 
5 4 S Cl NH2 28±1 43±16 - 
6 - - - NH2 n.a. n.i. - 
7 - - - NH2 n.a. 22±17 - 
8 - - - NH2 n.a. n.i. - 
9 4 O Cl NH2 n.a. 40±9 - 
31 3 S Cl NH2 105±11 n.i. - 
32 3 O Cl NH2 n.a. 76±12 26.7 
33 2 S Cl NH2 48±1 n.i. - 
34 2 O Cl NH2 22±5 n.i. - 
35 3 O H NH2 28±3 n.i. - 
36 3 O Br NH2 n.a. 105±6 7.5 
37 3 O CF3 NH2 n.a. 111±13 7.5 
38 3 O CN NH2 n.a. 84±1 17.8 
39 3 O OCF3 NH2 n.a. 69±6 46.5 
40 3 O OMe NH2 n.a. n.i. - 
41 3 O Me NH2 n.a 55±20 57.8
c
 
42 3 O t-Butyl NH2 n.a. 42±11 - 
47 3 O CF3 H n.a. 49±22 101.2 
48 3 O CF3 Me n.a. n.i. - 
49 3 O CF3 OMe n.a. n.i. - 
50 3 O CF3 CF3 n.a. n.i. - 
51 3 O CF3 NHMe n.a. n.i. - 
52 3 O CF3 CONH2 39±6 n.i. - 
53 - - - - 41±4 n.i. - 
aAgonistic and Antagonistic properties were evaluated in an E. coli reporter gene assay. 
Agonistic activity was determined by measuring the PqsR stimulation induced by 100 µM of the 
test compound compared to 50 nM PQS (= 100%); n.a. = no agonism (agonistic activity ≤ 20%). 
Antagonistic activity was determined by measuring the inhibition of the PqsR stimulation 
induced by 50 nM PQS in the presence of 100 µM test compound (full inhibition = 100%); n.i. = 
no inhibition (antagonistic activity ≤ 20%). Mean values of at least two independent experiments 
with n = 4. 
b
Concentration
 
of the half maximal antagonistic activity. Mean values of at least two 
independent experiments with compounds tested in at least 6 different concentrations and n = 
4. cpartial antagonist 
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Characterization of Fragment Binding Mode. Despite many efforts,
50,51
 the 3D structure of 
the PqsR protein is not available. The amino acids Q194 and F221 are located within the LBD 
of PqsR and are potential partners for non-covalent interactions.29 We could clearly show that 
Q194 and F221 are involved in the binding of benzamide 2 employing site-directed mutagenesis 
in combination with ITC analysis.29 Accordingly, the optimized compound 37 and the screening 
hit naphthalene-2-carboxamid 4 showing highest affinity were evaluated for their binding to the 
Q194A and F221A PqsR mutants by ITC (Table 3). 
 
Table 3: Effect of site-directed mutations on the thermodynamic parameters of PqsR ligands. 
 Q194A F221A 
Ligand ΔΔG 
[kcal mol
-1
] 
ΔΔH  
[kcal mol
-1
] 
-TΔΔS 
[kcal mol
-1
] 
ΔΔG 
[kcal mol
-1
] 
ΔΔH 
[kcal mol
-1
] 
-TΔΔS 
[kcal mol
-1
] 
2 -1.3±0☆ -4.4±0.3☆  3.1±0.3☆ -1.0±0.1☆ -7.6±0.3☆  6.6±0.4☆ 
4 -1.1±0.1☆  -3.2±0.2☆  2.1±0.2☆ -0.4±0.1★ -7.1±0.2☆  6.7±0.2☆ 
37 -0.6±0.1☆  -0.3±0.6 -0.3±0.7 -0.6±0.1☆ -7.1±0.5☆  6.5±0.6☆ 
ΔΔG, ΔΔH, and –TΔΔS are ΔGWT – ΔGmutant, ΔHWT – ΔHmutant, and –T(ΔSWT – 
ΔSmutant), respectively. Negative values indicate a loss, positive values a gain compared to 
wild-type. Errors indicate SD calculated via Gaussian error propagation. Significance: effect of 
the point mutation on the thermodynamic parameters of ligand binding compared to the wild-
type. ☆ p < 0.003; ★ p < 0.05. 
Comparing the thermodynamic signatures of 4 binding to Q194A mutant and wild-type PqsR a 
loss in ΔH of 3.2 kcal/mol was observed. Given that a well-placed H-bond makes a favorable 
enthalpic contribution in a range from 4 to 5 kcal/mol,52 this value indicates the presence of a 
weak H-bond between 4 and Gln194. The enthalpic contribution of 4 binding to the F221A 
mutant was significantly reduced compared to the wild-type (ΔΔH = -7.1 kcal/mol). F221 might 
be involved in a π-π interaction with the naphthalene core of 4. However, theoretical 
investigations revealed an interaction energy of only 4.0 to 4.2 kcal/mol for the benzene-
naphthalene complex.53 In all cases the loss in enthalpy is partly compensated by a gain in 
entropy. This might be due to a higher conformational flexibility of the complex in the absence of 
specific non-covalent interactions. Overall, the measured data indicate that napthalene-2-
carboxamide 4 adopts the same binding mode as the benzamide 2. 
In contrast, there was no significant difference in the enthalpic contribution observed for the 
oxadiazole 37 when binding to Q194A mutant and wild-type PqsR. This indicates that the side-
chain of Gln194 is not directly involved in the binding of 37. As observed for 4, the binding of 37 
was also affected by the F221A mutation (ΔΔH = -7.1 kcal/mol). The phenyl moiety of 37 might 
be involved in a π-stacking interaction with F221. Overall, these data lead to the conclusion that 
aromatic carboxamides 2 and 4 as well as the oxadiazole 37 interact with different amino acids 
within the LBD by adopting different binding modes.  
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Figure 4. Competitive binding of 2 and 37 to PqsR (a) Raw ITC data (top) and integrated 
normalized data (bottom) for titrations of 43 µM PqsR with 500 µM 37 in the absence of 2 (■) 
and in the presence of 500 µM compound 2 (Δ). (b) NOESY spectrum of a mixture of 500 µM 2 
and 400 µM 37 in the presence of 10 µM PqsR; interligand NOEs between the tert-butyl moiety 
of 2 and the phenyl ring of 37 (top), between the two phenyl rings (bottom); (*) indicates 
interligand INPHARMA NOEs mediated by PqsR; (**) indicates intramolecular transferred NOEs. 
Signals marked with (*) or (**) were not detected in a control experiment recorded under identical 
conditions in the absence of PqsR. 
ITC analysis was applied to analyze whether both fragments bind to the same site. PqsR was 
saturated with an excess of 2 and 37 was titrated subsequently into the same solution (Figure 
4a). No additional heat release was detected which gives strong evidence that both compounds 
compete for binding to PqsR. Additionally, the vice versa experiment was performed to exclude 
that the binding of 2 induces a conformational change which hinders the binding of 37. This 
experiment led to the same result (SI Figure S4) confirming that both fragments bind to the 
same site. In order to further validate the competitive binding (2, 37) we applied NMR 
INPHARMA experiments.54 This technique allows to detect protein-mediated interligand NOEs, 
if both compounds bind competitively to the same site of the protein. When we conducted a 2D 
NOESY experiment of a mixture of 2 and 37 in the presence of PqsR, clear interligand NOEs 
between the tert-butyl group of 2 and the phenyl ring of 37 were observed (Figure 4b, upper 
panel). Additionally, weaker interligand NOEs between the two phenyl moieties of 2 and 37 
were detected (Figure 4b, lower panel). These findings corroborated our ITC data that both 
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ligands bind competitively to the same site of PqsR. Given that both fragments interact with 
F221 and compete with PQS as shown for the structural analogs 4 and 5 in SPR competition 
experiments, we conclude that 2 and 37 have overlapping binding sites within the LBD. 
Biophysically Guided Structural Modifications. Structural modifications of 37 in combination 
with thermodynamic analysis were performed to evaluate the relative contributions of the 
different functional groups. The CF3 moiety was replaced by a methyl group and the 
thermodynamic signature of the resulting compound 41 was compared to that of 37 (Figure 5). 
 
 
Figure 5. Relative thermodynamic contributions of functional groups. Negative values indicate a 
loss; positive values a gain compared to compound 37; ☆p < 0.003; ★p < 0.05 
Compound 41 showed a reduced affinity for PqsR compared to 37 (Table 1), which was due to 
a significant loss in ΔH of 4.4 kcal/mol (Figure 5). This corroborates the proposed π-stacking 
between F221 and the phenyl moiety of the oxadiazole 37 as electron-withdrawing groups like 
CF3 can intensify such interactions either through enhanced electrostatic
55,56 or direct effects of 
the substituents.57 Considering the loss in enthalpy that is caused by the F221A mutation (7.1 
kcal/mol) and the loss in enthalpy that is due to the exchange of the CF3 by CH3 (4.4 kcal/mol), 
the enthalpic contribution of a possible π-π interaction between 37 and Phe221 might be 2.7 
kcal/mol. Remarkably, this is consistent with the binding energy of the gas-phase benzene 
dimer ranging from 2.0 to 3.0 kcal/mol.58 
The thermodynamic profile of compound 37 binding to Q194A suggested that the amino group 
of 37 does not make an H-bond with the polar side-chain of Gln194. To investigate whether the 
amino group is involved in the formation of an H-bond with polar backbone atoms or other side-
chains in the LBD of PqsR it was replaced by hydrogen. The binding affinity of the resulting 
compound 47 was reduced (Table 1). The same tendency was observed for the functional 
Chapter A 44 
 
 
properties (Table 2). But even more interesting, there was no significant difference in the 
enthalpic contributions (Figure 5). These findings initially led us to the conclusion that the amino 
group is not involved in a specific non-covalent interaction (e.g. H-bond) with PqsR. Hence, we 
decided to replace the amino function for apolar moieties with different electronic properties like 
methyl (48), methoxy (49) and CF3 (50) in order to overcome the enthalpy penalty associated 
with desolvation of the polar amino group.52 In contrast to our assumption, compound 48 
displayed a reduced affinity toward PqsR (Table 1), which results from a significant decrease in 
ΔH of 4.7 kcal/mol (Figure 5) typical for a loss of a well-placed H-bond.52 Furthermore, these 
modifications (48-50) completely abolished the antagonistic activity (Table 2). These findings 
led us reconsider our hypothesis of a non-interacting amino function: the C-H bond in 2-position 
of the 1,3,4-oxadiazole (47) is highly polarized and can interact through a non-classical 
hydrogen bond.59 In our case such an interaction could be mediated by a water molecule that is 
displaced in the presence of an amino function (37). This explanation is sustained by the loss in 
entropy (-1.5 kcal/mol) due to the exchange of NH2 by H. Theoretical investigations revealed an 
interaction energy for highly similar 5-membered heterocycles like oxazoles and isoxazoles in 
the range of 3.0 to 3.5 kcal/mol.59 Such an interaction might compensate the loss in enthalpy by 
omitting the amino group.  
In order to evaluate whether both hydrogen atoms of the amino substituent (37) are involved in 
ligand-receptor interaction we synthesized the N-methylated analogue 51. The latter showed no 
antagonistic activity (Table 2) as did the carboxamide (52) and oxadiazol-2-on (53) indicating 
that the amino group is essential for full antagonistic activity even if the exact function in the 
ligand-receptor interaction remains speculative. 
Effects on alkylquinolone signaling and virulence factor pyocyanin formation in 
P. aeruginosa. Following our strategy of inhibiting P. aeruginosa pathogenicity, we evaluated 
the effect of different oxadiazole derivatives on the production of alkylquinolones and the major 
virulence factor pyocyanin in the highly virulent clinical isolate P. aeruginosa PA14. The 
activation of PqsR upregulates the pqsABCD(E) operon which is essential for HHQ and PQS 
biosynthesis.16,19,20 Furthermore, PQS is reported to influence biofilm shape.21  Accordingly, we 
examined the effect of 37 on extracellular levels of PQS in wild-type P. aeruginosa. As we 
reported for the HHQ derived antagonist25 no remarkable reduction of PQS levels was observed 
(data not shown). We assumed that the autoinductive effect of high intrinsic PQS levels ranging 
from 30 to 60 µM in the culture supernatant might compensate the antagonistic activity of 37. 
Therefore, we further investigated the effect of compound 37 on HHQ formation in the absence 
of PQS.17 We employed a P. aeruginosa isogenic strain lacking PqsH, a monooxygenase 
catalyzing the conversion of HHQ to PQS.19,20 Interestingly, we observed a reduction of 
extracellular HHQ (42±0% at 250 µM of 37). The level of HQNO (2-heptyl-4-hydroxy quinoline-
N-oxide), another alkylquinolone under the control of PqsR,20 was also clearly decreased 
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(43±3% at 250 µM of 37). The reduction of both alkylquinolones demonstrates that PqsR 
antagonists block the QS system in P. aeruginosa. Future experiments will extend the fragment 
structure aiming at antagonists with improved affinity. Such compounds would hopefully disrupt 
the self-inductive effect of high intrinsic PQS levels and potentially affect biofilm shape in wild-
type P. aeruginosa. 
The biological effects on the major virulence factor pyocyanin were examined subsequently. 
Pyocyanin is a redox-active secondary metabolite released by P. aeruginosa that plays a critical 
role during acute infections by provoking oxidative stress and inflammatory responses in host 
cell tissue.60 Biological studies indicate a connection between the PQS system and pyocyanin 
production,18,61 supported by the fact that a PqsR deficient mutant (pqsR-) is incapable to 
produce pyocyanin.20,62 Analogously, the HHQ derived antagonist 125 and the hydroxamic acid 
3
29
 diminish pyocyanin in P. aeruginosa. The PqsR antagonist 37 likewise clearly reduced the 
pyocyanin level (46±9% at 250 µM). The weaker antagonists 38 and 41 showed a moderate or 
only little reduction, respectively (32±3% at 250 µM of 38; 18±3% at 250 µM of 41). In contrast 
the inactive compound 40 showed no effect. The correlation of these data with the antagonistic 
properties indicates that the reduction of pyocyanin is caused by PqsR antagonism. A growth 
curve of P. aeruginosa incubated with 37 confirmed that the observed effects are not due to an 
antibacterial activity of the compound (SI, Figure S6). While in the absence of functional PqsR 
(pqsR-) no significant levels of pyocyanin and PQS were detected,20 our results show that in the 
presence of weaker antagonists pyocyanin production is more sensitive to PqsR antagonism 
than PQS biosynthesis. This finding might facilitate a more detailed understanding of the 
underlying mechanisms. Overall these results demonstrate that the interference with the PQS 
system by the oxadiazole type antagonists is a suitable approach to reduce P. aeruginosa 
pathogenicity. 
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CONCLUSION 
Considering the hydrophobic character of the natural effectors HHQ and PQS, the LBD of PqsR 
is expected to be a mainly lipophilic pocket. This renders the transcriptional regulator PqsR a 
quite challenging drug target. Nevertheless, we identified chemically diverse PqsR ligands by 
employing an SPR fragment screening. The thermodynamic profiles of the top five hit 
compounds were evaluated using ITC methodology. The discovered hits showed enthalpy 
driven binding and excellent LEs. Furthermore, the functional properties of the best fragments 
were analyzed in a ß-galactosidase reporter gene assay as an additional guidepost for hit 
selection. The thiadiazole-2-amine derivative 5 displayed a mixed agonistic/antagonistic profile 
and was chosen as starting point for structural modification. A functionality-guided optimization 
process afforded the pure antagonist 37 showing improved affinity and potency with consistently 
high LE (5, LE = 0.57 kcal/mol vs. 37, LE = 0.50 kcal/mol). In contrast to the HHQ derived 
antagonists (for example 1, Figure 1), 37 showed a more favorable logP and higher aqueous 
solubility. The 2-amino-1,3,4-oxadiazole moiety present in the optimized ligand 37 has not been 
reported as a chelating agent for metal ions, contrary to the hydroxamic acid motif of fragment 3 
(Figure 1). Furthermore, an in-silico toxicology prediction (Derek Nexus, Version 
2.0.3.201206121715) of compound 37 revealed no safety issues.63 Taken together these data 
emphasize the high potential of the optimized fragment 37. 
To shed light on the binding mode of different fragment classes, site-directed mutagenesis in 
combination with thermodynamic analysis was applied. The oxadiazole 37 and the 
carboxamides 2 and 4 bind competitively to PqsR but do not cover exactly the same space in 
the LBD. This provides the potential for hit-to-lead optimization using fragment growing 
strategies. Additionally, structural modifications of 37 together with calorimetric evaluation were 
performed to evaluate the relative importance of the functional groups in order to guide future 
optimization strategies. Furthermore, compound 37 is able to reduce the virulence factor 
pyocyanin in wild-type P. aeruginosa without affecting bacterial growth. Thus, the identified 
PqsR antagonists represent an interesting starting point for the development of novel anti-
infectives. 
Future experiments will aim at merging the best features of the different fragments to develop 
drug-like molecules which may provide novel therapeutic options to counter the burden of P. 
aeruginosa infections.  
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EXPERIMENTAL SECTION 
 
Surface Plasmon Resonance. SPR binding studies were performed using a Biacore T100 
instrument optical biosensor (GE Healthcare). CSIRO fragment library collection consisted of 
720 compounds with a molecular weight range of 100 to 350 Da. The expression, purification 
and minimal biotinylation of H6SUMO-PqsR
C87 as well as the immobilization onto the 
streptavidin chip surface and is described in detail in the Supporting Information.  
 
SPR Library Screening. 10 mM DMSO stock solutions of compounds were diluted in 1.05 x 
DMSO free screening buffer (52.5 mM HEPES, pH 7.4, 157.5 mM NaCl, 0.0525% Tween-20 
(v/v)) to 500 µM. Final ligand concentrations (100 μM) were achieved by diluting 1:5 (v/v) in the 
instrument running buffer (50 mM HEPES, pH 7.4, 150 mM NaCl, 0.05% Tween-20 (v/v) and 
5% DMSO (v/v)). Two separate fragment screens were performed each time screening 360 
fragments against protein targets immobilized on chips I and II. Fragment solutions (100 µM) 
were injected over the protein sensor surface for 30 s at 60 µL/min at 4 °C. After every 120 
injections, a positive control compound (PQS in the first 360 compound screen and fragment 4 
in the second screen) was injected for control binding purposes. Regeneration of the surfaces 
between subsequent binding experiments was achieved by washing the surface at 60 µL/min 
for 30 s with the instrument running buffer as well as by using a “carry-over injection” of running 
buffer at 40 µL/min for further 30 s. To determine binding affinity, candidate hit fragments were 
analyzed using dosage experiments. Fresh 100 mM DMSO fragment solutions were diluted 
directly into instrument running buffer to a final concentration of 81 µM and then diluted 3-fold 
down to 1 µM aiming for a 5-point concentration series range. Each compound was injected for 
30 s association- and 60 s dissociation time at 20 °C at a constant flow rate of 60 µL/min. 
Scrubber 2 (www.biologic.com.au) and Microsoft Excel software packages were utilized for data 
processing and analysis. Using Scrubber software, SPR signals were referenced against the 
blank surface (streptavidin + D-biotin) and further corrected for DMSO refractive index change 
as previously described.64 A normalization scheme of Giannetti et al.43 was applied to the 
processed data based on the maximal binding response (Rmax) that has been determined from 
experiments with the control compound (initially PQS and later fragment 4). For the initial 
ranking of the best hits, the KD values were estimated using equation derived from the Langmuir 
adsorption isotherm (1): 
 
    
      
 
    (1) 
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Rmax, R, and C correspond to the normalized saturation response of the compound, the 
normalized response of the test compound, and the concentration of the test solution, 
respectively.  
To determine binding affinities (KD) from dosage experiments, binding responses at equilibrium 
were fit to a 1:1 steady state affinity model available within Scrubber. As described above, 
normalized saturation response (Rmax), derived using reference compound(s), was applied to 
response curves obtained with fragment hits at non-saturating concentration. Equilibrium 
isotherm containing the assumed Rmax was used to determine KD values (SI, Figure S1). 
Isothermal Titration Calorimetry ITC titrations were carried out as previously reported29 and a 
detailed protocol as well as representative titration curves are included in the Supporting 
Information.  
INPHARMA NMR Experiments To detect interligand NOEs, 10 M H6SUMO-PqsR
C87 was 
mixed with 500 M 2 and 400 M 37 in PBS buffer (50 mM potassium phosphate, pH 7.4, 150 
mM NaCl, 5% DMSO-d6 (v/v), 5 % D2O (v/v)). Spectra were acquired at 25 °C on a 700 MHz 
Bruker Avance III spectrometer equipped with a cryoprobe. Two-dimensional NOESY spectra 
were recorded with a mixing time of 600 ms, 16 scans for each of 400 complex points in the 
indirect dimension and 512 complex points in the direct dimension, a sweep width of 9 ppm and 
a recycle delay of 1.5 sec. Dephasing of water signals was achieved by a WATERGATE 
sequence. A control experiment under identical conditions without H6SUMO-PqsR
C87 was 
carried out. Data were processed using Bruker TOPSPIN 3.1 software using squared sine bell 
functions and zero filling to 2048 and 1024 complex points in the direct and indirect dimension, 
respectively, for apodization. 
Reporter Gene Assay in E. coli. The ability of the compounds to either stimulate or antagonize 
the PqsR-dependent transcription was analysed as previously described
25
 using a β-
galactosidase reporter gene assay in E. coli expressing PqsR with some modifications to enable 
a higher throughput.65 Briefly, a culture of E. coli DH5α cells containing the plasmid pEAL08-248 
which encodes PqsR under the control of the tac promoter and the β-galactosidase reporter 
gene lacZ controlled by the pqsA promoter were co incubated with test compound. Antagonistic 
effects of compounds were assayed in the presence of 50 nM PQS. After incubation 
galactosidase activity was measured photometrically using POLARstar Omega (BMG Labtech) 
and expressed as ratio of controls. For the determination of EC50 value, compounds were tested 
at least in six different concentrations. The given data represent mean of at least two 
experiments with n = 4. The log (inhibitor) vs. response model (Prism 5.0) was applied for 
nonlinear regression and determination of EC50-values. 
Reporter Gene Assay in P. aeruginosa. In order to evaluate the antagonistic properties of 
compound 37, the PqsR-dependent transcription was evaluated as previously described25 using 
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a β-galactosidase reporter gene assay system48 in P. aeruginosa. In brief, a P. aeruginosa 
PA14 strain carrying a nonfunctional pqsA gene was used to eliminate intrinsic HHQ and PQS 
production. A culture of P.aeruginosa PA14ΔpqsA cells containing the plasmid pEAL08-248 were 
co incubated with 37 and 50 nM PQS. After incubation galactosidase activity was measured 
photometrically using POLARstar Omega (BMG Labtech) and expressed as ratio of controls. 
For the determination of EC50 value, 37 was tested at nine different concentrations. The given 
data represent mean of two experiments with n = 4. The log (inhibitor) vs. response model 
(Prism 5.0) was applied for nonlinear regression and determination of EC50-values. 
Pyocyanin Assay. Pyocyanin produced by P. aeruginosa PA14 was determined as described 
previously66 according to the method of Essar et al.67 In short, cultures inoculated with a starting 
OD600 of 0.02 were grown in the presence of inhibitors or DMSO as a control in PPGAS medium 
at 37 °C, 200 rpm and a humidity of 75% for 16 h. For pyocyanin determination, cultures were 
extracted with chloroform and re-extracted with 0.2 M HCl. The OD520 was determined using 
FLUOstar Omega (BMG Labtech) and normalized to cell growth measured as OD600. For each 
sample, cultivation and extraction were performed in triplicates. 
Determination of Extracellular HHQ and HQNO Levels. Extracellular levels of HHQ and 
HQNO were determined according to the methods of Lépine et al.68,69 with some modifications: 
Briefly, cultures of P. aeruginosa PA14ΔpqsH mutant were inoculated with a starting OD600 of 
0.02 and grown in LB medium in the presence of DMSO as a control or DMSO solutions of 
inhibitors at 37 °C, 200 rpm and a humidity of 75 % for 17 h. For HHQ and HQNO analysis, 500 
µl of bacterial cultures were supplemented with 50 µL of a 10 µM methanolic solution of the 
internal standard (IS) 5,6,7,8-tetradeutero-2-heptyl-4(1H)-quinolone (HHQ-d4) and extracted 
with 1 mL of ethyl acetate by vigorous shaking. After centrifugation (14, 000 rpm, 12 min), 400 
µL of the organic phase were evaporated to dryness in LC glass vials and dissolved in 
methanol. For each sample, cultivation and extraction were performed in triplicates. UHPLC-
MS/MS analysis was performed as described in detail by Storz et al.
67
 The following ions were 
monitored (mother ion [m/z], product ion [m/z], scan time [s], scan width [m/z], collision energy 
[V], tube lens offset [V]): HHQ: 244, 159, 0.5, 0.01, 30, 106; HQNO: 260, 159, 0.1, 0.01, 25, 88; 
HHQ-d4 (IS): 248, 163, 0.1, 0.01, 32, 113. Xcalibur software was used for data acquisition and 
quantification with the use of a calibration curve relative to the area of the IS.  
 
Chemical and Analytical Methods. 1H and 13C NMR spectra were recorded on a Bruker DRX-
500 instrument. Chemical shifts are given in parts per million (ppm), and referenced against the 
residual solvent peak. Coupling constants (J) are given in hertz. Purity control of final 
compounds was carried out using a SpectraSystems-MSQ LCMS system (Thermo Fisher 
Scientific) consisting of a pump, an autosampler, VWD detector and a ESI quadrupole mass 
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spectrometer by determination of the relative peak area in the UV trace. Purities were greater 
than 95%.  Mass spectrometry was performed on an MSQ electro spray mass spectrometer 
(Thermo Fisher Scientific). High resolution mass spectra were recorded on a maXis 4G hr-ToF 
mass spectrometer (Bruker Daltonics). Reagents were used as obtained from commercial 
suppliers without further purification. Procedures were not optimized regarding yield. Microwave 
assisted synthesis was carried out in a Discover microwave synthesis system (CEM). Column 
chromatography was performed using the automated flash chromatography system Combiflash 
Companion (Teledyne Isco) equipped with RediSepRf silica columns. Final products were dried 
under reduced pressure at 40 °C or in high vacuum. Melting points were determined using the 
melting point apparatus SMP3 (Stuart Scientific) and are uncorrected.  
Screening hits 4-8 were obtained from the CSIRO fragment library and used for biological 
studies. 5 was resynthesized as described below. 2 was purchased from Alfa Aesar; 9, 34 and 
35 were purchased from Sigma Aldrich. 
Preparation of Thiodiazole-2-amines (General Procedure 1)33 Benzoic acid (1 mmol) and 
hydrazinecarbothioamide (1 mmol) were filled into a sealed reaction vial. Phosphorus 
oxychloride (4 mmol) was added while cooling on an ice bath. Afterwards, the mixture was 
heated to 80 °C for 2.5 h in a metal block. Built up pressure was released every hour. The 
reaction mixture was poured into water at 0 °C and stirred vigorously for 30 min. The mixture 
was alkalized using a 10 M solution of KOH. The resulting suspension was extracted with ethyl 
acetate (3 times). The combined organic layers were washed with brine, dried over MgSO4, and 
concentrated to yield the expected 5-phenyl-[1,3,4]-thiadiazole-2-amine. 
Preparation of benzoylthiosemicarbazides (General Procedure 2)34 
Hydrazinecarbothioamide (3 mmol) and THF (5 ml) were filled into a three necked round bottom 
flask. Benzoyl chloride (1 mmol) was added through a dropping funnel at 0 °C (ice-bath). The 
mixture was stirred at RT under nitrogen atmosphere for 24 h. The mixture was quenched by 
the addition of water and alkalized using a saturated aqueous solution of NaHCO3. Afterwards, 
THF was evaporated under reduced pressure until precipitation of a solid. The suspension was 
filtered and the resulting cake was washed with water to afford the expected 
benzoylthiosemicarbazide. 
Preparation of Oxadiazole-2-amines (General Procedure 3)34 Benzoylthiosemicarbazide (1 
mmol) was filled into a three necked flask and suspended in IPA (7 ml). The suspension was 
mixed with a solution of potassium iodide (0.3 mmol) in water (0.5 mL). The reaction was cooled 
to 0 °C on an ice-bath and a 5 M solution of NaOH (1.5 mmol) was added. 
Dibromodimethylhydantoine (0.75 mmol) dissolved in ACN (3 ml) was added through a 
dropping funnel over 1 h while maintaining the temperature below 10 °C. Afterwards, the 
reaction was aged for 1 h below 10 °C. The reaction mixture was quenched using NaHSO3 sat. 
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(0.25 mL) and water was added. The pH was adjusted to >12 using a saturated solution of 
NaHCO3. The suspension was filtered and low boiling solvents were removed from the filtrate 
under reduced pressure to give a precipitate. The suspension was filtered and the cake rinsed 
with water and IPA to give the 5-phenyl-[1,3,4]-oxadiazole-2-amine. 
5-(4-Chlorophenyl)-1,3,4-thiadiazol-2-amine (5) was prepared according to General 
Procedure 1 starting from 4-chlorobenzoic acid (10, 1.00 g, 6.39 mmol) and 
hydrazinecarbothioamide (0.582 g, 6.39 mmol). The obtained solid was recrystallized from 
ethanol to give the pure product as white needles (0.51 g, 2.44 mmol, 38% yield).  1H NMR (500 
MHz, DMSO-d6) δ ppm 7.47 (s, 2 H), 7.50 - 7.55 (m, 2 H), 7.73 - 7.79 (m, 2 H);
 13C NMR (126 
MHz, DMSO-d6) δ ppm 127.88 (2 C), 129.13 (2 C), 129.82, 133.92, 155.08, 168.81; mp 231-
232 °C; LC-MS (ESI): m/z: 252.88 (M+H+CH3CN)+; 98%  
5-(3-Chlorophenyl)-1,3,4-thiadiazol-2-amine (31)35 2-(3-
chlorobenzoyl)hydrazinecarbothiamide (23, 0.50 g, 2.18 mmol) was dissolved in sulfuric acid (3 
ml). The mixture was stirred for 2 h at RT. The reaction mixture was slowly poured into water 
and basified using ammonia solution 20% while cooling on an ice bath. The resulting 
suspension was filtered and the resulting cake was washed with water to give the pure product 
as a white solid (0.37 g, 1.75 mmol, 80% yield). 1H NMR (500 MHz, DMSO-d6) δ ppm 7.47 - 
7.50 (m, 2 H), 7.52 (s, 2 H), 7.66 - 7.72 (m, 1 H), 7.77 - 7.81 (m, 1 H); 13C NMR (126 MHz, 
DMSO-d6) δ ppm 125.07, 125.39, 129.23, 131.04, 132.87, 133.78, 154.72, 169.05; mp 214-
218°C; MS (ESI): m/z: 212.00 (M+H)+, 252.82 (M+H+CH3CN)
+; 96%. 
5-(3-Chlorophenyl)-1,3,4-oxadiazol-2-amine (32) was prepared according to General 
Procedure 3 starting from 2-(3-(chloro)benzoyl)hydrazinecarbothioamide (23, 0.500 g, 2.18 
mmol). The titled product was obtained as yellow solid (0.199 g, 1.02 mmol, 47% yield). 1H 
NMR (500 MHz, DMSO-d6) δ ppm 7.34 (s, 2 H) 7.56 - 7.58 (m, 2 H) 7.71 - 7.77 (m, 2 H); 
13
C 
NMR (126 MHz, DMSO-d6) δ ppm 123.60, 124.43, 126.23, 130.10, 131.31, 133.81, 156.12, 
164.08; mp 251-255°C; MS (ESI): m/z: 236.81 (M+H+CH3CN)
+ ; 95%. 
5-(2-Chlorophenyl)-1,3,4-thiadiazol-2-amine (33) was prepared according to General 
Procedure 1 starting from 2-chlorobenzoic acid (12, 1.00 g, 6.39 mmol) and 
hydrazinecarbothioamide (0.582 g, 6.39 mmol). The obtained solid was adsorbed on silica gel 
and purified by flash-chromatography using a gradient of hexane/ethyl acetate (7:3) to ethyl 
acetate to give the expected product as a white solid (0.482 g, 2.28 mmol, 36% yield). 1H NMR 
(500 MHz, DMSO-d6) δ ppm 7.39 - 7.52 (m, 4 H), 7.53 - 7.66 (m, 1 H), 7.92 - 8.04 (m, 1 H); 
13
C 
NMR (126 MHz, DMSO-d6) δ ppm 127.65, 129.57, 130.27, 130.41, 130.43, 130.90, 151.58, 
170.10; mp 191-192 °C; MS (ESI): m/z 211.99 (M+H)+, 252.89 (M+H+CH3CN)
+; 98%. 
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5-(3-Bromophenyl)-1,3,4-oxadiazol-2-amine (36) was prepared according to General 
Procedure 3 starting from 2-(3-bromobenzoyl)hydrazinecarbothioamide (24, 0.506 g, 1.85 
mmol). The crude product was triturated with DCM/MeOH and filtered to afford a yellow solid as 
the pure product (0.225 g, 0.890 mmol, 48% yield) 1H NMR (500 MHz, DMSO-d6) δ ppm 7.34 
(br. s, 2 H), 7.49 (t, J=7.9 Hz, 1 H), 7.71 (ddd, J=8.0, 2.8, 0.9 Hz, 1 H), 7.78 (ddd, J=7.9, 2.5, 0.9 
Hz, 1 H), 7.90 (t, J=1.6 Hz, 1 H); 13C NMR (126 MHz, DMSO-d6) δ ppm 122.21, 123.94, 126.45, 
127.29, 131.50, 132.97, 155.98, 164.08; mp 240-243°C; MS (ESI): m/z 239.84 (M+H)+, 280.87 
(M+H+CH3CN)
+; 98%. 
5-(3-(Trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-amine (37) was prepared according to 
General Procedure 3 starting from 2-(3-(trifluoromethyl)benzoyl)hydrazinecarbothioamide (25, 
2.00 g, 7.60 mmol). The precipitate was triturated with ethyl acetate and filtered. The resulting 
solid was purified by flash chromatography on silica gel using DCM:MeOH (98:2 to 97:3) to 
afford the product as a white solid (0.741 g, 3.23 mmol, 43% yield). 1H NMR (500 MHz, DMSO-
d6) δ ppm 7.39 (s, 2 H), 7.78 (t, J=7.9 Hz, 1 H), 7.87 (d, J=7.9 Hz, 1 H), 8.01 (s, 1 H), 8.08 (d, 
J=7.9 Hz, 1 H); 
13
C NMR (126 MHz, DMSO-d6) δ ppm 121.16, 123.70 (d, 
1
J(C,F)=270.4 Hz, 1 
C), 125.35, 126.73 (q, 3J(C,F)=3.7 Hz, 1 C), 128.80, 129.79 (q, 2J(C,F)=31.2 Hz, 1 C), 130.67, 
156.17, 164.19; mp 219-224 °C; MS (ESI): m/z 229.95 (M+H) +, 270.88 (M+H+CH3CN)
+; 99%. 
3-(5-Amino-1,3,4-oxadiazol-2-yl)benzonitrile (38) was prepared according to General 
Procedure 3 starting from 2-(3-cyanobenzoyl)hydrazinecarbothioamide (26, 0.500 g, 2.27 
mmol). The crude product was purified by flash-chromatography on silica gel using ethyl 
acetate:THF (9:1). The resulting yellow solid was triturated with ethyl acetate and a few drops of 
MeOH. The suspension was filtered to give the product as yellow solid (80 mg, 0.430 mmol, 
19% yield). 
1
H NMR (500 MHz, DMSO-d6) δ ppm 7.40 (s, 2 H), 7.74 (t, J=7.9 Hz, 1 H), 7.96 (d, 
J=7.9 Hz, 1 H), 8.08 (d, J=7.9 Hz, 1 H), 8.13 (s, 1 H); 13C NMR (126 MHz, DMSO-d6) δ ppm 
112.43, 117.97, 125.52, 128.26, 129.36, 130.59, 133.65, 155.82, 164.23; mp 242-244; MS 
(ESI): m/z 227.94 (M+H+CH3CN)
+
; 99%. 
5-(3-(Trifluoromethoxy)phenyl)-1,3,4-oxadiazol-2-amine (39) was prepared according to 
General Procedure 3 starting from 2-(3-(trifluoromethoxy)benzoyl)hydrazinecarbothioamide (27, 
0.500 g, 1.79 mmol). The product was obtained as yellow solid (90 mg, 0.349 mmol, 20% yield). 
1H NMR (500 MHz, DMSO-d6) δ ppm 7.37 (s, 2 H), 7.52 (d, J=8.2 Hz, 1 H), 7.63 - 7.71 (m, 2 H), 
7.81 (dt, J=7.8, 1.3 Hz, 1 H); 13C NMR (126 MHz, DMSO-d6) δ ppm 116.98, 121.01 
(t,1J(C,F)=257.50 Hz, 1 C), 122.72, 123.99, 126.38, 131.65, 148.68 (q, 3J(C,F)=1.80 Hz, 1 C), 
156.30, 164.30; mp 197-200°C; MS (ESI): m/z 286.87 (M+H+CH3CN)
+; 95%. 
5-(3-Methoxyphenyl)-1,3,4-oxadiazol-2-amine (40) was prepared according to General 
Procedure 3 starting from 2-(3-methoxybenzoyl)hydrazinecarbothioamide (28, 0.500 g, 2.22 
mmol). The crude product was purified by flash-chromatography using ethyl acetate to obtain 
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the pure product as a white solid (152 mg, 0.795 mmol, 36% yield). 
1
H NMR (500 MHz, DMSO-
d6) δ ppm 3.81 (s, 3 H), 7.07 (dd, J=8.20, 2.52 Hz, 1 H), 7.25 (s, 2 H), 7.29 (dd, J=2.52, 1.26 Hz, 
1 H), 7.37 (dt, J=7.80, 1.14 Hz, 1H), 7.44 (t, J=7.88 Hz, 1 H); 13C NMR (126 MHz, DMSO-d6) δ 
ppm 55.23, 109.83, 116.34, 117.33, 125.57, 130.48, 157.18, 159.53, 163.86; mp 192-195°C; 
MS (ESI): m/z 192.02 (M+H)+; 99%. 
5-(4-Tolyl)-1,3,4-oxadiazol-2-amine (41) was prepared according to General Procedure 3 
starting from 2-(3-(methyl)benzoyl)hydrazinecarbothioamide (29, 0.500 g, 2.39 mmol). The 
crude product was recrystallized from ethanol to obtaine the product as a pale yellow solid (86 
mg, 0.466 mmol, 20% yield). 1H NMR (500 MHz, DMSO-d6) δ ppm 2.37 (s, 3 H), 7.21 (s, 2 H), 
7.27 - 7.34 (m, 1 H), 7.41 (t, J=7.6 Hz, 1 H), 7.56 - 7.60 (m, 1 H), 7.60 - 7.62 (m, 1 H); 13C NMR 
(126 MHz, DMSO-d6) δ ppm 20.87, 122.19, 124.31, 125.39, 129.11, 130.99, 138.54, 157.37, 
163.78; mp 213-216 °C; MS (ESI): m/z 176.06 (M+H)
 +
, 217.07 (M+H+CH3CN)
+
; 96%. 
5-(3-(Tert-butyl)phenyl)-1,3,4-oxadiazol-2-amine (42) was prepared according to General 
Procedure 3 starting from 3-(tert-butyl)benzoyl) thiosemiamidecarbazide (30, 1.00 g, 3.98 
mmol). The quenched reaction mixture was extracted twice with ethyl acetate. The combined 
organic phases were washed with a saturated solution of NaHCO3 and brine. The organic layer 
was dried over MgSO4 and filtered. Heptane was added and ethyl acetate was evaporated to 
give a yellow suspension. The suspension was filtered and the cake washed with heptane/ethyl 
acetate to yield a white solid as the pure product (0.265 g, 1.22 mmol, 31% yield). 1H NMR (500 
MHz, DMSO-d6) δ ppm 1.31 (s, 9 H), 7.23 (s, 2 H), 7.45 (t, J=7.7 Hz, 1 H), 7.55 (d, J=7.9 Hz, 1 
H), 7.61 (d, J=7.6 Hz, 1 H), 7.79 (s, 1 H); 13C NMR (126 MHz, DMSO-d6) δ ppm 30.90 (3 C), 
34.48, 121.49, 122.36, 124.15, 127.48, 129.04, 151.60, 157.59, 163.80; mp 216-219°C; MS 
(ESI): m/z 218.12 (M+H)
+
, 259.09 (M+H+CH3CN)
+
; 96%. 
2-(3-(Trifluoromethyl)phenyl)-1,3,4-oxadiazole (47)
37
 A sealed reaction vial was charged with 
3-(trifluoromethyl)benzohydrazide (43, 0.400 g, 1.96 mmol) and triethyl orthoformate (4.00 mL, 
24.0 mmol). The mixture was heated under an argon atmosphere for 2 h at 160 °C. The 
reaction mixture was poured into a precooled saturated aqueous solution of Na2CO3 while 
stirring vigorously at 0 °C. The aqueous phase was extracted twice with ethyl acetate and the 
combined organic phases were washed with brine (2 times). The organic phase was dried over 
MgSO4 and concentrated. The resulting yellow oil was adsorbed on silica gel and purified by 
flash chromatography using hexane/ethyl acetate (95:5) to (8:2) to give a colorless oil, which 
crystallized in the fridge (0.262 g, 1.22 mmol, 62% yield). 1H NMR (500 MHz, DMSO-d6) δ ppm 
7.87 (t, J=7.9 Hz, 1 H), 8.00 - 8.04 (m, 1 H), 8.26 (s, 1 H), 8.30 - 8.34 (m, 1 H), 9.44 (s, 1 H); 13C 
NMR (126 MHz, DMSO-d6) δ ppm 123.6 (q, 
1
J(C,F)=272.2 Hz, 1 C), 123.0 (q, 3J(C,F)=3.7 Hz, 1 
C), 124.3, 128.5 (q, 3J(C,F)=3.7 Hz, 1 C), 130.1 (q, 2J(C,F)=32.1 Hz, 1 C), 130.7, 130.9, 155.0, 
162.6; mp 35°C; MS (ESI): m/z 255,91 (M+ H+CH3CN)
+; 97%. 
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2-Methyl-5-(3-(trifluoromethyl)phenyl)-1,3,4-oxadiazole (48)
37
 3-(Trifluoromethyl)- 
benzohydrazide (43, 0.500 g, 2.45 mmol) was filled into a sealed reaction vial. Triethyl 
orthoacetate (8.00 mL, 43.4 mmol) was added to give a clear solution. The solution was heated 
to 150 °C in a metal block over-night. The reaction mixture was poured into a precooled 
saturated solution of Na2CO3 while stirring vigorously at 0 °C. The water phase was extracted 
twice with ethyl acetate and the combined organic layers were washed with brine. The organic 
phase was dried over MgSO4 and concentrated to obtain a pale yellow oil. Scratching with a 
spatula afforded a white solid. The white solid was triturated with hexane and filtered. The 
resulting cake was washed with hexane to give the pure product as white crystals (0.230 g, 1.01 
mmol, 41% yield). 1H NMR (500 MHz, DMSO-d6) δ ppm 2.61 (s, 3 H), 7.84 (t, J=7.9 Hz, 1 H), 
7.99 (d, J=7.9 Hz, 1 H), 8.19 (s, 1 H), 8.26 (d, J=7.9 Hz, 1 H); 
13
C NMR (126 MHz, DMSO-d6) δ 
ppm 10.33, 123.58 (q, 1J(C,F)=273.1 Hz, 1 C), 128.19 (q, 3J(C,F)=3.7 Hz, 1 C), 130.06 (q, 
2J(C,F)=33.9, Hz, 1 C), 130.23, 130.83, 162.81, 164.49; mp 79-82°C; MS (ESI): m/z 228.96 
(M+H)+, 270.00 (M+H+CH3CN)
+. 
2-Methoxy-5-(3-(trifluoromethyl)phenyl)-1,3,4-oxadiazole (49)
36
 Methyl 2-(3-
(trifluoromethyl)benzoyl)hydrazinecarboxylate (44, 0.500 g, 1.91 mmol) and Burgess reagent 
(0.680 g, 2.86 mmol) were dissolved in dry THF (9 mL) in a MW vial flushed with argon. The 
reaction mixture was heated in the MW for 2 min (dynamic heating 100W max power, 150 °C 
safe temperature). The reaction mixture was poured into a saturated aqueous solution of 
NaHCO3. The aqueous phase was extracted twice with ethyl acetate. The combined organic 
layers were percolated through a filter loaded with silica gel. The filtrate was concentrated to 
give a yellow oil. The oil was triturated with diethyl ether to afford a suspension. The solid was 
removed by filtration. The filtrate was adsorbed on silica gel and purified by flash 
chromatography with DCM:hexane (1:1) to yield the product as colorless needles (167 mg, 
0.684 mmol, 36% yield). 
1
H NMR (500 MHz, DMSO-d6) δ ppm 4.20 (s, 3 H), 7.82 (t, J=7.9 Hz, 1 
H), 7.96 (d, J=7.9 Hz, 1 H), 8.11 (s, 1 H), 8.17 (d, J=7.9 Hz, 1 H); 13C NMR (126 MHz, DMSO-
d6) δ ppm 59.88, 121.94 (q, 
3J(C,F)=3.7 Hz, 1 C), 123.58 (d, 1J(C,F)=272.2 Hz, 1 C), 124.64, 
127.89 (q, 3J(C,F)=3.7 Hz, 1 C), 129.61, 130.01 (d, 2J(C,F)=32.1 Hz, 1 C), 130.75, 158.64, 
166.11; mp 42-43 °C; HRMS: m/z calcd 245.0532 (M+H)+ found 245.0557. 
2-(Trifluoromethyl)-5-(3-(trifluoromethyl)phenyl)-1,3,4-oxadiazole (50)36 N'-(2,2,2-
trifluoroacetyl)-3-(trifluoromethyl)benzohydrazide (45, 0.500 g, 1.66 mmol) and Burgess reagent 
(0.595 g, 2.50 mmol) were dissolved in dry THF (9 mL) in a MW vial flushed with argon. The 
reaction mixture was heated in the MW for 2 min (dynamic heating 100W max power, 150 °C 
safe temperature). The reaction mixture was poured into a saturated aqueous solution of 
NaHCO3. The aqueous phase was extracted twice with ethyl acetate. The combined organic 
layers were percolated through a filter loaded with silica gel. The filtrate was concentrated to 
give a yellow oil. The oil was triturated with ethyl acetate and DCM. The resulting suspension 
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was cooled in the fridge and filtered. The filtrate was adsorbed on silica gel and purified by flash 
chromatography using a gradient of hexane/ethyl acetate (95:5) to (70:30) to yield a yellow oil. 
The oil crystallized in the fridge to give the pure product as yellow needles (205 mg, 0.730 
mmol, 43% yield). 1H NMR (500 MHz, DMSO-d6) δ ppm 7.91 (t, J=7.9 Hz, 1 H), 8.10 (d, J=7.9 
Hz, 1 H), 8.31 (s, 1 H), 8.39 (d, J=7.9 Hz, 1 H); 13C NMR (126 MHz, DMSO-d6) δ ppm 116.14 (d, 
1J(C,F)=272.2 Hz, 1 C), 123.45 (d, 1J(C,F)=271.3 Hz, 1 C), 123.26, 123.71 (q, 3J(C,F)=3.7 Hz, 1 
C), 129.56 (q, 3J(C,F)=3.7 Hz, 1 C), 130.20 (q, 2J(C,F)=32.1 Hz, 1 C), 131.05, 131.40, 154.33 
(d, 2J(C,F)=44.0 Hz, 1 C), 164.92; mp 25 °C; MS (ESI): m/z not found (M+H)+, 99%; HRMS: m/z 
calcd 283.0300 (M+H)+ found 283.0313. 
N-methyl-5-(3-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-amine (51)40 N-methylhydrazine- 
carbothioamide (186 mg, 1.770 mmol) was dissolved in DCM (8 ml). 3-(trifluoromethyl)benzoyl 
chloride (17, 0.250 mL, 1.770 mmol) was added. The resulting suspension was stirred for 15 
min at RT, then EDC (0,500 mL, 3,81 mmol) was added to give a yellow solution. The solution 
was stirred for 24 h at RT. Another amount of EDC (0.25 ml, 1.905 mmol) was added and the 
solution stirred over night at 40 °C. The reaction mixture was added dropwise to an aqueous 
citric acid solution (10%). The aqueous layer was extracted with ethyl acetate (3 times). The 
combined ethyl acetate layers were washed with saturated aqueous NaHCO3 solution (2 times) 
and brine (2 times). The organic layer was concentrated to dryness and purified by flash-
chromatography (hexane/ethyl acetate 1:1) to give the product as white solid (60 mg, 0,247 
mmol, 14% yield). 1H NMR (500 MHz, DMSO-d6) δ ppm 2.88 (d, J=4.7 Hz, 3 H) 7.73 - 7.81 (m, 
2 H) 7.88 (dt, J=7.9, 0.8 Hz, 1 H) 8.03 (s, 1 H) 8.08 - 8.12 (m, 1 H); 13C NMR (126 MHz, DMSO-
d6) δ ppm 28.99, 121.22 (q, 3J(C,F)=3.7 Hz, 1 C), 124.78 (d, 1J(C,F)=272.2 Hz, 1 C), 122.62, 
125.28, 126.79 (q, 3J(C,F)=3.7 Hz, 1 C), 128.88, 129.92 (q, 2J(C,F)=33.9 Hz, 1 C), 130.65, 
156.46, 164.42; mp 190-192°C; MS (ESI): m/z 243,89 (M+H)+, 96% 
5-(3-(Trifluoromethyl)phenyl)-1,3,4-oxadiazole-2-carboxamide (52)39 Ethyl 5-(3-
(trifluoromethyl)phenyl)-1,3,4-oxadiazole-2-carboxylate (46, 0.800 g, 2.80 mmol) was dissolved 
in MeOH (6 mL) and diethyl ether (3 mL) in a sealed reaction vial. Ammonia in MeOH (4.00 mL, 
28.0 mmol) was added, the reaction mixture was agitated and aged at RT without stirring for 48 
h. The reaction mixture was concentrated to dryness to give the product as white solid (720 mg, 
2,80 mmol, 100 % yield). 1H NMR (500 MHz, DMSO-d6) δ ppm 7.90 (t, J=7.9 Hz, 1 H), 8.07 (d, 
J=7.9 Hz, 1 H), 8.30 (br. s, 1 H), 8.34 (s, 1 H), 8.39 (d, J=7.9 Hz, 1 H), 8.74 (br. s, 1 H); 13C 
NMR (126 MHz, DMSO-d6) δ ppm 123.57 (q, 
2
J(C,F)=272.2 Hz, 1 C), 123.45 (q, 3J(C,F)=4.6 
Hz, 1 C), 124.04, 128.98 (q, 3J(C,F)=4.6 Hz, 1 C), 130.12 (q, 2J(C,F)=32.9 Hz, 1 C), 130.92, 
130.99, 154.27, 158.83, 163.75; mp: 151-153 °C; MS (ESI): m/z not found (M+H)+, 98%; HRMS: 
calcd m/z 258.0484 (M+H)+ found 258.0494. 
5-(3-(Trifluoromethyl)phenyl)-1,3,4-oxadiazol-2(3H)-one (53)41 3-(Trifluoromethyl) 
benzohydrazide (43, 0.500 g, 2.45 mmol) was dissolved in DCM (25 mL) and triethylamine 
Chapter A 56 
 
 
(0.512 mL, 3.67 mmol). Carbonyldiimidazole (0.596 g, 3.67 mmol) was added under constant 
stirring. The reaction mixture was aged at RT for 30 min. The reaction mixture was washed with 
a 5% aqueous solution of citric acid (2 times) and twice with brine. The organic layer was dried 
over MgSO4, filtered and concentrated to give a white solid. The solid was triturated with 
DCM/hexane, filtered and the resulting cake was washed with DCM/hexane to afford the 
product as a white solid (0.206 g, 0.895 mmol, 37% yield). 1H NMR (500 MHz, DMSO-d6) δ ppm 
7.80 (t, J=7.9 Hz, 1 H), 7.94 (d, J=7.9 Hz, 1 H), 8.00 (s, 1 H), 8.08 (d, J=7.9 Hz, 1 H), 12.75 (br. 
s, 1 H);  13C NMR (126 MHz, CHLOROFORM-d) δ ppm 123.40 (q, 1J(C,F)=271.3 Hz, 1 C), 
122.74 (q, 3J(C,F)=3.7 Hz, 1 C), 124.61, 128.29 (q, 3J(C,F)=3.7 Hz, 1 C), 128.84, 129.74, 
131.81 (q, 2J(C,F)=33.0 Hz, 1 C), 154.09, 154.67; mp 112-123 °C; HRMS: m/z calcd 231.0375 
found 231.0380. 
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3.2 Chapter B: 
Flexible-Fragment-Growing Boosts Potency of Quorum 
Sensing Inhibitors against Pseudomonas aeruginosa 
virulence 
The coworkers listed below made the following experimental contributions to this chapter: 
Florian Witzgall: Performed PqsR crystallization experiments, built and refined PqsR 
models. 
Alexander Kiefer: Performed parts of the chemical synthesis work 
Benjamin Kirsch: Established and planed E. coli reporter gene assays 
Christine K. Maurer:  Established and planed alkylquinolone and pyocyanin assays 
Andreas Kany:  Performed parts of the ITC measurements 
Ningna Xu:  Performed parts of the PqsR crystallization experiments 
Carsten Börger: Performed parts of compound purification work and MS analytics 
Martin Empting: Performed the in silico experiments 
 
INTRODUCTION 
Pseudomonas aeruginosa is an opportunistic Gram-negative pathogen. It provokes different 
acute and chronic infections especially in immune-compromised and hospitalized patients.1 
Alarmingly, the occurrence of multi-resistant and pan-resistant strains renders currently 
available antibiotics ineffective and leads to an urgent need for novel treatment options.2 P. 
aeruginosa employs an arsenal of virulence-associated factors that allow this pathogen to be 
effective in various host organisms.3 The release of many virulence factors is controlled and 
synchronized by a process called quorum sensing (QS).4 QS allows bacteria to collectively 
regulate gene expression depending on their population density. Small diffusible molecules 
(auto-inducers) are secreted from the cells and once a certain threshold concentration has been 
achieved, transcriptional regulators are activated. This leads to a population-wide alteration of 
gene expression, resulting in concerted phenotypic actions.
5
 This ability is essential during the 
course of acute and chronic infections6 as well as for lowered antibiotic susceptibility7. 
Respective cell-to-cell communication in P. aeruginosa is mainly based on three distinct QS 
circuitries. The las8 and the rhl9 QS systems use different N-acylated homoserine lactones 
(AHLs) as signaling molecules10. AHLs-based communication is most widespread ‘language’ 
found in Gram-negative bacteria.11 On the contrary, the third system called pqs12 employs 4-
hydroxy-2-alkylquinolones (HAQs)13,14 and occurs only in Pseudomonas and Burkholderia 
strains (Figure 1).15 The signaling molecules PQS (Pseudomonas Quinolone Signal; 3,4-
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dihydroxy-2-heptylquinoline) and its precursor HHQ (4-hydroxy-2-heptylquinoline) activate the 
receptor. 
 
Figure 1: Schematic representation of the PQS quorum sensing system. 
Our group has previously obtained the first PqsR antagonists by chemical modification of the 
natural ligand HHQ.21 These compounds were further improved regarding their efficacy in P. 
aeruginosa.22,23 In a similar approach, antagonists containing a quinazolinone scaffold were 
developed and helped resolving the crystal structure of the ligand binding domain of PqsR.24 
Very recently, an HTS campaign led to benzamide-benzimidazole antagonists showing efficacy 
in different mouse models, which emphasizes the in vivo relevance of targeting PqsR in 
infectious diseases.25 To overcome the poor physico-chemical profiles of the HHQ-derived 
antagonists, we initiated two fragment screenings using surface plasmon resonance (SPR) 
technology.
26,27
 These approaches led to the hydroxamic acid 1 and the 2-amino-oxadiazole 2 
(Table 1). First attempts to enlarge these structures have not been successful so far or led to 
compounds lacking activity in P. aeruginosa (data not shown). 
Here, we applied enthalpic efficiency28,29 as a metric to select screening hit 3 as alternative 
starting point. During initial fragment–growing efforts, we were successful in stepwisely 
enlarging the fragment structure. Notably, we determined the crystal structure of a ligand-
receptor complex. This enabled us to devise an elegant structure-guided optimization strategy 
considering the binding pose of the natural ligand HHQ. The introduction of a flexible linker 
finally led to compounds with nanomolar antagonistic activities in an E. coli reporter gene assay 
and complete pyocyanin inhibition in P. aeruginosa. 
 
RESULTS AND DISCUSSION 
Selection of an optimal starting point. Selecting the best starting point is a pivotal decision in 
the early stage of a drug discovery project. In previous projects, ligand efficiency30 (LE) was 
used as major criterion for hit selection.27 The LE values represent the mean binding 
contribution per heavy atom (LE=∆G/N) allowing to compare hits of different sizes.30 Taken into 
account that the ligand binding site of PqsR is highly lipophilic,24 the engineering of well-placed 
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hydrogen bonds will be a difficult task. Hence, an ideal screening hit should establish most 
effective non-covalent interactions. Enthalpic contribution (∆H) is a convenient indicator for the 
establishment and the breaking of specific interactions during the formation of the protein-ligand 
complex.28,29 In a simple model, ∆H describes the sum of bond breaks between solvent and 
ligand and on the other hand bond formation between ligand and protein.28 Hence, enthalpic 
efficiency (EE) was used as guideline to derive an alternative starting point.28 EE normalizes the 
enthalpic contribution for the heavy atom count (EE= ∆H/N). Hence, this concept allows 
comparing ligands of different sizes.  
During two previously reported fragment optimization approaches, antagonists 127 and 226 
(Table 1) were discovered. The thermodynamic profiles of these optimized fragments were 
compared to the best screening hits derived from previously reported SPR screenings.26,27 
Initially, compound 3 was ranked lower due to its lower affinity, even if it showed strikingly better 
EE and LE values (Table 1). In the light of these considerations, fragment 3 was evaluated as a 
promising alternative starting point. 
Table 1: Thermodynamic profiling of fragment-sized PqsR ligands guiding the selection of the 
optimal starting point for further compound development. 
 
 
 
 
 
 
ITC titrations were performed at 298 K. Data represent mean ± SD from at least two 
independent experiments; aEE = -ΔH/(heavy atom count); bLE = –ΔG/(heavy atom count).cno 
heat release detectable at solubility maximum. 
 
Chemistry. Compounds 3-8 (Table 1) were obtained from commercial suppliers. The synthesis 
to access the key intermediate 4e is outlined in Scheme 1. The de-novo construction of the 
2,4,6 substituted pyridine ring followed a modified protocol described by Adam et al.31 starting 
with the acetylation of ethyl-3-amino-4,4,4-trifluorocrotonate with ethyl-malonyl-chloride. Ring 
closing was achieved using potassium tert-butoxide to obtain 4a. Hydrolysis and 
Comp KD (ITC) 
[µM] 
ΔG 
[kcal mol
-1
] 
ΔH 
[kcal mol
-1
] 
-TΔS 
[kcal mol
-1
] 
EE
a
 
[kcal mol
-1
] 
LE
b
 
[kcal mol
-1
] 
1 4.1 ± 0.6 -7.4±0.1 -8.9±0.2 1.5±0.3 0.63 0.53 
2 1.3±0.3 -8.0±0.1 -8.5±0.5 0.4±0.6 0.53 0.50 
3 10.0±1.3 -6.8±0.1 -9.3±0.4 2.5±0.4 1.17 0.85 
4 > 50
c
 - - - - - 
5 21.3±3.4 -6.4±0.1 -5.8±0.1 -0.6±0.2 0.72 0.80 
6 > 50
c
 - - - - - 
7 3.1±0.5  -7.5±0.1 -11.5±0.9 3.7±1 1.05 0.70 
8 > 50
a
 - - - - - 
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decarboxylation of 4a by hydrochloric acid and reflux provided 4b. 4b was reacted with triflic 
anhydride to give 4c, which was further converted into the corresponding 2,4-diiodo-pyridine 
(4d) by substitution with iodide after protonation of the pyridine with triflic acid. Both steps can 
also be performed as a one-pot procedure.32 For the introduction of the amino group in position 
two of the pyridine ring, aqueous ammonia and copper/phenanthroline as catalyst were applied, 
which yielded compound 4e in 65% isolated yield, while the reaction provided a 84:16 
regioselectivity for the desired product. Additionally, the protected precursors 4f and 4g were 
synthesized by standard protocols.  
Scheme 1. Synthesis of key intermediates 
 
Reagents and Conditions: (a) Pyridine, DCM, RT; (b) potassium tert-butoxide, EtOH, 70°C to 
RT; (c) 6M HCl, RF; (d) Triflic anhydride, pyridine, acetonitrile 5°C to RT (e) KI, triflic acid, RT; 
(f) NH3aq, 1,10-phenanthroline, Cu2O, DMSO, 15°C to RT (f) Boc anhydride, Et3N, DMAP, t-
BuOH; 35°C (g) hexane-2,5-dione, pTsOH, toluene, RF.  
Key building block 4e was suitable for palladium- and copper-catalyzed coupling reactions as 
shown in Scheme 2. 4e and 4-fluorophenylboronic acid were reacted under standard Suzuki 
coupling conditions using Pd(dppf)Cl2 as catalyst to obtain 9. 4e and cyclopropylacetylene were 
coupled by modified Sonogashira coupling protocol33 using a combination of Pd(PPh3)2Cl2 and 
TBAF to give 10. The introduction of the particular amines was achieved using Buchwald-
Hartwig conditions. 2-amino pyridines are known to be challenging substrates for most 
palladium-catalyst reactions; hence various protocols had to be tested. However, the procedure 
of Marion et al.34 using a Pd NHC catalyst was the only one which allowed access to amines 11-
14 and 17,18. Compound 22 was synthesized via a copper-catalyzed amination reaction.35  
As outlined in Scheme 3, the benzyl alcohol was attached to 4g by SNAr reaction using sodium 
hydride as base to give 15a. Deprotection was achieved using hydroxylamine hydrochloride and 
Chapter B 65 
 
 
triethylamine to afford 15.
36
 The synthesis of 16 required the use of the Boc protected precursor 
4f and modified Buchwald-Hartwig conditions. 16 was obtained following a standard 
deprotection procedure using TFA/DCM. Compounds 19-21 were not accessible with the Pd 
NHC catalyst mentioned before. The particular amines were introduced to 4d by a microwave 
assisted SNAr reaction (Scheme 4). Copper-mediated amination of the aryl iodines (19a-21a) 
led to final products (19-21). 
Scheme 2. Reactions applied for fragment growing 
  
Reagents and Conditions: (a) (4-fluorophenyl) boronic acid, Pd(dppf)Cl2, Na2CO3, DME/water 
1:1( v/v), 80°C; (b) cyclopropylacetylene, Pd(PPh3)2Cl2, TBAF (neat), 80°C; (c) amine, 
(SIPR)Pd(cinnamyl)Cl, KOtBu, DME, 80°C (d) 2-amino-N-(4-fluorophenyl)acetamide, CuI, 
dimethylaminoethanol, K3PO4, ACN/H2O(2/1), 90°C. 
Scheme 3. Synthesis of 15 and 16 
 
Reagents and Conditions: (a) (4-fluorphenyl)methanol, NaH, DMF, 50°C (b) hydroxylamine·HCl, 
Et3N, EtOH/H2O, RF (c) 4-fluorobenzamide, Cs2CO3; Pd2(dba)3, Xantphos, dioxane, 80°C (d) 
TFA, DCM, 0°C to RT. 
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Scheme 4. Route towards compounds 19-21 
 
Reagents and Conditions: (a) amine, Huenig’s base, ACN,MW 130°C; (b) NH3aq, 1,10-
phenanthroline, Cu2O, NMP/water RT.  
 
Fragment Growing. The combination of fragment-based screening and structure- based drug 
design strategies improves the chances to develop highly active lead molecules tremendously.37 
For 3 no crystal structure in complex with PqsR could be obtained. In order to derive a first SAR 
and to find a potential vector for growing the fragment, close commercial analogs (4-8) were 
investigated for their affinity to PqsR by ITC analysis (Table 1). This revealed that the position of 
the bromine substituent was fundamental for affinity. A bromo substituent in 3- and 5-position (4 
and 6) abolished the affinity, whereas in 4-position (5) the affinity was slightly decreased, which 
promoted the 4-position as potential growth vector. The exchange of the bromine for a sterically 
more demanding trifluoromethyl group in 6-position (7) led to a threefold increase of affinity 
caused by a gain in the enthalpic term. Candidate compounds were tested in an E. coli lacZ 
reporter gene system for their ability to antagonize or agonize PqsR.38 This heterologous 
system provides higher sensitivity and a clear-cut readout due to the absence of the entire pqs 
system present in P. aeruginosa. Our previous studies indicated that the system employing an 
E.coli laboratory strain poses a smaller biological barrier to small molecules for reaching the 
intracellular target.22 Hence, it facilitates a straightforward evaluation and comparison of PqsR 
antagonists regarding their on-target activities. Noteworthy, this assay system provides a more 
reliable estimation of cellular effectivity than cell-free affinity measurements. For example, the 
reported affinity of the native agonist PQS towards the ligand binding domain is rather low (KD = 
1.2±0.3 µM).39 In contrast, the PQS-mediated effect in E.coli-based assays and P.aeruginosa 
occurs at drastically lower concentrations (EC50(E.coli) = 6.3 nM
22, EC50(P.aeruginosa) = 24 nM). This 
discrepancy might be explained by the fact that functional PqsR is a homotetramer capable of 
binding to DNA and adopting different conformational states.40 This higher-ordered architecture 
of the bacterial target is not resembled in cell-free assays employing only a monomeric N-
terminally truncated protein.  
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Table 2: Antagonistic activity of PqsR antagonists
a 
 
 Structure IC50 [µM]
b
 clogD7.4
c 
7 H 33.6±8.2 1.7 
8 - n.i. 1.6 
9  n.i. 3.1 
10  29 % @ 100 µM 3.7 
11  2.6±0.8 3.5 
12  5.1±0.5 3.1 
13  5.9±0.9 3.6 
14  4.9±0.9 3.9 
15  18.5±7.3 3.6 
16  35±5 %@  µM 3.3 
17  42.8±19.5 4.2 
18  n.i. 4.3 
19  3.4±0.2 3.4 
20  0.14±0.04 3.8 
21  3.6±1.1 3.6 
22  0.49±0.17 2.8 
aAgonistic and antagonistic activities were evaluated in an E. coli reporter gene assay. 
bAntagonistic activity was determined in the presence of 50 nM PQS; n.i. = no inhibition 
(antagonistic activity ≤ 15%). IC50 represents the concentration
 of the half maximal antagonistic 
activity. ccalculated using ACD/Percepta 2015  
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Figure 2: Fragment optimization approach 
Taken together, these findings led to the decision to keep the scaffold 7 constant and to 
introduce further substituents into the 4-position (Figure 2). At first, rigid cyclopropyl-ethynyl (9) 
and 4-fluorophenyl (10) moieties were attached as molecular probes. Both modifications 
abolished the antagonistic activity almost completely. A closer look at the thermodynamic profile 
of 9 disclosed a significant loss in the enthalpic contribution (SI Table1: 7: ∆H = -11.5 kcal/mol 
vs. 9: ∆H = -3.7 kcal/mol) that is partially compensated by a gain in entropy. These findings 
suggest that the formation of specific interactions were hindered due to the attached moiety. 
Hence, we introduced a more flexible linker into the 4-position with the aim to regain specific 
interactions of the amino-pyridine headgroup. For this purpose, several compounds enlarged 
with different benzylamine moieties (11-13) were synthesized. Indeed, these compounds (11-
12) displayed up to 12-fold increase in the antagonistic activities. Overall, the 4-fluoro 
substituted compound 11 evolved as the most potent antagonist of this series. Notably, also the 
affinity measured by ITC was improved up to 5-fold. (SI, Table S1). Taken together, the 
following general concept was derived from these previous findings (Figure 2): the amino-
pyridine headgroup is connected via a flexible linker part to another aromatic moiety.  
We determined a co-crystal structure of 11 in complex with the ligand binding domain of PqsR 
(Figure 3a), clearly showing that the linker establishes an angled connection between the 2-
amino-pyridine headgroup, which occupies the space of the quinolone core of the natural 
ligands while the 4-fluorophenyl ring which points into the alkyl-chain pocket. Both aromatic 
systems of 11 are flanked by the alkyl side chains of isoleucine residues enabling CH-π 
interactions. The 2-amino moiety can form an H-bond interaction with the backbone carbonyl of  
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Figure 3: a) Crystal structure of 11 (light blue carbon) in complex with PqsRc91 (ribbon: black 
carbon; surface: white carbon). b) Crystal structure of HHQ (grey carbon) in complex with 
PqsRc91 (ribbon: black carbon; surface: white carbon). c) Overlay of a) and b). The orange arrow 
indicates the applied rational for linker modification toward 20. Fluorine: green, nitrogen: blue, 
oxygen: red, sulfur: yellow. Hydrogen omitted for clarity. 
Leu207 and the NH of the benzylamine linker interacted with the hydroxyl moiety of Thr265. 
However, a comparison of the thermodynamic signatures of 11 binding to PqsRwt and 
PqsRT265A, respectively (SI, Figure S3) displayed no significant difference in the enthalpic 
contribution which argues against a beneficial H-bond interaction. Notably, we detected an 
additional putative H-bond between the pyridine nitrogen lone pair and a water molecule (Figure 
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S1) that had been observed in ligand-receptor-complexes of the congener 22 (described below) 
and PDB entry 4JVC.24In the further proceeding, modifications of the linker part were prioritized 
(Figure 2) in order to develop preferably small and efficient antagonist. Following this strategy, 
we evaluated the role of the NH within the linker; the N-methylated derivative 14 and the benzyl 
alcohol 15 were synthesized. Compound 14 showed a slightly decreased antagonistic activity 
corroborating the notion that the H-bond observed in the X-ray structure does not translate into 
a significant gain in binding affinity, whereas the exchanged of NH to O (16) led to a more 
significant drop in potency. Usually, unfavorable entropic penalties resulting from ligand 
flexibility are addressed by rigidization of compounds through reduction of rotatable bonds.42 
Hence, we made several efforts to introduce less flexible and cyclic structures into the linker 
region (16-18). However, none of these modifications led to improved potency. For example, the 
rigidized amide linker (16) is not able to adapt the angled conformation of 11; as a consequence 
the antagonistic activity was almost abolished. The same trend was observed for cyclized 
derivatives 17 and 18. Especially in the case of the indane derivative 17, this loss of activity was 
surprising. Based on the crystal structure of 11 we assumed that neither the angled 
conformation nor the observed interactions would be affected by introduction of this 5-
membered ring (SI, Figure S2). These findings underline that the optimal geometric 
arrangement of the pyrimidine headgroup and the second aromatic system is difficult to be 
mimicked by rigid ligand structures. In this regard we used the crystal structure in complex with 
the native ligand HHQ was resolved (Figure 3b). A superimposition with HHQ and 11 (Figure 
3C) raised the idea to introduce a prolonged, even more flexible linker to mimic the alkyl 
sidechain of these compounds. Therefore, compounds 19-22 were synthesized. The 
antagonistic activity of 19 was unchanged compared to 11.  
Interestingly, introduction of four-atom linkers resulted in remarkable antagonistic potencies in 
the heterologous reporter gene assay (20-22). The n-propyl amine linker (20) showed a 20-fold 
boost in potency (Table 2; 11 IC50 = 2.6±0.8 µM vs. 20 IC50 = 0.14±0.04 µM). A co-crystal 
structure of 20 in complex with PqsRc91 showed that the extended linker pointed deeper into the 
pocket occupied by the alkyl chain of the natural ligand, enabling additional CH-π interactions 
with Tyr258 while the interactions of the aminopyridine head group were retained (Figure 4). 
However, the affinity of 20 was reduced according to ITC analysis (SI, Table S1; 11: KD = 0.6±0.2 
µM vs. 20 KD =2.8±0.5 µM). As described above, this discrepancy might be explained by the use 
an artificial PqsR construct (H6SUMOPqsRC87) for ITC measurements which is not able to form 
the native tetrameric structure of the receptor.  
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Figure 4: a) Overlay of crystal structures of 20 (orange carbon) and HHQ (grey carbon) in 
complex with PqsRc91 (ribbon: black carbon; surface: white carbon). b). Crystal structure of 20 
highlighting the main interactions with PqsR (hydrogen bonds: light blue, CH-π interactions: 
yellow). Fluorine: green, nitrogen: blue, oxygen: red, sulfur: yellow. Hydrogen omitted for clarity. 
The alkyl chain (20) was exchanged by an ethanolamine (21) and glycine (22) linker moiety to 
lower clogD; the latter was inspired by the recently discovered benzamide-benzimidazole 
antagonists.25 Compound 22 showed only a slightly reduced antagonistic activity, whereas 21 
showed a significant drop. Overall, 20 emerged as the top candidate from this fragment-growing 
approach, showing a superior combination of nanomolar antagonistic activity, enthalpy-driven 
binding (EE = 0.50 kcal/mol) and reasonable physico-chemical properties (clogD=3.8). 
Remarkably, in contrast to the usual drug optimization process relying on reducing the amount 
of rotatable bonds, we gained potency through allowing ligand flexibility here.  
Effects in P. aeruginosa 
P. aeruginosa applies an arsenal of quorum sensing controlled virulence factors. Knock-out 
studies19,43 and synthetic antagonists22,25 clearly showed that inhibition of PqsR-mediated 
transcription leads to reduced P. aeruginosa pathogenicity. Therefore, the most interesting 
compounds during the development process were tested for their effect on virulence factor 
pyocyanin as well as on the alkylquinolons HHQ and HQNO (2-heptyl-4-hydroxy quinoline-N-
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oxide). Pyocyanin is the most prominent and characteristic virulence factors released by P. 
aeruginosa during acute and chronic infections.44 The redox-active blue pigment has cytotoxic 
and immunomodulating properties.44 Moreover, it has been clearly demonstrated that pyocyanin 
promotes the development of a pulmonary pathophysiology in mice similar to the lung of 
infected cystic fibrosis patients.45 Hence, it was of major interest to demonstrate that 2-amino-
pyridines were able to translate the antagonistic activity measured in E.coli into antivirulence 
activity in P. aeruginosa as early as possible. In this regard, it is important to point out, that P. 
aeruginosa shows low intrinsic outer-membrane permeability for xenobiotics and applies a 
multitude of different efflux pumps.44 
Table 3: Effects on pyocyanin in P. aeruginosa 
 
 Pyocyanin
a
 
IC50 [µM] 
PEI
b
 MW 
R1 0.12 0.0165 420.4 
R2 2.0 0.0172 331.4 
7 43% @ 250 µM - 162.1 
11 102 0.0140 285.2 
20 5.9  0.0168  313.3 
21 58% @ 100 µM   - 315.3 
22 37% @ 100 µM - 328.3 
aPhotometric quantification of Pyocyanin from PA14 cultures; given values represent the mean 
of at least two independent experiments; SD<25%. bPEI Pyocyanin Efficiency Index 
PEI=pIC50/MW. 
 
Therefore, compounds 7, 11 and 20-22 were evaluated for the inhibition of pyocyanin in the 
highly virulent clinical isolate PA14 (Table 3). Compound 7 showed albeit in high concentration 
a significant effect on pyocyanin. Antagonist 11 showed low micromolar antagonistic activity in 
the E.coli assay (11 IC50=2.6±0.8 µM) and inhibited pyocyanin with an IC50 = 105±13 µM. 
Antagonist 20 displayed the highest cellular efficacy (IC50 = 5.9±0.7 µM). The literature-known 
compounds R1-R2 were included as references in Table 3. The PqsR antagonist R1 originated 
from an HTS screening.25 R2 was developed in-house by modification of HHQ.22 We established 
a metric called PEI (pyocyanin efficiency index; Table 3) which normalized the effect on 
pyocyanin for the molecular weight of the inhibitors to enable a better comparison. The 
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antagonist 20 clearly displayed efficiency in the range of the benchmark compounds R1 and R2. 
This clearly emphasized the high potential of the developed antagonist 20. In contrast, the 
slightly less active compounds 21 and 22 were not able to inhibit pyocanin to the same extent. 
This might be due to efflux or permeation problems. The phenomenon that even small changes 
within a molecule can have drastic effects on the activity in P. aeruginosa was also observed in 
other projects and emphasizes the need for further insights on the requirement for intracellular 
activity, especially in the case of Gram-negative pathogens.22,46 
The activation of PqsR drives the expression of the HHQ biosynthesis operon pqsA-E, leading 
to enhanced AHQ levels and finally to an auto-inductive loop. P. aeruginosa produces more 
than 50 different AHQ congeners.47 Among others HHQ and HQNO are most prevalent.47 
HQNO showed Gram-positive antibacterial activity that promotes a growth advantage for P 
aeruginosa in mixed microbial communities.
48
 Subsequently, the most interesting antagonists 
were also evaluated for their effect on HHQ and HQNO levels in a PA14pqsH strain. Antagonist 
11 was able to significantly affect HHQ (48±4% inhibition at 200 µM) and HQNO (36±3% 
inhibition at 200 µM). The enlarged compound 20 showed a HHQ (56±4% inhibition at 100 µM) 
and HQNO (48±1 inhibition at 100 µM). These results were in line with already reported data 
showing that the expression of virulence factors and the levels of AQs are differently sensitive to 
the antagonization of PqsR.22,25  
Conclusion 
The rapid development and spreading of resistances against conventional antibiotics has raised 
the awareness of a broader public in recent years. This ability of pathogens demonstrates the 
power of evolutionary adaption processes.49 The development of PqsR antagonists pursues the 
strategy to limit P. aerugonsa’s virulence without affecting bacterial fitness. Hence, these 
antivirulence compounds might be more robust to adaptive evolution because they avoid 
exerting selective pressure.50 Herein, we report on the discovery and development of 2-amino-
pyridines as potent PqsR antagonists. Starting from an SPR fragment screening26 ligand 3 was 
selected based on its unique EE, although it did not show significant antagonistic activity. 
Successfully growing and improving a fragment screening hit without structural information is a 
challenging approach and only rarely reported in the literature. Therefore, close commercial 
analogs were investigated, leading to compound 7. 7 showed improved affinity and comparable 
EE. Furthermore, 7 possessed moderate antagonistic activity. By the introduction of a flexible 
benzyl-amine linker into the 4-position (11) affinity and antagonistic activity were significantly 
improved. The solution of the crystal structure of 11 in complex with PqsRc87 facilitated further 
structure-guided optimization. Notably, the ligand assumed an angled conformation spanning 
over the quinolone- and alkylchain-pocket. Inspired by the alkyl chain of the natural ligand HHQ, 
we extended the linker moiety, which led to the top candidate 20 showing antagonistic activity in 
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the nanomolar range. The rather unusual approach of allowing more flexibility instead of 
rigidifying the ligand might be also applicable to a broader scope of drugable proteins. 
Especially in cases where the biological function of the drug target depends on different 
conformational states (e.g. inducable transcriptional regulators), this flexible fragment growing 
strategy might be a valuable tool to rapidly generate lead-like molecules. Usually, a selected 
fragment-sized hit already provides efficient directed interactions with the target. Allowing 
compound flexibility during the enlargement process could help to retain the beneficial binding 
geometry while granting access to additional sites of the binding pocket resulting in enhanced 
potency. 
The developed PqsR antagonist is a remarkably small compound and efficiently reduces 
pyocyanin in P. aeruginosa without affecting bacterial viability. Compound 20 represents an 
excellent starting point for further lead optimization studies. With these findings we try to fill the 
gap of lacking treatment options against severe P. aeruginosa infections by following an 
innovative approach towards novel anti-infectives which are less prone to resistance 
development. 
 
EXPERIMENTAL SECTION 
PqsR Reportergeneassay in E. coli The agonistic and antagonistic activity of potential PqsR 
ligands was evaluated in a β-galactosidase reporter gene assay in E. coli as previously 
described.21 In short, test compounds were co-incubated with E. coli DH5α cells containing the 
plasmid pEAL08-238, which expresses PqsR and the β-galactosidase LacZ under the control of 
the pqsA promoter. The antagonistic activity of compounds was measured in the presence of 50 
nM PQS. After incubation, galactosidase activity was quantified photometrically and expressed 
as ratio of controls. The given IC50 values represent the mean of at least two independent 
experiments using at least eight different concentrations of test compound with n = 4. Non-linear 
regression analysis was done using the log (inhibitor) vs. response model included in the 
GrapPad Prism 5.0 software package. 
Protein crystallization, Data Collection and Structure Solution. Initial crystals of PqsR91-319 
in complex with HHQ, fragment 11 or 20 were obtained by co-crystallization in a sitting drop 
vapor diffusion set-up using the commercially available JCSG Core Suites I-IV (Qiagen), Cryos 
Suite (Qiagen) and Index HT screen (Hampton Research) at 20°C. Initial screening hits were 
optimized in 96 well plates using a Formulator liquid handling station (Formulatrix). 
Crystallization drops consisted of 0.2 µl protein-ligand solution and 0.2 µl mother liquor and 
were prepared with a Honeybee 961 robot (Digilab). The morphology of PqsR91-319-HHQ crystals 
was improved with the Additive Screen (Hampton Research) by the addition of 0.1 M CsCl. 
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Protein/ligand concentrations and final crystallization conditions that yielded diffraction quality 
crystals are described in Table S1 for each ligand. The crystals were flash-frozen in liquid 
nitrogen, and X-ray diffraction data were collected at 100 K at beamlines BL14.1/BL14.2 of the 
BESSY II synchrotron and at beamline X06DA of the Swiss Light Source (Table S1). Diffraction 
data were processed with XDS51 and AIMLESS52 from the CCP4 suite.53 The   
dataset of PqsR91-319 in complex with compound 11 was corrected for anisotropy using the 
UCLA Diffraction Anisotropy Server54 (http://services.mbi.ucla.edu/anisoscale/) with the 
resolution limits of 3.4 Å, 3.2 Å and 2.8 Å along the a*, b*, and c* directions for ellipsoidal 
truncation. The structures were determined by molecular replacement with PHASER55 or rigid-
body refinement with REFMAC556 using the PDB entry 4JVC. Model building and refinement 
were performed with COOT
57
 and with phenix.refine
58
 from the PHENIX suite.
59
 
Ligand-receptor-interaction studies. Complex structures of HHQ as well as compounds 11 
and 20 bound to the ligand-binding domain of PqsR were analyzed using Molecular Operating 
Environment MOE (Chemical Computing Group) after applying the “QuickPrep” protocol using 
the MMFF94x force field (see Figure S1 in the Supporting Information). Default parameters 
were used, while receptor, ligands, and solvents were thetered (“strength” parameter of 10). A 
prominent water molecule observed in crystal structure of PqsR in complex with 20 was also 
considered when investigating the interactions of compound 11. Figures 3 and 4 of the main 
text were rendered with PovRay. 
Pyocyanin Assay The inhibition of virulence factor pyocyanin was measured as described 
previously21 following a procedure established by Essar et al.62 Briefly, Pseudomonas 
aeruginosa PA14 cultures were grown in the presence of inhibitors or DMSO as control for 16 h. 
Pyocyanin was determined photometrically after extraction of the cultures with chloroform and 
re-extraction with 0.2 M HCl. Values were expressed in relation to the DMSO control. Each 
value is the mean of at least two independent experiments with n=3. The given IC50 values 
represent the mean of at least two experiments using at least five different concentrations. 
Curve fitting was performed using the log (inhibitor) vs. response model with constrained bottom 
= 0 and top =100 (GraphPad Prism 5.0).  
HHQ and HQNO Quantification Extracellular HHQ and HQNO were measured as previously 
reported22 following a modified procedure of Lépine et al.47,63: Briefly, P. aeruginosa PA14pqsH 
cultures were grown in the presence of DMSO as a control or DMSO solutions of inhibitors for 
17 h. HHQ and HQNO were quantified from ethyl acetate extracts using 5,6,7,8-tetradeutero-2-
heptyl-4(1H)-quinolone (HHQ-d4) as internal standard (IS). UHPLC-MS/MS analysis was 
performed as described in detail by Storz et al.64 The following ions were monitored (mother ion 
[m/z], product ion [m/z], scan time [s], scan width [m/z], collision energy [V], tube lens offset [V]): 
HHQ: 244, 159, 0.5, 0.01, 30, 106; HQNO: 260, 159, 0.1, 0.01, 25, 88; HHQ-d4 (IS): 248, 163, 
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0.1, 0.01, 32, 113. Data acquisition and quantification was performed using Xcalibur software 
with the use of a calibration curve relative to the area of the IS. Given data represent the mean 
of at least two independent experiments with n=3 and were expressed as percentage inhibition 
relative to DMSO control.  
Chemical and Analytical Methods. 1H and 13C NMR spectra were recorded as indicated on a 
Bruker DRX-500 or a Bruker Fourier 300 instrument. Chemical shifts are given in parts per 
million (ppm), and referenced against the residual solvent peak. Coupling constants (J) are 
given in hertz. Low resolution mass analytics and purity control of final compounds was carried 
out either using a SpectraSystems-MSQ LCMS system (Thermo Fisher Scientific) consisting of 
a pump, an autosampler, VWD detector and a ESI quadrupole mass spectrometer or a Waters 
LCMS-Sytsem consisting of a 767 sample Manager, a 2545 binary gradient pump, a 2998 PDA 
detector and a 3100 electron spray mass spectrometer. High resolution mass spectra were 
recorded on a maXis 4G hr-ToF mass spectrometer (Bruker Daltonics). Reagents were used as 
obtained from commercial suppliers without further purification. Procedures were not optimized 
regarding yield. Microwave assisted synthesis was carried out in a Discover microwave 
synthesis system (CEM). Column chromatography was performed using the automated flash 
chromatography system CombiFlash Rf 150 (Teledyne Isco) equipped with RediSepRf silica 
columns. Final products were dried at high vacuum.  
Method A: General Procedure for Buchwald-Hartwig cross coupling reactions:34 
Heteroaryl halide (0.35 mmol), potassium tert-butoxide (1.1 mmol) and (SIPr)Pd(cinnamyl)Cl (3 
mol%) were combined into MW-vial (Biotage). The vial was evacuated and flushed with argon 
(3 times). Dry dimethoxyethane (1 ml) was added. The reaction mixture was purged with argon 
and the amine (1.1 mmol) was slowly added. The reaction was stirred over night at 80°C. The 
mixture quenched with diethyl ether, filtered through Cellite and the filtrate was concentrated to 
dryness. The crude was further purified by preparative HPLC or chromatography on silica gel. 
Method B: Copper-mediated amination reaction 2-iodo-6-(trifluoromethyl)pyridin-4-amine 
(0.3 mmol) was dissolved in NMP/water (3ml; 2/1(V/V)) using crimp reaction vial. (Biotage). 
1,10-phenanthroline (0.1 mmol) and copper (I) oxide (0.1 mmol) were added. The reaction 
mixture was purged with argon and NH3(aq) 28% (~5 mmol) was added. The mixture was stirred 
over night at RT. The crude product was purified by automated flash chromatography.  
4-(cyclopropylethynyl)-6-(trifluoromethyl)pyridin-2-amine (9): -iodo-6-(trifluoromethyl) 
pyridin-2- amine (4e; 100 mg, 0.415 mmol), PdCl2(PPh3)2 (7 mg, 10 µmol), tetrabutylammonium 
fluorid (1.0 mmol) and ethynylcyclopropane (34 mg, 0.52 mmol) were filled into a crimp vial 
(neat reation). The vial was evacuated and purged with argon (3 times). The reaction mixture 
was heated at 80°C overnight. The reaction was quenched by addition of water. The aqueous 
layer was extracted with ethylacetat (3 times). Combined organics were washed with brine, 
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dried over MgSO4 and concentrated. The crude product was purified by automated flash 
chromatography (PE:EA 95:5 to PE:EA 80:20) to give the titled compound (74 mg, 0.33 mmol, 
94 % yield) as pale yellow solid. 1H NMR (500 MHz, CHLOROFORM-d)  ppm 0.82 - 0.87 (m, 2 
H), 0.91 - 0.96 (m, 2 H), 1.42 - 1.48 (m, 1 H), 4.75 (br. s., 2 H), 6.59 (d, J=0.6 Hz, 1 H), 6.95 (d, 
J=0.9 Hz, 1 H); 13C NMR (126 MHz, CHLOROFORM-d)  ppm 1.00, 8.94 (2 C), 73.19, 99.37, 
112.76 (d, 3J(C,F)=3.7 Hz, 1 C), 113.34, 121.35 (q, 1J(C,F)=274.0 Hz, 1 C), 134.77, 146.53 (q, 
2J(C,F)=33.9 Hz, 1 C), 158.46; MS (ESI+) m/z 268 (M+ACN+H)+. 
(4-fluorophenyl)-6-(trifluoromethyl)pyridin-2-amine (10): 4-iodo-6-(trifluoromethyl)pyridin-2-
amine (4e; 100 mg, 0.35 mmol), (4-fluorophenyl)boronic acid (73 mg, 0.52 mmol) and 
Pd(dppf)Cl2 (12 mg, 0.016 mmol) were filled into a crimp reaction vial. The vial was evacuated 
and flushed with argon (2 times). Na2CO3 (3 ml, 3.0 mmol) 1M solution were added. The mixture 
was purged with argon and stirred at 80°C for overnight. The mixture was quenched by addition 
of water and extracted by ether. The combined organics were washed with brine, dried over 
MgSO4 and concentrated. The crude was attached purified by automated flash chromatography 
(PE to PE:EA 80:20) to give the titled compound (67 mg, 0,262 mmol, 75 % yield) as a white 
solid. 1H NMR (300 MHz, CHLOROFORM-d)  ppm 4.92 (br. s., 2 H), 6.78 (s, 1 H), 7.07 - 7.24 
(m, 3 H), 7.49 - 7.65 (m, 2 H); 13C NMR (75 MHz, CHLOROFORM-d)   ppm 108.89, 108.92 (q, 
3J(C,F)=3.0 Hz, 1 C), 116.16 (d, 2J(C,F)=22.4 Hz, 2 C), 121.61 (q, 1J(C,F)=274.2 Hz, 1 C), 
128.74 (d, 
3
J(C,F)=8.9 Hz, 2 C), 133.80 (d, 
4
J(C,F)=3.7 Hz, 1 C), 147.24 (q, 
2
J(C,F)=33.5 Hz, 1 
C), 150.51, 159.12, 163.60 (d, 2J(C,F)=249.6 Hz, 1 C); MS (ESI+) m/z 257 (M+H)+; 298 
(M+ACN+H)+. 
N4-(4-fluorobenzyl)-6-(trifluoromethyl)pyridine-2,4-diamine (11) was synthesized according 
to Method A from 4-iodo-6-(trifluoromethyl)pyridin-2-amine (4e; 100 mg, 0.35 mmol) and (4-
fluorophenyl)methanamine (130 mg, 1.04 mmol). The crude was purified by combyflash 
(PE:dieethylether 80:20 to 60:40) to give a pale brown solid. The solid was titurated with diethyl 
ether/pentane and filtered to give the titled compound (27 mg, 0.095 mmol, 27% yield) as a 
brown-white solid. 1H NMR (500 MHz, CHLOROFORM-d)  ppm 4.33 (d, J=5.4 Hz, 2 H), 4.46 
(br. s., 2 H), 4.56 (br. s., 1 H), 5.68 (d, J=1.6 Hz, 1 H), 6.37 (d, J=1.9 Hz, 1 H), 7.00 - 7.12 (m, 2 
H), 7.20 - 7.35 (m, 2 H); 13C NMR (126 MHz, CHLOROFORM-d)  ppm 46.17, 90.66, 98.52, 
115.56 (d, 2J(C,F)=21.1 Hz, 2 C), 121.36 (d, 1J(C,F)=273.1 Hz, 1 C), 128.62 (d, 3J(C,F)=8.2 Hz, 
2 C), 132.83 (d, 4J(C,F)=3.7 Hz, 1 C), 146.65 (q, 2J(C,F)=33.0 Hz, 1 C), 154.83, 159.57, 162.04 
(d, 1J(C,F)=246.5 Hz, 1 C); MS (ESI+) m/z 286 (M+H)+. 
N4-benzyl-6-(trifluoromethyl)pyridine-2,4-diamine (12) was synthesized according to Method 
A from 4-iodo-6-(trifluoromethyl)pyridin-2-amine (4e; 100 mg, 0.35 mmol) and 
phenylmethanamine (112 mg, 1.04 mmol). The crude product was purified by combyflash 
(PE:diethylether gradient, elution 30:70 PE:ether) to give the titled compound as pale yellow 
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solid (48 mg, 0.18 mmol, 52% yield). 
1
H NMR (500 MHz, CHLOROFORM-d)  ppm 4.34 (d, 
J=5.7 Hz, 2 H), 4.43 - 4.93 (m, 1 H), 5.68 (d, J=1.9 Hz, 1 H), 6.35 (d, J=1.9 Hz, 1 H), 7.28 - 7.34 
(m, 3 H), 7.34 - 7.41 (m, 2 H); 13C NMR (126 MHz, CHLOROFORM-d)  ppm 47.01, 90.83, 
98.68 (d, 3J(C,F)=3.7 Hz, 1 C), 121.71 (q, 1J(C,F)=274.9 Hz, 1 C), 127.21 (2 C), 127.68, 128.84 
(2 C), 137.48, 146.78 (q, 2J(C,F)=33.0 Hz, 1 C), 155.20, 159.85; MS (ESI+) m/z 259 (M+H)+ 299 
(M+ACN+H)+ 
N4-(2,4-difluorobenzyl)-6-(trifluoromethyl)pyridine-2,4-diamine (13) was synthesized 
according to Method A from 4-iodo-6-(trifluoromethyl)pyridin-2-amine (4e; 100 mg, 0.35 mmol) 
and (2,4-difluorophenyl)methanamine (149 mg, 1.04 mmol). The crude product was purified by 
preparative HPLC to give the titled compound (21 mg, 0,069 mmol, 20 % yield) as brown oil. 1H 
NMR (500 MHz, METHANOL-d4)  ppm 4.37 (s, 2 H), 5.78 (d, J=1.6 Hz, 1 H), 6.42 (d, J=1.9 Hz, 
1 H), 6.87 - 7.02 (m, 2 H), 7.36 (td, J=8.2, 6.6 Hz, 1 H); 13C NMR (126 MHz, METHANOL-d4)  
ppm 40.61 (d, 3J(C,F)=4.6 Hz, 1 C), 90.70, 99.84, 104.68 (t, 2J(C,F)=25.7 Hz, 1 C), 112.30 (dd, 
2J(C,F)=20.2, 3.7 Hz, 1 C), 123.07 (q, 1J(C,F)=273.1 Hz, 1 C), 122.55 (dd, 3J(C,F)=14.7, 3.7 Hz, 
1 C), 131.47 (dd, 3J(C,F)=9.6, 6.0 Hz, 1 C), 145.77 (q, 2J(C,F)=33.9 Hz, 1 C), 157.12, 162.26 
(dd, 1J(C,F)=243.8, 11.9 Hz, 1 C), 161.74, 163.84 (dd, 1J(C,F)=246.5, 12.8 Hz, 1 C); MS (ESI +) 
m/z 304 (M+H)+. 
N4-(4-fluorobenzyl)-N4-methyl-6-(trifluoromethyl)pyridine-2,4-diamine (14) was 
synthesized according to Method A from 4-iodo-6-(trifluoromethyl)pyridin-2-amine (4e; 100 mg, 
0.35 mmol) and 1-(4-fluorophenyl)-N-methylmethanamine (145 mg, 1,042 mmol). The crude 
product was purified by automated flash chromatography using a gradient of Hex:EA (8:2 to 6:4) 
to give the titled compound (19 mg, 0.063 mmol, 18% yield) as white solid. 1H NMR (300 MHz, 
CHLOROFORM-d)  ppm 3.04 (s, 3 H), 4.52 (s, 4 H), 5.76 (d, J=2.0 Hz, 1 H), 6.48 (d, J=2.1 Hz, 
1 H), 6.97 - 7.07 (m, 2 H), 7.08 - 7.16 (m, 2 H); 13C NMR (75 MHz, CHLOROFORM-d)  ppm 
37.94, 54.57, 90.92, 96.73 (d, 3J(C,F)=3.7 Hz, 1 C), 115.80 (d, 2J(C,F)=20.9 Hz, 1 C), 121.88 (q, 
1J(C,F)=274.2 Hz, 1 C), 127.99 (d, 3J(C,F)=8.2 Hz, 2 C), 132.48 (d, 4J(C,F)=3.7 Hz, 1 C), 
147.34 (q, 2J(C,F)=32.8 Hz, 1 C), 156.08, 159.78, 162.14 (d, 1J(C,F)=245.9 Hz, 1 C); MS (ESI 
+) m/z 300 (M+H)+.  
4-((4-fluorobenzyl)oxy)-6-(trifluoromethyl)pyridin-2-amine (15) 2-(2,5-dimethyl-1H-pyrrol-1-
yl)-4-((4-fluorobenzyl)oxy)-6-(trifluoromethyl)pyridine (15a; 80 mg, 0.22 mmol), triethylamine 
(0.061 ml, 0.44 mmol) and hydroxylamine hydrochloride (153 mg, 2.20 mmol) were dissolved in 
EtOH/water 3/1 and the solution was refluxed overnight. An additional amount of hydroxylamine 
hydrochloride (153 mg, 2.20 mmol) and triethylamine (0.061 ml, 0.44 mmol) was added and 
again refluxed overnight. The mixture was quenched by addition of EA and water. The aqueous 
phase was extracted (EA 3 times). Combined organcis were washed with brine, dried (MgSO 4) 
filtered and concentrated. The crude was purified by column chromatography (step gradient 9:1 
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to 1:1 PE:EA) to give the titled compound (40 mg, 0.14 mmol, 64 % yield) as pale yellow 
crystals. 1H NMR (300 MHz, DMSO-d6)  ppm 5.12 (s, 2 H), 6.22 (d, J=1.8 Hz, 1 H), 6.44 (s, 2 
H), 6.59 (d, J=2.0 Hz, 1 H), 7.13 - 7.33 (m, 2 H), 7.50 (dd, J=8.7, 5.5 Hz, 1 H); 13C NMR (75 
MHz, DMSO-d6)  ppm 68.58, 94.36, 98.49 (d, 
4J(C,F)=3.0 Hz, 1 C), 115.31 (d, 2J(C,F)=22.4 
Hz, 2 C), 121.61 (q, 1J(C,F)=274.2 Hz, 1 C), 130.13 (d, 3J(C,F)=8.2 Hz, 2 C), 132.21 (d, 
4J(C,F)=3.0 Hz, 1 C), 146.25 (q, 2J(C,F)=33.5 Hz, 1 C), 161.89 (d, 1J(C,F)=244.4 Hz, 1 C), 
161.80, 165.70; MS (ESI+) m/z 287 (M+H)+; 328 (M+ACN+H)+. 
N-(2-amino-6-(trifluoromethyl)pyridin-4-yl)-4-fluorobenzamide (16): tert-butyl (4-(4-
fluorobenzamido)-6-(trifluoromethyl)pyridin-2-yl)carbamate (16a; 46 mg, 0.11 mmol) was 
dissolved in DCM (4 ml) and cooled on an ice bath. Trifluoroacetic acid (1 ml) was added and 
the mixture was aged at RT for 3 h. The reaction was quenched by addition of DCM and 
Na2CO3 saturated solution. The aqueous layer was extracted with DCM (3 times) and EtOAc (3 
times). Both organics were dried over MgSO4, filtered and concentrated. The crude was purified 
by automated flash chromatography (PE:EA 75:25) to give the titled compound (11 mg, 0.04 
mmol, 32% yield) as white solid. 1H NMR (300 MHz, DMSO-d6)  ppm 6.53 (br. s, 2 H), 7.26 - 
7.33 (m, 2 H), 7.33 - 7.44 (m, 2 H), 7.93 - 8.12 (m, 2 H), 10.50 (br. s, 1 H); 13C NMR (75 MHz, 
DMSO-d6)  ppm 100.07, 101.06 (q, 
3J(C,F)=3.0 Hz, 1 C), 115.93 (d, 2J(C,F)=21.6 Hz, 2 C), 
122.28 (q, 1J(C,F)=273.4 Hz, 1 C), 131.06, 131.13 (d, 3J(C,F)=8.9 Hz, 1 C), 145.91 (q, 
2
J(C,F)=32.0 Hz, 1 C), 147.88, 161.61, 164.84 (d, 
1
J(C,F)=248.9 Hz, 1 C), 165.77; MS (ESI+) 
m/z 300 (M+H)+, 341 (M+ACN+H)+ 
N4-(5-fluoro-2,3-dihydro-1H-inden-1-yl)-6-(trifluoromethyl)pyridine- 2,4-diamine (17) was 
synthesized according to Method A from 4-iodo-6-(trifluoromethyl)pyridin-2-amine (4e; 100 mg, 
0.35 mmol) and and 5-fluoro-2,3-dihydro-1H-inden-1-amine (157 mg, 1.04 mmol). The crude 
product was purified by preparative HPLC to give the titled compound (48 mg, 0.15 mmol, 44 % 
yield) as brown solid. 1H NMR (300 MHz, CHLOROFORM-d)  ppm 1.87 - 2.08 (m, 1 H), 2.53 - 
2.69 (m, 1 H), 2.80 - 3.11 (m, 2 H), 4.41 (d, J=7.8 Hz, 1 H), 4.53 (br. s., 2 H), 4.97 (q, J=6.9 Hz, 
1 H), 5.83 (d, J=1.8 Hz, 1 H), 6.37 (d, J=1.9 Hz, 1 H), 6.82 - 7.04 (m, 2 H), 7.16 - 7.37 (m, 1 H); 
13C NMR (75 MHz, CHLOROFORM-d)  ppm 30.21, 33.84, 57.04, 91.04, 98.78 (d, 3J(C,F)=3.7 
Hz, 1 C), 112.03 (d, 2J(C,F)=23.1 Hz, 1 C), 114.05 (d, 2J(C,F)=23.1 Hz, 1 C), 121.70 (d, 
1J(C,F)=273.4 Hz, 1 C), 125.28 (d, 3J(C,F)=8.9 Hz, 1 C), 138.39 (d, 4J(C,F)=2.2 Hz, 1 C), 
145.89 (d, 3J(C,F)=8.2 Hz, 1 C), 147.33 (q, 2J(C,F)=32.0 Hz, 1 C), 154.73, 159.80, 163.24 (d, 
1J(C,F)=245.9 Hz, 1 C); MS (ESI+) m/z 312 (M+H)+. 
4-(3-(4-fluorophenyl)pyrrolidin-1-yl)-6-(trifluoromethyl)pyridin-2-amine (18)was synthesized 
according to Method A from 4-iodo-6-(trifluoromethyl)pyridin-2-amine (4e, 100 mg, 0.35 mmol) 
and and 3-(4-fluorophenyl)pyrrolidine (172 mg, 1.04 mmol). The crude product was purified by 
automated flash chromatography (PE:Diethylether gradient) to give the titled compound (90 mg, 
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0.28 mmol, 80 % yield) as pale yellow solid. 
1
H NMR (300 MHz, CHLOROFORM-d)  ppm 2.02 
- 2.21 (m, 1 H), 2.43 (m, 1 H), 3.33 (t, J=9.0 Hz, 1 H), 3.38 - 3.61 (m, 3 H), 3.74 (dd, J=9.3, 7.7 
Hz, 1 H), 4.49 (br. s., 2 H), 5.65 (d, J=1.8 Hz, 1 H), 6.34 (d, J=1.9 Hz, 1 H), 6.93 - 7.11 (m, 2 H), 
7.14 - 7.26 (m, 2 H); 13C NMR (75 MHz, CHLOROFORM-d)  ppm 32.47, 42.64, 46.70, 53.42, 
90.23 (d, J=6.0 Hz, 1 C), 96.76 (d, 3J(C,F)=3.7 Hz, 1 C), 115.11 (d, 2J(C,F)=18.6 Hz, 2 C), 
121.49 (d, 1J(C,F)=274.2 Hz, 1 C), 128.03 (d, J=7.4 Hz, 2 C), 136.52 (d, 3J(C,F)=3.7 Hz, 1 C), 
146.63 (q, 2J(C,F)=32.8 Hz, 1 C), 153.15, 158.97, 161.37 (d, 1J(C,F)=245.1 Hz, 1 C); MS (ESI+) 
m/z 326 (M+H)
+
, 367 (M+ACN+H)
+
 
N4-(4-fluorophenethyl)-6-(trifluoromethyl)pyridine-2,4-diamine (19) was synthesized 
according to Method B from N-(4-fluorophenethyl)-2-iodo-6-(trifluoromethyl)- pyridin-4-amine 
(100 mg, 0.24 mmol). The crude product was purified by automated flash chromatography 
(PE:DE 7:3 to 3:7) to give the titled compound (55 mg, 0.18 mmol, 75 % yield) as white solid.
1
H 
NMR (500 MHz, DMSO-d6)  ppm 2.80 (t, J=7.4 Hz, 2 H), 3.18 - 3.26 (m, 2 H), 5.72 (d, J=1.6 
Hz, 1 H), 5.95 (br. s., 2 H), 6.27 (d, J=1.6 Hz, 1 H), 6.67 (br. s., 1 H), 7.08 - 7.16 (m, 2 H), 7.27 - 
7.34 (m, 2 H); 13C NMR (126 MHz, DMSO-d6)  ppm 33.43, 43.65, 88.92, 97.12, 115.02 (d, 
2
J(C,F)=20.2 Hz, 2 C), 122.09 (q, 1J(C,F)=274.0 Hz, 1 C), 130.53 (d, 3J(C,F)=8.2 Hz, 2 C), 
135.51 (d, 3J(C,F)=2.8 Hz, 1 C), 144.59 (q, 2J(C,F)=30.2 Hz, 1 C), 154.92, 160.92 (d, 
1J(C,F)=241.9 Hz, 1 C), 160.70; MS (ESI+) m/z 300 (M+H)+; HRMS found 300.11091 calc. 
300.11184 (M+H)
+
. 
N4-(3-(4-fluorophenyl)propyl)-6-(trifluoromethyl)-pyridine-2,4-diamine (20) was synthesized 
according to Method B from N-(3-(4-fluorophenyl)propyl)-2-iodo-6-(trifluoromethyl)pyridin-4-
amine (130 mg, 0.31 mmol). The crude product was purified by purified by automated flash 
chromatography (gradient PE:diethylether) to give the titled compound (45 mg, 0.14 mmol, 47 
% yield) as pale yellow solid 1H NMR (500 MHz, DMSO-d6)  ppm 1.80 (quin, J=7.3 Hz, 1 H), 
2.65 (t, J=7.3 Hz, 2 H), 2.93 - 3.03 (m, 2 H), 5.62 (d, J=1.3 Hz, 1 H), 5.88 (s, 2 H), 6.25 (d, J=1.9 
Hz, 1 H), 6.55 (t, J=5.2 Hz, 1 H), 7.07 - 7.14 (m, 2 H), 7.21 - 7.28 (m, 2 H); 13C NMR (126 MHz, 
DMSO-d6)  ppm 30.00, 31.57, 41.20, 88.82, 96.79, 114.93 (d, 
2
J(C,F)=21.1 Hz, 2 C), 122.15 
(q, 1J(C,F)=274.0 Hz, 1 C), 129.97 (d, 3J(C,F)=7.3 Hz, 2 C), 137.63 (d, 3J(C,F)=3.7 Hz, 1 C), 
144.95 (q, 2J(C,F)J=32.1 Hz, 1 C), 155.03, 160.58 (d, 1J(C,F)=241.0 Hz, 1 C), 160.88; MS 
(ESI+) 314 (M+H)+; HRMS found 314.12708 calc 314.12749 (M+H)+. 
N4-(2-(4-fluorophenoxy)ethyl)-6-(trifluoromethyl)-pyridine-2,4-diamine (21) was 
synthesized according to Method B from N-(2-(4-fluorophenoxy)ethyl)-2-iodo-6-
(trifluoromethyl)pyridin-4-amine (21a; 30,0 mg, 0.07 mmol). The crude product was purified by 
automated flash chromatography (PE:EA gradient). The isolated product was further purified by 
preparative HPLC to give the titled compound (7 mg, 0.022 mmol, 31% yield) as white solid. 1H 
NMR (500 MHz, METHANOL-d4)  ppm 3.52 (t, J=5.4 Hz, 2 H), 4.12 (t, J=5.5 Hz, 2 H), 5.88 (d, 
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J=1.9 Hz, 1 H), 6.41 (d, J=1.9 Hz, 1 H), 6.91 - 6.97 (m, 2 H), 6.97 - 7.04 (m, 2 H); 
13
C NMR (126 
MHz, METHANOL-d4)  ppm 43.01, 68.05, 90.74, 99.48, 116.69 (d, 
2J(C,F)=22.9 Hz, 2 C), 
116.82 (d, 3J(C,F)=7.8 Hz, 2 C), 123.34 (q, 1J(C,F)=273.1 Hz, 1 C), 146.79 (q, 2J(C,F)=33.0 Hz, 
1 C), 156.43 (d, 4J(C,F)=1.8 Hz, 1 C), 157.39, 158.81 (d, 1J(C,F)=236.4 Hz, 1 C); MS (ESI+) 
316 (M+H)+; HRMS found 316.10667 calc. 316.10675 (M+H)+.  
2-((2-amino-6-(trifluoromethyl)pyridin-4-yl)amino)-N-(4-fluorophenyl)acetamide (22) 4-
iodo-6-(trifluoro methyl)pyridin-2-amine (22a; 150 mg, 0.52 mmol), 2-amino-N-(4-
fluorophenyl)acetamide (131 mg, 0.78 mmol), copper (I) iodide (99 mg, 0.52 mmol), K3PO4 (221 
mg, 1.04 mmol) and 2-(dimethylamino)ethanol (46 mg, 0.5 mmol) were filled into a crimp vial. 
The vial was evacuated and backfilled with argon (3 times). Acetonitrile (4 ml) and water (2 ml) 
were added and the mixture degassed with argon .The reaction was heated at 90 °C over night. 
The mixture was poured into saturated NH4Cl solution. The aqueous phase was extracted using 
EtOAc (3 times). The combined organics were washed with brine, dried (MgSO4), filtered and 
adsorbed onto silica gel. The crude product was first purified by automated flash 
chromatography (PE:EA gradient) and further by prep HPLC to give the titled compound (25 
mg, 0,076 mmol, 15 % yield) as white solid. 1H NMR (500 MHz, DMSO-d6)  ppm 3.89 (d, J=6.0 
Hz, 2 H), 5.62 (s, 1 H), 5.97 (s, 2 H), 6.37 (d, J=1.9 Hz, 1 H), 6.87 (t, J=6.1 Hz, 1 H), 7.05 - 7.22 
(m, 2 H), 7.54 - 7.66 (m, 2 H), 10.12 (s, 1 H). 13C NMR (126 MHz, DMSO-d6)  ppm 45.79, 
89.55, 97.15, 115.28 (d, J=20.2 Hz, 2 C), 122.11 (q, 
1
J(C,F)=274.0 Hz, 1 C), 121.03 (d, J=7.3 
Hz, 2 C), 135.14 (d, J=2.8 Hz, 1 C), 144.99 (q, J=32.1 Hz, 1 C), 155.07, 158.01 (d, 
1J(C,F)=239.2 Hz, 1 C), 160.80, 167.91; MS (ESI+) 329.2 (M+H)+. HRMS found 329.10171 calc. 
329.10200 (M+H)
+ 
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3.3 Chapter C: 
Effects of Next Generation PqsR-targeting Anti-infectives 
against Biofilm and Virulence of Pseudomonas aeruginosa 
 
The coworkers listed below made the following experimental contributions to this chapter: 
Antonio G. G. de Mello Martins: Performed parts of the biofilm experiments 
Christian Brengel: Performed parts of the biofilm experiments 
Giuseppe Allegretta: Established and performed 2-AA assays 
Lorenz Siebenbürger: Performed metabolic stability assays 
Benjamin Kirsch: Planed E. coli reporter gene assays 
Jens Eberhard: Developed MS methods for metabolic stability measurements 
Stefanie Wagner: Performed lectin expression western blot analysis 
Christine K. Maurer:  Established and planed alkylquinolone and pyocyanin assays 
Martin Empting: Performed modeling and docking studies 
 
INTRODUCTION 
“It is time to close the book on infectious diseases, and declare the war against pestilence won” 
– even if the origin of this statement cannot be precisely tracked down1, it reflects the 
conventional wisdom2 over decades in the 20th century. But this popular belief was quickly 
abandoned due to the alarming occurrence of multi- and pan-resistant microbial pathogens.3 
This situation has even been worsened by shortening the research efforts in the field of 
antibacterial drug discovery.
4,5
 Nowadays, we are facing a lack of novel treatment options for 
many human pathogens which acquired resistance against nearly all available antibiotics.6 The 
development of compounds which reduce bacterial virulence without affecting viability has 
attracted increasing attention during the last years. These antivirulence drugs have the potential 
to overcome the burden of rapid development and spreading of resistance mechanisms  and 
may help to regenerate the antimicrobial development pipeline.7 
Inspired by this idea, we and others targeted the virulence of Pseudomonas aeruginosa, a 
Gram-negative opportunistic human pathogen, by interference with bacterial cell-to-cell 
communication.8 The release of virulence determinants is regulated mainly by a process called 
quorum sensing (QS).9 QS enables P. aeruginosa to coordinate gene expression collectively 
dependent on bacterial cell-density via the release and sensing of small diffusible molecules.9 P. 
aeruginosa employs the las10,11 and rhl12,13 QS systems which use acetyl homoserine lactones 
(AHLs) as signaling molecules, prevalent among Gram-negative bacteria. Furthermore, this 
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bacterium uses a rather unique system called pqs
14
 (Pseudomonas quinolone signal) applying 
alkylquinolones (AQs). The autoinducers 2-heptyl-3-hydroxy-4(1H)-quinolone (PQS) and its 
precursor 2-heptyl-4-quinolone (HHQ) activate the transcriptional regulator PqsR15 
(Pseudomonas quinolone signaling receptor also referred to as MvfR).16,17,18 The activated 
receptor regulates the expression of various genes involved in the production of virulence 
factors e.g. pyocyanin16, elastase, lectines etc.19 Additionally PqsR up-regulates the expression 
of the HHQ biosynthesis operon pqsA-E to form an autoinductive loop.20,21 Moreover, the pqs 
system is involved in the establishment of P. aeruginosa biofilms via multiple ways. Mutants 
lacking of a functional pqs system showed a reduced release of eDNA22 and expression of 
lectins A/B19. Both are integral parts for the P. aeruginosa biofilm architecture.22,23 P. aeruginosa 
strains which switched to a sessile biofilm lifestyle are the main cause of chronic persistent 
pneumonia found in cystic fibrosis patients.24,25 Bacteria growing in the biofilm mode adapt to 
intense antibiotic treatment and to the host immune response.25 Taken together, the pqs system 
and its central regulator PqsR play a critical role during the acute and chronic infections. 
Following a ligand-based approach, we were able to transform the native agonist HHQ into the 
potent antagonists showing a lack of activity due to metabolic conversion in P. aeruginosa.26,27 
Further optimization led to the analog 1 which was able to fully protect Galleria mellonella larvae 
from a lethal P. aeruginosa infection providing the first in vivo proof of concept.27 In a similar 
approach quinazolinone-based antagonists were developed and the first crystal structure of the 
ligand-binding domain (LBD) of PqsR was solved.28 The potential of PqsR as drug target was 
further corroborated by the benzamido-benzimidazole antagonists 2 and 3. These antagonists 
originated from a high throughput screening (HTS) campaign. 3 was demonstrated to be 
efficacious in mouse acute infection models as standalone treatment and as a pathoblocker-
antibiotic combination therapy.29 All discovered antagonist suffer from poor physicochemical 
properties. To address this issue, we initiated two fragment screening campaigns
30,31
 which led 
to chemically diverse ligands. The optimization of 2-amino-pyridine derivatives (4) resulted in 
nanomolar active antagonists as described in Chapter B.  
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Figure 11: Published PqsR antagonists (1-4) and schematic representation of the applied 
medicinal chemistry strategy 
This chapter deals with the nifty development of hybrid compounds by merging of the reported 
HTS hit 2 and the fragment-screening-derived antagonist 4. We were able to generate a 
plausible binding-pose of 2 based on a pharmacophore-guided docking approach. An overlay 
with the crystal structure of 4 led to the synthesis of hybrid compounds consisting of a 
trifluoromethyl-pyridine headgroup derived from a fragment screening described in Chapter B 
and the thioglycolamide-aryl moieties of 2 and 3, respectively. These hybrid compounds 
showed an improved physico-chemical profile while keeping high on-target and antivirulence 
activities. Furthermore, these compounds displayed specific effects on P. aeruginosa biofilms 
by abolishing the release of eDNA. 
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RESULTS AND DISCUSSION 
 
Chemistry. Fragment hits 5 and 6 were obtained from commercial suppliers. The synthesis of 
the key precursors 2a and 3a is shown in Scheme 1. The particular anilines were condensed 
with thioglycolic acid in neat reaction at 130°C under an argon atmosphere.32 After cooling to 
RT the product was isolated in good yields by simple trituration with isopropanol and filtration.  
 
Scheme 1. Synthesis of Thioglycolamide Precursorsa 
 
aReagents and Conditions: a) pressure vial, neat, 130°C, Ar. 
 
The heteroaryl halide 7a was synthesized as described in Chapter B. Precursors 8a, 9a and 
13a were obtained from commercial suppliers. Hybrid compounds 7-12 were synthesized as 
outlined in Scheme 2. Heteroaryl halides 7a-9a, 13a were reacted with 2a and 3a in a classical 
SNAr reaction using potassium carbonate as base to give the final products 7-13. 
 
Scheme 2. Synthesis of Hybrid Compounds  
 
aReagents and Conditions: a) K2CO3, DMF, -20°C to RT, Ar. 
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In-silico studies. Fragment-based lead discovery and HTS are often described as “mutually 
exclusive” strategies although there are complementary aspects of both approaches as well.33 
The discovery of benzamido-benzimidazole PqsR antagonists29 (2 and 3) by a HTS screening 
inspired us to investigate on their binding mode (Figure 1) in order to combine these insights 
with structural information of the identified fragment hits. The nitro moiety was identified as 
obvious common feature in the quinolone class (1)26 and in the benzamido-benzimidazole class 
(2 and 3)29. Hence, we hypnotized that both antagonist classes overlap at this position in the 
LBD. The structure of the LBD in complex with the quinolone derivatives NHQ28 (2-nonyl-4-
quinolone) and HHQ were resolved. Based on these crystallographic results we derived a 
binding pose of the highly similar antagonist 1 (Figure 2A). Following our hypothesis, the nitro 
moiety and the adjacent aryl ring were defined as essential pharmacophore points. 
Subsequently, a pharmacophore-guided docking study with compound 2 was conducted. 2 was 
used due to lower number of rotatable bounds compared to 3 what facilitated a more accurate 
docking due to lower degrees of conformational freedom in the ligand.  
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Figure 2: PqsR docking studies: a) overlay of modeled binding mode of 1 (blue) and highest 
scored docking pose for 2 (yellow) b) overlay of the crystal structure of 4 and highest ranked 
docking pose of 2 (yellow) c) alternative binding pose of 2 (yellow) superimposed with crystal 
structure of 4 
The thioglycol amide linker adopted an angled position in all generated docking poses which 
positioned the 4-chloro-phenyl ring in the alkyl sidechain pocket of HHQ. We superimposed 
these docking poses with the crystal structure of 4 (Figure 2B and 2C). The trifluoromethyl 
moiety of 4 is similarly oriented as the nitro group of 1 and 2. This finding was in line with the 
SAR observed by Lu et al. where the nitro group was exchanged by trifluoromethyl without any 
change of the antagonistic activity.26 To further validate our binding hypothesis, we used 
fragment competition studies. The amino-pyridine headgroup of 4 binds into the quinolone 
pocket (Figure 2B) and fragment 5 was used as a mimic thereof. According to our hypothesis 
the 5-nitro-benzimidazole heterocycle of 2 also occupies the same part of the pocket. In this 
case, fragment 6 was used. 
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Figure 3: ITC competition experiments. Raw ITC data are shown on top and integrated 
normalized data on bottom. Titration of 150 µM PqsR with 1500 µM 6 (■, black curve); Titration 
of 150 µM PqsR with 1500 µM 6 in the presence of 1500 µM compound 5 (Δ, red curve). 
According to isothermal titration calorimetry (ITC) competition experiments both fragments 
compete for binding to PqsR (Figure 3) what is indicated by the loss of heat release when 6 is 
titrated to PqsR in the presence of 5. This finding clearly corroborates our binding model. 
Overall, the most striking difference between the particular docking poses of 2 was observed for 
the most flexible linker part. Comparing the poses depicted in Figure 2B and 2C, the position of 
the benzimidazole is shifted leading to altered linker geometry. These results promoted the 
positions 2-4 at the pyridine as possible attachment points for the thioglycolamide aryl moiety 
(Figure 1). In a parallel approach, the 4-position was discovered as vector for growing the 
trifluoromethyl pyridine headgroup (see Chapter B).Thus, this position was included and the fact 
that similar heteroaryl compounds were also reported as hits from the HTS campaign34 
encouraged us to pursue also the 2-position as possible attachment point. The 3-position, 
however, was lower ranked in priority due to the more difficult synthetic feasibility caused by the 
higher electron density in meta-position of the pyridine ring.  
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Hybrid antagonists. Compounds 7 and 8 were rapidly accessible via a nucleophilic substitution 
reaction in 2- and 4-position of the pyridine ring, respectively. At first, potential PqsR 
antagonists were evaluated in a heterologous E. coli reporter gene system. This system allows 
an undistorted analysis of agonistic or antagonistic properties without the penetration problems 
observed in P. aeruginosa and possible bacteria-mediated deactivation of test compounds.27 
Compounds displaying sufficient antagonistic properties were further analyzed for their effect on 
the virulence factor pyocyanin and the signaling molcecule HHQ in P. aeruginosa. Moreover, 
the solubility of the compounds under assay conditions was determined. Subsequently, the 
ligand lipophilicity efficiency (LLE) was calculated which evaluates the potency normalized for 
the heavy atom count of a compound taking also lipophilicity into account.35 Hybrid molecules 7 
and 8 showed antagonistic activities in the nanomolar range and were able to translate these 
activities into inhibition of pyocyanin in the low micromolar range (Table 1). Additionally, both 
compounds were able to affect the levels of the signaling molecule HHQ and their 
superimposition suggested synthesizing compound 9. The latter showed a comparable profile to 
8 regarding antagonistic activity and pyocyanin inhibition but a significantly lowered clogD, 
which was also reflected in a slightly improved LLE.  
Encouraged by these results and inspired by the SAR reported by Starkey et al.29 we decided to 
exchange the chloro substituent for a phenoxy moiety (10-12). For all three headgroups an 
enhanced antagonistic activity was observed. There was a 22 fold (7 vs. 10) and 33 fold (9 vs. 
12) boost in activity for the 4-position linked headgroups with amino function, whereas we 
measured a 2-fold increase (8 vs. 11) for the at the 2-position linked pyridine. These findings 
raised the question whether the presence of the NH2 moiety or the positioning of 
thioglycolamide linker in 2- or 4-position of the pyridine nitrogen is pivotal for antagonistic 
activity. As an answer, the missing link 13 was synthesized. The latter showed a 2-fold 
improved antagonistic activity (10 IC50 = 0.019±0.001 µM vs. 13 IC50 = 0.008±0.003 µM) leading 
to the conclusion that the amino group is an accessory feature to enhance the physicochemical 
properties but not fundamental for activity when combined with the R2 tail. In contrary, the 
positioning of the pyridine nitrogen is more determining. The attachment of the linker in 4-
position of the pyridine is clearly favored (11 IC50 = 0.086±0.05 µM vs. 13 IC50 = 0.008±0.003 
µM).  
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Table 1: Biological and physico-chemical properties of PqsR antagonists
 
 
Num
ber 
Structure Antagonistic 
Activity 
IC50 [µM]
a
 
Pyocyanin 
Inhibition 
IC50 [µM]
b
 
HHQ 
Inhibition 
[µM]
c
 
Solubility 
[µM]
d
 
clogD 
pH 7.4
e
 
LLE 
(Astex)
f
 
3 
(M64)  
0.005±0.001 0.12±0.01 0.22* 25 4.7 0.29 
7 
 
0.426±0.10 12±0.7 42±1 
@ 50 µM 
100 3.7 0.27 
8 
 
0.176±0.10 4.8±0.3 
30±8  
@ 50 µM 
50 3.7 0.30 
9 
 
0.233±0.02 8.3± 4.6 40±2 
@ 50 µM 
100 3.0 0.33 
10 
 
0.019 ±0.001 0.276±0.02 0.52±0.05 25 4.4 0.28 
11 
 
0.086±0.05 0.822±0.30 44±3 
@ 5 µM 
12.5 4.5 0.24 
12 
 
0.007±0.004 0.384±0.13 2.29±0.1 50 3.0 0.36 
13 
 
0.008±0.003 0.339±0.02 0.54±0.05 12.5 4.3 0.30 
 aevaluated in an E. coli reporter gene assay in the presence of 50 nM PQS; IC50 represents the 
concentration of the half maximal antagonistic activity. bmeasured photometrically after 
extraction from PA14 cultures; IC50 represents the concentration of 50% inhibition. 
cmeasured 
by UPLC-MS from PA14pqsH cultures and referenced against DMSO control. ddetermined in 
PPGAS medium at 1% DMSO by visual inspection ecalculated using ACD/Percepta 2015. 
fligand lipophilicity efficiency36 determined from antagonistic activity, heavy atom count and 
clogD. *measured once.  
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It was of major interest to quantify the effect of the top candidates 10 and 12 on the 2-amino-
acetophenone (2-AA) in PA14 wt. 2-AA is a shunt product of the AHQ biosynthesis process36 
and promotes chronic infection phenotypes37 as well as accumulation of persister cells38 in 
P. aeruginosa. Compound 10 showed potent inhibition of 2-AA production (IC50 = 1.2 ± 0.2 µM) 
whereas the effect of compound 12 leveled out at around 50% (Figure 4). Remarkably, both 
compounds showed comparable effects regarding pyocyanin inhibition (Figure 4) and 
antagonistic activity in the reporter gene assay (Table 1). A similar scenario was observed for 
the inhibition of HHQ production (10 IC50 = 0.54±0.05 µM vs. 12 IC50 = 2.29±0.1 µM). These 
data emphasizes that small changes (pyridine to pyrimidine) within a molecule can drastically 
influence the efficacy of the antagonists to inhibit the AHQ biosynthesis and virulence 
expression (pyocyanin).  
 
 
Figure 4: Dose-response curves for the inhibition of pyocyanin and 2-AA in PA14 wt for 
compound 10 (A, upper row) and 12 (B lower row). Given data represent the mean of at least 
two independent experiments with n=3. Non linear regression analysis (continuous black line) 
was applied to determine IC50 values using a four variables model with constrains (bottom = 0 
and top = 100 % except for the effect of 12 on 2-AA) included in Graph Pad Prism (5.04).  
Compounds containing an amino-pyridine and -pyrimidine scaffold are frequently reported as 
inhibitors of different kinases.39,40 Therefore, we analyzed selected compounds for potential 
cytotoxic effects on eukaryotic HEK293 cells (SI Table S1). None of the tested compounds 
affected cell viability except for compound 7 but only at a significantly higher concentration than 
the measured effect on pyocyanin. Additionally, the scaffolds were subjected to an in silico 
toxicology prediction41 using the Derek Nexus database. This screening displayed no alerts 
concerning the amino-pyridine and -pyrimidine headgroups.  
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Overall, compound 12 showed the best combination of nanomolar antagonistic activity, potent 
pyocyanin inhibition and remarkable physicochemical properties, which is reflected by a 
strikingly better LLE value compared to the benchmark compound 3.  
 
Effects on static biofilms and lecB expression in P. aeruginosa. Compound 12 was 
selected for further evaluation in a static biofilm assay. The bacteria growing in sessile biofilm 
phenotype are prevalently found in most chronic infections caused by P. aeruginosa.
25
 Biofilms 
are bacterial communities embedded in a self-produced polymeric matrix attached to a 
surface.42 The structural components of this matrix are mainly polysaccharides, proteins and 
DNA.
43
 The establishment of a biofilm is a complex regulatory process, which necessitates 
close coordination by the involved regulatory systems. The pqs QS system clearly affects P. 
aeruginosa biofilm formation19 regulatory mechanisms by triggering the release of eDNA22 and 
lectinA/B expression.23 Besides its function as cell-connecting component during biofilm 
development,44 eDNA protects sessile bacteria from host immune response and antibacterial 
treatment by the complexation of cationic peptides and xenobiotics.45  
LectinA/B are carbohydrate-binding proteins which play important roles for surface attachment 
and stability of P. aeruginosa biofilms.23,46 The effect of PqsR antagonists on P. aeruginosa 
biofilms was first reported by Ilangovan et al.28 However, the doses employed for these 
experiments have not been reported. Hence, we sought to investigate the biofilm effects of our 
antagonist in more detail. PA14 static biofilms were grown in the presence of 5 µM of the 
antagonist 12 for 24 h. We evaluated total biofilm volume (biomass) as well as the pqs-
dependent biofilm component eDNA (Figure 4A). While the PqsR antagonist 12 displayed only 
minor effects on the whole biovolume, it completely inhibited the accumulation of eDNA. This 
observation is in line with our results for the pqsR negative mutant. Moreover, compounds 10 
and 12 showed potent inhibition of lectinB in P. aeruginosa (Figure 4B). Notably, these 
experiments were performed in planktonic PAO1 cultures due to experimental feasibility and the 
specificity of the used antibody. Nonetheless, the results of these experiments clearly underline 
the specific antivirulence effects of these compounds.  
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Figure 4. A) Effects of compound 12 on PA14 static biofilms. While only a low effect was 
observed on total biofilm volume, compound 12 was able to drastically reduce eDNA 
accumulation to levels comparable with the pqsR
-
 mutant strain. Error bars represent standard 
error of at least two independent experiments.**** = p < 0.0001. B) Western blot analysis of 
LecB eexpression in P. aeruginosa PAO1. Total cell (TC) fractions were analyzed by 
immunoblotting using anti-LecB serum. Cultures were grown for 24 h in absence or presence of 
compound 10 or 12 (5 µM or 25 µM).  
 
CONCLUSION 
Growing in a biofilm mode is the native form of bacterial lifestyle.47 This lifestyle allows bacteria 
to colonize different niches and protects the single organism against severe external 
conditions.42,47 These insights altered the perspective on our bacterial opponent - from 
planktonic unicellular organisms to highly organized sessile communities. Nevertheless, 
learning, how these communities are organized, enables the development of alternative 
treatment strategies for the post antibiotic era.48 In this study, we describe the development of 
improved lead compounds interfering with P. aeruginosa cell-to-cell communication with the aim 
to contribute to the development pipeline towards novel, innovative antimicrobials. Based on 
cocrystal structures and in silico methods, we developed a plausible binding-pose for the HTS 
hit 2.29 An overlay with the cocrystal-structure of in-house fragment derived antagonist 4 showed 
that both scaffolds partially overlap in the quinolone binding pocket of PqsR. This finding raised 
the idea to merge the trifluoro-pyridine headgroup with the benzamido-benzimdazole scaffold (2 
and 3). This strategy resulted in the straightforward development of hybrid PqsR antagonists 
resulting in potent pyocyanin, HHQ and 2-AA inhibition in P. aeruginosa while keeping superior 
physicochemical properties. In doing so, the potentially problematic nitro moiety at the 
benzimidazole core was exchanged by a more drug-like trifluoromethyl group. Subsequently, 
these compounds were profiled for their effects on PA14 static biofilms. For some of the 
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described biofilm inhibiting compounds the exact mode of action is poorly understood or their 
effect might be mediated through a direct physicochemical interaction with the biofilm matrix.49 
In contrast, the effects of our PqsR antagonist were in accordance with the biofilm profile 
generated by a pqsR mutant strain: the overall biovolume was only slightly affected but the pqs-
mediated release of eDNA was completely abolished. To what extent the reduction of eDNA 
and expression of lectinB affects the biofilm structure and permeability will be addressed in 
future experiments.  
Taken together, in this approach we successfully combined the best features of two apparently 
mutual worlds – phenotypic HTS and fragment screening – in order to push the development of 
antivirulence agents against severe P. aeruginosa infections.  
 
EXPERIMENTAL SECTION 
In silico studies. The structure of the PqsR:1 complex was modelled based on a solved X-ray 
structure of HHQ (Chapter B) bound to its receptor. The original coordinates were loaded into 
Molecular Operating Environment (MOE 2014, Chemical Computing Group) and the additional 
carboxamide and nitro substituents were attached to the ligand using the “Builder” function. 
Then the resulting complex structure was energy minimized using the standard LigX parameters 
together with the AMBER10:EHT forcefield to yield the model of compound 1 in complex with 
PqsR.The structure of the PqsR:2 complex was generated through a pharmacophore-guided 
docking. To this end, a two-feature pharmacophore model comprising an aromatic cycle and an 
electron-withdrawing group, which were placed inside the quinolone pocket of PqsR. A solved 
X-ray structure of bound antagonist 4 was used as template (see Chapter B). Then, the built-in 
“induced-fit” docking protocol was applied using the described pharmacophore as placement 
constraint, AMBER10:EHT force field, and standard parameters. The two highest scoring 
docking poses of compound 2 were additionally energy minimized to yield the complex 
structures depicted in Figure 2. 
Reporter Gene Assay in E. coli. The ability of the compounds to either stimulate or antagonize 
the PqsR-dependent transcription was analysed as previously described26 using a β-
galactosidase reporter gene assay in E. coli50 expressing PqsR. 
Pyocyanin Assay. Pyocyanin produced by P. aeruginosa PA14 was determined as reported 
previously26 according to the method of Essar et al.51 
Isothermal titration calorimetry ITC titrations were carried out as previously reported.30,31 
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Determination of Extracellular HHQ and 2-AA. Extracellular levels of HHQ from PA14 pqsH 
cultures were determined as previously reported27,52 according to the methods of Lépine et al.53 
For the quantification of 2-AA PA14 wt was used following the same protocol as for HHQ 
quantification whether a slightly modified sample work-up was performed. Briefly, 750 µL of 
culture was diluted with the same volume of 1 µM d4HHQ in acetonitrile, shaken for 5 min at 
1,500 rpm, and centrifuged at 14,000 rpm for 10 min. Afterwards 1 mL of supernatant of each 
sample was transferred in a vial for analysis by HPLC-MS/MS. Calibration curve of 2-AA was 
prepared according to the same procedure using PA14 pqsA mutant as biomatrix. 
Biofilm assay in PA14 For the determination of biofilm components in PA14 static biofilms, we 
followed reported procedures with a few modifications.22,54 Briefly, cultures of PA14 (or 
PA14pqsR) were grown in M63 medium in 96 well plates (Greiner, clear flat bottom) for 24 h at 
37°C in the presence of test compound added as DMSO stock solution or DMSO as control to 
give 1% (v/v) final DMSO concentration. After washing the matured biofilm with PBS and water, 
biofilm components were stained either with crystal violet (0.1 mg/ml dissolved in water/ethanol 
95/5 (v/v)) for the whole biomass or with propidium iodine solution (0.05 mg/ml dissolved in 
water). For quantification of the whole biomass absorbance was measured at 590 nm and for 
eDNA florescence at 620 nm using FLUOstar Omega (BMG Labtech). Given values represent 
the mean of at least two independent experiments with n=5. Differences in between treated and 
untreated samples were evaluated using a one way ANOVA followed by a two-sided Holm-
Sidak’s multiple comparison test using GraphPad Prism version 6.0f for Mac OS X, GraphPad 
Software. Differences were considered significant at a p-value < 0.05. 
LectinB expression P. aeruginosa PAO1 cultures were grown in LB medium at 37 °C. 
Compounds were dissolved in DMSO. Compound 10 or 12 was added to 2.5 mL LB and the 
DMSO concentrations were adjusted to keep the same concentrations in all samples. Overnight 
cultures were used to inoculate fresh LB medium to an OD600 of 0.02 and 2.5 mL of this 
bacterial culture was added to the 2.5 mL LB samples containing compound 10 or 12 or only 
DMSO. The final cultures had an starting OD600 of 0.01 and final compound concentration of 5 
µM or 25 µM. Bacterial cultures were incubated at 37 °C (200 rpm) for 24 h. Bacteria were 
harvested by centrifugation at 21380 rcf for 10 minutes. The supernatant was discarded and 
pellets were resuspended in SDS loading buffer (50 mM Tris-HCl pH 6.8, 10% (v/v) glycerol, 2% 
(v/v) SDS, 100 mM DTT, bromphenolblue) and denatured by heating (98 °C, 5 min). Total cell 
extracts were analyzed by 15% SDS–PAGE and Coomassie staining (SI Figure S3) or immune 
blotting. In each case, total cell extracts of approximately 2x108 bacteria were loaded per lane. 
For detection of LecB in total cells, proteins were transferred onto a nitrocellulose membrane 
(Amersham; GE Healthcare). After blocking the membrane (5% milk in PBST (137 mM NaCl, 
2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4 and 0.2% Tween)) immunodetection was 
carried out using rabbit antiserum against LecB (1:500 in 5% milk in PBST). Detection was 
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performed using the goat anti-rabbit secondary antibody conjugated to horseradish peroxidase 
(1:5000 in 5% milk in PBST; Dianova), before development with chemiluminescent substrate 
(100 mM Tris-HCl pH 8.5, 0.009% H2O2, 1.25 mM luminol, 225 µM coumaric acid) and detection 
with a Fusion imager (Vilber Lourmat). 
Chemical and Analytical Methods. 1H and 13C NMR spectra were recorded as indicated on a 
Bruker DRX-500 instrument or a Bruker Fourier 300 instrument. Chemical shifts are given in 
parts per million (ppm), and referenced against the residual solvent peak. Coupling constants 
(J) are given in hertz. Mass spectrometry and purity determination (LC/MS) was performed 
either on a SpectraSystems-MSQ LCMS system (Thermo Fisher Scientific) consisting of a 
pump, an autosampler, VWD detector or on Waters LCMS-System consisting of a 767 sample 
Manager, a 2545 binary gradient pump, a 2998 PDA detector and a 3100 electron spray mass 
spectrometer. All solvents were HPLC grade. The purity of tested final products was > 95%. 
Procedures were not optimized regarding yield. Microwave assisted synthesis was carried out in 
a Discover microwave synthesis system (CEM). Column chromatography was performed using 
the automated flash chromatography system Combiflash Rf+ (Teledyne Isco) equipped with 
RediSepRf silica columns. Final products were dried in high vacuum.  
General Procedure A: N-phenyl-2-mercaptoacetamide precursors. Aniline (1 eq) was filled 
into a crimp vial (Biotage®). The vial was evacuated and backfilled with argon (3 times). 2-
mercaptoacetic acid (1 eq) was added (neat reaction) and the vial flushed with argon (5 min). 
The reaction mixture was heated to 130°C in a metal block for 1.5 h. The mixture was allowed 
to cool to RT. The resulting solid was suspended in isopropanol and filtered. The resulting white 
cake was washed with IPA to give the titled product. 
General Procedure B: Hybrid compounds.Heteroaryl halide (0.35 mmol) and K2CO3 (1.05 
mmol) was suspended in DMF (1 ml) using a crimp vial (Biotage
®
). The vial was purged with 
argon. A solution of N-phenyl-2-mercaptoacetamide (0.38 mmol) in 1 ml DMF was added while 
cooling in an ice-bath. The mixture was again purged with argon. The reaction was aged at RT 
for 6 h. The mixture was poured into water and extracted with ethylacetate (3 times). The 
combined organics were washed with Na2CO3 saturated solution and brine. The organic extract 
was dried over Na2SO4, filtered and dried. Purification was done by automated flash 
chromatography or preparative HPLC. 
2-((2-amino-6-(trifluoromethyl)pyridin-4-yl)thio)-N-(4-chlorophenyl)acetamide (7) was 
synthesized according to general procedure B from 4-iodo-6-(trifluoromethyl)pyridin-2-amine 
(100 mg, 0.347 mmol and N-(4-chlorophenyl)-2-mercaptoacetamide (77 mg, 0.382 mmol). The 
crude product was purified by automated flash chromatography using a gradient of petroleum 
ether to pure ether. Further purification by prep HPLC afforded the titled product as white solid 
(24 mg, 0.066 mmol, 19 % yield). 1H NMR (300 MHz, DMSO-d6)  ppm 3.99 (s, 2 H), 6.56 (s, 3 
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H), 6.89 (d, J=1.3 Hz, 1 H), 7.23 - 7.45 (m, 1 H), 7.52 - 7.68 (m, 2 H), 10.44 (s, 1 H); 
13
C NMR 
(75 MHz, DMSO-d6)  ppm 35.12, 105.53 (q, 
3J(C,F)=2.2 Hz, 1 C), 106.79, 125.21 (q, 
1J(C,F)=275.0 Hz, 1 C), 120.77 (2 C), 127.19, 128.71 (2 C), 137.62, 145.00 (q, 2J(C,F)=32.8 Hz, 
1 C), 149.43, 159.75, 166.06; MS (ESI +) m/z 362 (M+H)+, 403 (M+ACN+H)+. 
N-(4-chlorophenyl)-2-((6-(trifluoromethyl)pyridin-2-yl)thio)acetamide (8) was synthesized 
according to general procedure B from 2-bromo-6-(trifluoromethyl)pyridine (226 mg, 1,000 
mmol) and N-(4-chlorophenyl)-2-mercaptoacetamide (212 mg, 1.050 mmol). The mixture was 
stirred for 1 h at -78 °C and than at 0°C for 1h. Purification was done by automated flash 
chromatography using a gradient of petroleum ether and ethylacetate. The crude product was 
titurated with DCM/pentane and filtered to give the titled product as a white solid (65 mg, 0.19 
mmol, 18 % yield). 1H NMR (500 MHz, DMSO-d6)  ppm 4.11 (s, 2 H), 7.30 - 7.39 (m, 2 H), 7.53 
- 7.64 (m, 3 H), 7.70 (d, J=7.9 Hz, 1 H), 7.92 (t, J=6.9 Hz, 1 H), 10.40 (s, 1 H); 
13
C NMR (126 
MHz, DMSO-d6)  ppm 34.73, 116.59, 121.23 (q 
1J(C,F)=272.0 Hz, 1 C), 120.66 (s, 2 C), 
125.17, 126.86, 128.58 (s, 2 C), 137.92, 138.38, 146.10 (q, 2J(C,F)=32.0 Hz, 1 C), 159.57, 
166.10; MS (ESI +) m/z not found. 
2-((6-amino-2-(trifluoromethyl)pyrimidin-4-yl)thio)-N-(4-chlorophenyl)acetamide (9) was 
synthesized according to general procedure B from 6-chloro-2-(trifluoromethyl)pyrimidin-4-
amine (100 mg, 0.51 mmol) and N-(4-chlorophenyl)-2-mercaptoacetamide (102 mg, 0.51 mmol). 
Purification was done by automated flash chromatography using a gradient petroleum ether and 
ethylacetate (9/1 to 1/1) to give the titled compound as light yellow solid (45 mg, 0,124 mmol, 
24% yield). 1H NMR (500 MHz, DMSO-d6)  ppm 4.03 (s, 2 H), 6.50 (s, 1 H), 7.27 - 7.42 (m, 2 
H), 7.49 (br. s., 2 H), 7.53 - 7.67 (m, 2 H), 10.40 (s, 1 H); 13C NMR (126 MHz, DMSO-d6)  ppm 
34.22, 100.99, 119.42 (q, 1J(C,F)=275.8 Hz, 1 C), 120.73 (2 C), 127.00, 128.70 (2 C), 137.89, 
154.52 (q, 2J(C,F)=33.0 Hz, 1 C), 163.27, 166.06, 166.62; MS(ESI+) m/z 363 (M+H)+. 
2-((2-amino-6-(trifluoromethyl)pyridin-4-yl)thio)-N-(4-phenoxyphenyl)acetamide (10) was 
synthesized according to general procedure B from 4-iodo-6-(trifluoromethyl)pyridin-2-amine 
(100 mg, 0.35 mmol) and 2-mercapto-N-(4-phenoxyphenyl)acetamide (99 mg, 0.38 mmol). 
Purification was done by automated flash chromatography using a gradient of petroleum ether 
and diethyl ether (1/1 to 2/8). Further purification by prep HPLC to give 2-((2-amino-6-
(trifluoromethyl)pyridin-4-yl)thio)-N-(4-phenoxyphenyl)acetamide (20 mg, 0.05 mmol, 14 % yield) 
as white solid. 1H NMR (300 MHz, CHLOROFORM-d)  ppm 3.83 (s, 2 H), 4.76 (s, 2 H), 6.44 
(d, J=0.8 Hz, 1 H), 6.91 (d, J=1.4 Hz, 1 H), 6.95 - 7.05 (m, 4 H), 7.07 - 7.14 (m, 1 H), 7.29 - 7.37 
(m, 2 H), 7.39 - 7.47 (m, 2 H), 8.22 (s, 1 H); 13C NMR (75 MHz, DMSO-d6)  ppm 35.08, 105.56 
(q, 1J(C,F)=3.0 Hz, 1 C), 106.80, 117.93 (2 C), 119.43 (2 C), 121.61 (d, 1J(C,F)=274.0 Hz, 1 C), 
120.95 (2 C), 123.03, 129.95 (2 C), 134.55, 145.03 (q, 2J(C,F)=32.0 Hz, 1 C), 149.55, 152.08, 
157.22, 159.77, 165.71; MS(ESI+) m/z 420 (M+H)+, 461 (M+ACN+H)+. 
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N-(4-phenoxyphenyl)-2-((6-(trifluoromethyl)pyridin-2-yl)thio)acetamide (11) was 
synthesized according to general procedure B from 2-bromo-6-(trifluoromethyl)pyridine (100 
mg, 0.44 mmol) and 2-mercapto-N-(4-phenoxyphenyl)acetamide (115 mg, 0.44 mmol) e mixture 
was poured into water solution and extracted using EA. Combined organics were washed with 
brine, dried (Na2SO4), filtered and concentrated. Purification was done by automated flash 
chromatography using a gradient of petroleum ether and ethylacetate (9/1 to pure ethylacetate) 
to give the titled product as off white solid (135 mg, 0.334 mmol, 75 % yield). 1H NMR (500 
MHz, DMSO-d6)  ppm 4.12 (s, 2 H), 6.88 - 7.03 (m, 4 H), 7.09 (t, J=7.4 Hz, 1 H), 7.31 - 7.41 
(m, 2 H), 7.57 (d, J=8.8 Hz, 2 H), 7.60 (d, J=7.6 Hz, 1 H), 7.71 (d, J=8.2 Hz, 1 H), 7.92 (t, J=7.9 
Hz, 1 H), 10.32 (s, 1 H); 13C NMR (126 MHz, DMSO-d6)  ppm 34.66, 116.58 (q, 
1J(C,F)=2.8 
Hz, 1 C), 117.85 (2 C), 121.27 (q, 
1
J(C,F)=274.9 Hz, 1 C), 119.37 (2 C), 120.85 (2 C), 122.95, 
125.16, 129.92 (2 C), 134.83, 138.39, 146.10 (q, 2J(C,F)=33.9 Hz, 1 C), 151.79, 157.27, 159.70, 
165.72; MS(ESI+) m/z 427 (M+Na)+. 
2-((6-amino-2-(trifluoromethyl)pyrimidin-4-yl)thio)-N-(4-phenoxyphenyl)acetamide (12) 
was synthesized according to general procedure B from 6-chloro-2-(trifluoromethyl)pyrimidin-4-
amine (200 mg, 1.012 mmol) and 2-mercapto-N-(4-phenoxyphenyl)acetamide (263 mg, 1.012 
mmol). Purification was done by automated flash chromatography using a gradient of petroleum 
ether and ethylacetate (9/1 to pure ethylacetate) to give the titled product as white solid (45 mg, 
0.107 mmol, 11 % yield).1H NMR (500 MHz, DMSO-d6)  ppm 4.03 (s, 2 H), 6.51 (s, 1 H), 6.89 - 
7.04 (m, 4 H), 7.10 (t, J=7.4 Hz, 1 H), 7.30 - 7.40 (m, 2 H), 7.50 (br. s., 2 H), 7.55 - 7.62 (m, 2 
H), 10.30 (s, 1 H); 13C NMR (126 MHz, DMSO-d6) ppm 34.09, 100.91, 119.35 (q, 
1J(C,F) 
=275.8 Hz, 1 C), 117.86 (2 C), 119.40 (2 C), 120.87 (2 C), 122.97, 129.93 (2 C), 134.73, 
151.87, 154.46 (q, 2J(C,F)=34.8 Hz, 1 C), 157.24, 163.24, 165.61, 166.71. MS(ESI+) m/z 421 
(M+H)+. 
N-(4-phenoxyphenyl)-2-((2-(trifluoromethyl)pyridin-4-yl)thio)acetamide (13) was 
synthesized according to general procedure B from 4-bromo-2-(trifluoromethyl)pyridine (200 
mg, 0.885 mmol) and 2-mercapto-N-(4-phenoxyphenyl)acetamide (229 mg, 0.885 mmol). 
Purification was done by automated flash chromatography using a gradient of petroleum ether 
and ethylacetate (petroleum ether pure to 8/2) to give the titled product as white solid (210 mg, 
0.519 mmol, 59% yield). 1H NMR (500 MHz, DMSO-d6)  ppm 4.14 (s, 2 H), 6.90 - 7.04 (m, 4 
H), 7.05 - 7.19 (m, 1 H), 7.30 - 7.42 (m, 2 H), 7.50 - 7.61 (m, 2 H), 7.66 (dd, J=5.4, 1.6 Hz, 1 H), 
7.88 (d, J=1.6 Hz, 1 H), 8.56 (d, J=5.4 Hz, 1 H), 10.40 (s, 1 H); 13C NMR (126 MHz, DMSO-d6)  
ppm 34.85, 117.26 (d, 3J(C,F)=2.7 Hz, 1 C), 117.96 (2 C), 121.49 (q, 1J(C,F)=274.0 Hz, 1 C), 
119.45 (2 C), 120.95 (2 C), 123.06, 123.49, 129.95 (2 C), 134.44, 146.37 (q, 2J(C,F)=33.0 Hz, 1 
C), 149.47, 151.35, 152.14, 157.18, 165.59; MS(ESI+) m/z 405 (M+H)+.  
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ABSTRACT 
Pseudomonas aeruginosa uses quorum sensing (QS) as a cell-to-cell communication system to 
orchestrate the expression of virulence determinants. The biosynthesis of the important 
Pseudomonas quinolone signal (PQS) requires the pqsABCDE operon. Here, PqsE acts as a 
pathway-specific thioesterase, but it also contributes to the regulation of bacterial virulence via 
an unknown mechanism. In this manuscript, we report the discovery of PqsE inhibitors as tool 
compounds to gain further insights into its different functions. Differential scanning fluorimetry 
(DSF) was used to screen a fragment library and isothermal titration calorimetry (ITC) was 
employed as a secondary filter. As proven by X-ray crystallography, hit molecules bound to the 
active center inhibiting PqsE‘s thioesterase activity and in cell-based and in vitro assays. 
Notably, the ligands did not affect the levels of the PqsE-regulated virulence factor pyocyanin. 
These findings indicate that the regulatory function of PqsE is not linked to its thioesterase 
activity and must be encoded outside of the active center. This study highlights the potential of 
fragment-based screening for the discovery of tool compounds. This approach provided novel 
insight into complex biological systems, which could not be obtained by knockout studies. 
 
INTRODUCTION 
Pseudomonas aeruginosa is a Gram-negative opportunistically pathogenic bacterium that 
infects multiple host organisms.1 It is extremely adaptable and thrives under manifold 
environmental conditions.2 The pathogen is responsible for several chronic and acute infections 
especially in hospitalized and immunocompromised patients.3 Furthermore, P. aeruginosa-
mediated pneumonia is the major cause of death in people suffering from cystic fibrosis .4 It is 
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more and more recognized that bacterial communities such as those of P. aeruginosa have the 
capability to coordinate their activities collectively. This process is called quorum sensing (QS) 
and relies on the release and uptake of small diffusible signaling molecules also referred to as 
autoinducers (AIs). The concentration of AIs increases as a function of bacterial cell-density. As 
soon as a certain threshold is reached, the expression of particular genes is altered. In P. 
aeruginosa, more than 6 % of the complete genome is regulated by QS networks.5 The QS-
dependent regulon includes genes involved in production of virulence factors as well as in 
general metabolic processes, which accounts for the central role of QS during infection and 
adaptation processes.5 P. aeruginosa mainly uses three interconnected QS circuitries: The las6 
and the rhl7 quorum sensing systems use acyl homoserine lactones (AHLs) as signaling 
molecules, which are a very common AI scaffold among Gram-negative bacteria. In addition, P. 
aeruginosa uses a rather unique system called pqs8 (Figure 1), which applies the 
alkylquinolones (AQs) PQS (the Pseudomonas Quinolone Signal) and HHQ (2-heptyl-4(1H)-
quinolone) (Figure 2) as signaling molecules. 
 
Figure 1. Schematic representation of the pqs system in P. aeruginosa emphasizing the impact 
of PqsE on virulence regulation. MvfR (PqsR; blue circle) is the transcriptional regulator which 
responds to the autoinducers of the pqs system (PQS and HHQ; white triangles). PqsA-E are 
signal molecule synthases (for details see Figure 2). RhlR (brown circle) is the transcriptional 
regulator which responds to the autoinducer of the rhl system (C4HSL; black triangle). Virulence 
regulation by RhlR (brown arrow) is modulated by PqsE (green arrow) 
The biosynthesis of these quinolones (Figure 2) involves the expression of the pqsABCDE 
operon9,10 under the control of the signal receptor MvfR, often referred to as PqsR.11 AQs 
originate from anthranilic acid, which is first converted to anthraniloyl-CoA by PqsA.12 
Anthraniloyl-CoA is then condensed with malonyl-CoA by PqsD to form 2-aminobenzoylacetyl-
CoA (2-ABA-CoA).13,14 After hydrolysis by a thioesterase,15 the resulting 2-aminobenzoylacetate 
(2-ABA) is condensed with octanoyl-CoA by PqsBC to give HHQ,14 which undergoes 
hydroxylation catalyzed by PqsH to form PQS (Figure 2).16 Both alkylquinolones, HHQ and 
PQS, activate the receptor MvfR (PqsR) to upregulate their own biosynthesis via the 
pqsABCDE operon (autoinductive loop) and induce the production of several virulence factors.17 
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Figure 2. Biosynthesis of the signaling molecules HHQ and PQS 
PqsE takes part in AQ biosynthesis by catalyzing the hydrolysis of 2-ABA-CoA to form 2-ABA. 
This function, however, can to some extent be bypassed by housekeeping thioesterases, such 
as TesB, making PqsE dispensable for AQ biosynthesis.15 Importantly, it was demonstrated that 
PqsE is crucial for full P. aeruginosa virulence and even activates pqs-controlled virulence in the 
absence of a functional pqs system. This implies a pqs-independent regulatory role.10,18–20 Some 
of PqsE’s regulatory activities, for example the upregulation of the virulence factor pyocyanin, 
are mediated through the rhl system.18–20 
The crystal structure of PqsE shows a β-lactamase fold and a Fe(II)/Fe(III) center in the active 
site.21 An alanine scan identified key amino acids, which are required for the full production of 
pyocyanin.22 Taken together, despite many efforts, the exact biomolecular mechanism 
underlying the regulatory effect of PqsE remains elusive. However, due to its central role for P. 
aeruginosa virulence, PqsE might be an attractive future drug target. Hence, the discovery of 
specific tool compounds, which enable further insights into PqsE’s functions is highly desirable.  
To address this issue, a fragment screening using differential scanning fluorimetry (DSF) was 
conducted. This approach led to different carboxylic acid derivatives as top candidates (1-3; 
Figure 3). The hit molecules bound to the active center of PqsE and showed inhibition of the 
thioesterase activity in two different in vitro assays. The profiles of these compounds regarding 
AQs and pyocyanin in P. aeruginosa (PAO1) highlight a new facet of the putative role of PqsE 
in virulence regulation beyond its thioesterase function.  
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RESULTS AND DISCUSSION 
Fragment-Screening Approach. During a cell-free target-based drug discovery campaign, 
compounds with sufficient on-target activity have to be identified. In addition, good penetration 
through the bacterial cell envelope as well as evasion from efflux pumps have to be 
achieved.23,24 The physicochemical properties of most established antibiotics are strikingly 
different compared to compounds designed to hit eukaryotic targets.25 It is believed, that this 
discrepancy contributed to the disillusioning outcomes of many high-throughput screening 
campaigns in antibiotic drug discovery when using chemical libraries optimized for human 
targets.24 Fragment-based screening approaches are elegant tools to bypass these 
drawbacks.26,27 The screening of smaller libraries is sufficient to cover a large area of chemical 
space considering the possibility to grow, link, and merge fragments in subsequent optimization 
steps.
28
 
To identify PqsE ligands, a loose rule-of-three-compliant library sourced from Maybridge 
consisting of 500 fragments was screened by differential scanning fluorimetry (DSF). DSF is a 
spectroscopic technique that allows detection of a change in the protein melting temperature 
(∆TM) upon ligand binding.
28,29 For a positive control, we employed anthranilic acid, which had 
previously been identified to be a ligand of PqsE by isothermal titration calorimetry (ITC)21 and 
shifted the melting temperature by 2.6 K (at 1 mM). It has to be mentioned that a sharp melting 
curve required the presence of Mn2+ in the buffer. The fragments were tested at a concentration 
of 500 µM. Compounds showing a positive shift form a stabilized protein-ligand complex, which 
is reported as beneficial for further crystallization experiments.30 Hence, only fragments showing 
a ∆TM ≥ 1°K were considered. In total, this setup led to 10 confirmed hits accounting for a 2% hit 
rate (Figure 3A). Fragments containing a carboxylic acid motif were found predominantly (5 out 
of 10; SI Table 1) which was in accordance with the fact that a benzoic acid-shaped ligand was 
observed in the crystal structure.21 Nevertheless, the presence of this motif alone seems not to 
be sufficient given that only 5 of 35 carboxylic acids within the library showed a pronounced 
positive shift in melting temperature. We ranked the carboxylic acid-containing hits according to 
their ∆TM values and investigated top candidate 1 at different concentrations, which revealed a 
clear dose-dependency (Figure 3C). The other hit compounds were chemically diverse (SI, 
Table 1) and we decided to focus on the aforementioned carboxylic acid motif (1-3) as a 
privileged pharmacophore and on two additional unrelated scaffolds (4, 5). 
Compounds 1-5 were subjected to hit validation using ITC analysis (Figure 3B, 3D) which is 
considered as the gold standard secondary screening tool.31,32 The binding of the three top 
carboxylic acid derivatives (1-3) to PqsE was confirmed by ITC. Compound 1 showed a 
surprisingly good affinity (KD(ITC) = 0.9±0.3 µM) with respect to its fragment-like size. The binding 
was mostly enthalpy-driven, which accounts for specific non-covalent interactions between 1 
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and PqsE.
33
 A binding event was observed for screening hit 2, but the heat release was too low 
to derive a defined KD value under the tested conditions. Compound 3 showed a weaker affinity 
(KD(ITC) = 19.6±3.7 µM). The indole derivative 4 and phenoxazine 5 were not amenable to ITC 
analysis. 
 
Figure 3. PqsE fragment screening workflow. (A) DSF screening of 500 fragments; single ∆ 
represents the melting point shift in relation to DMSO control in °K (B) Structures of hit 
compounds showing highest ΔTM (1-3) and chemically diverse hits 4 and 5 (C) Dose-dependent 
melting point shift for 1; change of fluorescence while applying a temperature gradient shown as 
negative first derivative (D) representative ITC titration curve of 1 mM 1 against 100 µM 
H6PqsE; the recorded change of heat over time for 19 injections of ligand 1 (upper row); 
integrated heats (■) against the molar ratio of the reaction and 1:1 binding-model fit (continuous 
black line; lower row). 
X-ray crystallography. In a next step, we sought to gain insight into the exact binding modes of 
hit compounds 1-5 and to compare these with the structure of PqsE in complex with the reaction 
product 2-ABA.15 The short half-life (< 40s)15 of the PqsE substrate 2-ABA-CoA necessitated the 
use of the aforementioned hydrolysis product as a surrogate for crystallization experiments. To 
this end, crystals were soaked with the respective ligands. Only the carboxylic acid derivatives 
1-3 yielded complex structures at resolutions of 1.77 to 2.16 Å (Figure 4; Supplementary Table 
S2). Neither ITC (vide supra) nor crystallography indicated a specific binding of compound 4 
and 5 what disqualified these compounds from further biological profiling. The three carboxylic 
acid derivatives 1-3 (Figure 4B-D) occupy the same site as the β-keto acid 2-ABA (Figure 4A), 
but their binding mode around the binuclear active center differs from that of 2-ABA. The 
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complexes containing fragments 1-3 exhibit a water molecule bridging the two metal atoms. 
Notably, in the 2-ABA-bound structure, this position is occupied by the carboxylic acid moiety of 
the ligand. Both 2-ABA and ligands 1-3 are stabilized by mainly hydrophobic interactions 
mediated by Y72, E182, L193, F195, F276, L277, H282 and S285. In addition, the 2-NH2 group 
of 2-ABA forms a weak hydrogen bond with E182 (O-H distance: ~ 3.5 Å). Furthermore, the 
pyridine or pyrrole rings of compounds 1 and 2 undergo π-π-interactions with the side-chain of 
H71. For compound 3 an additional interaction between the sulfur of the thiophene group and 
the aromatic π-system of F195 is observed. 
 
Figure 4. Crystal structures of PqsE in complex with 2-aminobenzoylacetate (A) and screening 
hits 1-3 (B-D). The compounds are depicted in a ball-and-stick representation and their 
chemical structures are shown in the left corner of each panel. The di-iron center (light orange) 
and the side-chains forming the binding pocket (blue) of each compound are indicated. Fo-Fc 
difference electron density maps (green) before incorporation of the ligand are contoured at 3.0 
sigma. 
In vitro evaluation. Because the crystal structures of PqsE in complex with ligands 1-3 
revealed binding to the metal center in a similar position as 2-ABA, we investigated their 
inhibitory effect on the thioesterase activity of PqsE within AQ biosynthesis.15 The instability of 
PqsE’s substrate (2-ABA-CoA), which has an estimated half-life of ≤40 s,15 necessitated the 
development of a combined PqsDE assay. 2-ABA-CoA was generated in situ by PqsD from 
anthraniloyl-CoA and malonyl-CoA. 2-ABA-CoA can then either be hydrolyzed to 2-ABA by 
PqsE or decomposes to DHQ in an uncatalyzed reaction (SI, Figure S1). Quantification of 2-
ABA and DHQ was performed by LC-MS using a procedure that was optimized to prevent 2-
ABA decomposition to DHQ or 2-AA (as tested using chemically synthesized 2-ABA, see 
Experimental Section). In the absence of inhibitor, the reaction yielded a 1:1 mixture of 2-ABA 
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and DHQ, whereas inhibition of PqsE by compounds 1, 2, and 3 led to a dose-dependent 
increase of DHQ and a corresponding decrease in 2-ABA concentrations (Figure 5A). At highest 
inhibitor concentrations (1-3), the DHQ:2-ABA ratio was shifted to about 9:1, which clearly 
showed that the spontaneous decomposition of 2-ABA-CoA to DHQ predominated over the 
PqsE-mediated hydrolysis to 2-ABA. Due to the complexity of the coupled reaction, the 
apparent inhibition is not linearly correlating to PqsE thioesterase inhibition (model described in 
the SI, Figure S1), impeding exact quantitative conclusions. 
 
Figure 5. Coupled PqsDE assay. (A) effect of compounds 1, 2 and 3 (from left to right) on 2-
ABA concentration (depicted as □) and DHQ concentration (depicted as ○); inhibitor compound 
concentration shown on the x-axis. Data are from 2 independent experiments, each with 3 
technical replicates. Error bars denote standard errors (SEM). (B) Exemplary LC-MS 
chromatogram illustrating the separation of DHQ (161 Da) and 2-ABA (179 Da); upper row: UV 
trace (322 nm) of mixture of reference compounds; lower row: extracted ion chromatograms 
(m/z bandwidth 0.3 Da). 
 To address this issue and to simplify the assay conditions, we used S-(4-
nitrobenzoyl)mercaptoethane as an artificial PqsE substrate.21 According to the protocol of Yu et 
al., the release of ethanethiol was followed photometrically using Ellman’s reagent. Compounds 
1-3 were able to inhibit this reaction showing IC50 values in the micromolar range 
(1 IC50 = 25±4 µM; 2 IC50 = 155±38 µM; 3 IC50 = 40±12 µM). Taken together, the fragments 
identified by DSF showed inhibition of the isolated enzyme using an artificial substrate and were 
also active in a combined PqsDE assay reflecting a part of the natural AQ biosynthetic cascade. 
In vivo characterization. Given that the hit compounds (1-3) inhibited the thioesterase activity 
of PqsE in vitro, we next asked if they are also active in P. aeruginosa and interrupt PqsE’s role 
in virulence factor generation. To this end, we made use of the observation that a pqsE deletion 
mutant showed levels of HHQ comparable to those of wild-type P. aeruginosa,9,10 but strongly 
increased levels of DHQ.15 The biosynthesis of DHQ requires the enzymes PqsA and PqsD and 
DHQ emerges from spontaneous cyclisation of 2-ABA-CoA (Figure 2), whose concentration will 
be elevated in the absence of PqsE or when PqsE’s thioesterase activity is inhibited.13,14,34 
Consequently, compounds 1-3 were tested for their effect on HHQ and DHQ production in 
PAO1wt and PAO1pqsE. All three compounds (1-3) displayed a dose-dependent induction of 
DHQ formation in PAO1wt (Figure 6).  
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Figure 6. Effect of screening hits 1-3 on DHQ levels in PAO1. SD of the mean from at least two 
independent experiments with n=3. 
Compounds 1 and 3 increased the DHQ levels almost up to the level found in the pqsE mutant 
strain. In contrast to compound 3, 1 and 2 showed no additional inductive effect on DHQ 
production in the pqsE mutant, supporting an on-target mechanism of action in the living cell 
(SI, Figure S3). Moreover, no significant effect on HHQ levels (1 and 2) or only a low inhibition 
(3; SI, Figure S4) was found, which was in line with the results obtained for the pqsE mutant. 
Taken together, these findings clearly demonstrate that the PqsE thioesterase inhibitors (1-3) 
were able to permeate into P. aeruginosa and affect DHQ levels to a similar extent as deletion 
of the pqsE gene. Compounds (1-3) are therefore the first in vivo inhibitors of PqsE’s 
thioesterase activity. 
Knock-out studies clearly showed that production of the virulence factor pyocyanin, a blue 
redox-active phenazine pigment, depends on the presence of PqsE.10,18–20 Hence, hit 
compounds 1-3 were tested at 500 µM in PAO1 and the amount of pyocyanin was quantified 
photometrically after extraction. Notably, none of these PqsE thioesterase inhibitors had an 
inhibitory effect on pyocyanin production (Figure 7). This suggests that the regulatory function of 
PqsE is unrelated to its thioesterase activity.  
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Figure 7. Effect of screening hits 1-3 on pyocyanin levels in PAO1. SD of the mean from three 
independent experiments with n=3 
It has been shown that PqsE amplifies the induction of gene transcription by the QS regulator 
RhlR through an unknown mechanism, which leads to increased production of virulence factors 
(e.g. pyocyanin).18,20 To gain further insight, we sought to investigate the effect of our 
compounds on this PqsE-RhlR-mediated response. Farrow et al. described a heterologous E. 
coli reporter gene system to quantify the sensitizing effect of PqsE on C4-HSL-induced RhlR 
activity.18 We used this system to investigate whether the discovered PqsE ligands could 
attenuate this effect of PqsE. Compounds 1-3 were tested at 500 µM in two E. coli strains: the 
first harboring an rhlR-lacZ reporter plasmid and a plasmid constitutively expressing PqsE; the 
second carrying the same rhlR-lacZ reporter and an empty plasmid vector. When comparing 
both reporter strains, the galactosidase activity in response to 10 µM C4-HSL was enhanced 
2.4-fold in the presence of PqsE. This ratio was not significantly altered upon addition of 
compounds 1-3 (Figure 8). It has to be noted that RhlR-mediated expression was marginally 
increased by our compounds regardless of the absence or presence of PqsE. Nevertheless, our 
data clearly show that the thioesterase inhibitors 1-3 do not interfere with the RhlR mediated 
regulatory function of PqsE, which is consistent with the unaffected pyocyanin levels observed 
in P. aeruginosa. This further supports the hypothesis of the PqsE regulatory function not being 
linked to its thioesterase activity. 
 
Figure 8. Effects of compounds 1-3 on the PqsE sensitizing effect on RhlR in E. coli. 
Bars represent RhlR-mediated β-galactosidase expression in percent (control =100%), 
in the presence of 500 µM compound or DMSO as control. E. coli cultures harbour two 
plasmids: RhlR reporter gene plasmid and a plasmid for PqsE expression as indicated 
on the bars or the empty vector plasmid. RhlR was agonized with 10 µM C4HSL. 
Numbers on the black lines over the bars represent the ratio of the sensitizing effect. SD 
of the mean from two independent experiments with n=4. 
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Conclusion 
It has become more and more evident that P. aeruginosa colonies are not just an accumulation 
of unicellular organisms but rather highly organized communities. This behavior necessitates 
the use of fine-tuned regulatory mechanisms. In our study, we demonstrated the discovery of 
tool compounds, which shed light on the enigmatic role of PqsE within the complex QS 
regulatory systems of P. aeruginosa. A straightforward biophysical approach was initiated 
starting with a DSF screening of a fragment library, which led to various hits. Specific binding 
was proven for carboxylic acid derivatives 1-3 by ITC and protein crystallography. Moreover, the 
crystal structures revealed that all hit compounds bind to the catalytic center. The structure of 
PqsE in complex with its enzymatic product 2-ABA strongly indicated that all hits bind in 
competition to the native substrate 2-ABA-CoA. The identified PqsE ligands (1-3) inhibited the 
thioesterase activity of PqsE in two different in vitro assays. Applying these PqsE inhibitors to 
PAO1 cultures led to ambiguous results: On the one hand, an inductive effect on the DHQ 
levels similar to results of a pqsE mutant strain was observed. On the other hand, the 
production of virulence factor pyocyanin remained unaffected. These results are in accordance 
with the reported knock-out complementation studies showing that the effect of PqsE on 
pyocyanin does not depend on a functional pqs QS system.18,20 As virulence regulation is 
believed to be mainly mediated by RhlR, we evaluated the compounds in a combined PqsE-
RhlR reporter gene assay. None of our thioesterase inhibitors influenced the RhlR-sensitizing 
effect of PqsE.  
Based on these findings, we draw the conclusion that PqsE has two separate functions, the 
thioesterase enzymatic activity and the regulatory function, both working independently of each 
other. The use of small synthetic ligands allowed for the first time to distinguish between the two 
functions of PqsE. These results render the scenario quite unlikely that a so far not identified 
enzymatic activity of PqsE might be responsible for its regulatory function. The effect of PqsE 
on RhlR can be measured in a heterologous E. coli system in the absence of Pseudomonas 
aeruginosa QS specific components. Hence, we further hypothesize that this effect might arise 
rather from a protein-protein or protein-DNA/RNA interaction. Such interactions commonly occur 
on the protein surface, an area that was not affected upon binding of the PqsE ligands 1-3, 
explaining the different results of these compounds regarding pyocyanin and AQs levels. 
However, this hypothesis remains to be corroborated. Due to its strong impact on P. aeruginosa 
virulence, PqsE remains a promising anti-virulence target. Future drug development should aim 
at the discovery of compounds that affect the regulatory role of PqsE. To this end, our 
thioesterase inhibitors might serve as valuable reference compounds or could even be used as 
molecular anchors for the design of larger compounds which address additional sites on the 
protein surface harboring the virulence-regulating function of PqsE. 
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Finally, the novel insight presented herein could not be gathered through knockout studies, 
which are routinely applied for target evaluation. Hence, we believe that fragment screening 
provides a rapid and facile method towards investigation of targets with elusive modes-of-action 
and should be considered as a reasonable complement to genetic target validation procedures. 
 
EXPERIMENTAL PROCEDURES 
Materials. PqsE was expressed heterologously in E. coli; a detailed protocol is given in the SI. 
PqsD and anthraniloyl-CoA were prepared as previously described.15 Malonyl-CoA was 
purchased from Sigma Aldrich. HPLC grade solvents were from Roth, Karlsruhe, Germany. 
Compounds 1-3 were initially sourced from the Maybridge fragment library as DMSO stocks and 
afterwards obtained from commercial suppliers: 1 (ChemPur GmbH), 2 (Maybridge) and 3 
(ABCR GmbH). 2-ABA was synthesized as described previously,15 except that hydrogenation of 
the 2-nitrobenzoylacetate precursor was performed in 0.25 % ammonia solution at 25 psi for 30 
min. The preparation yielded 2-ABA with approximately 95% purity (according to HPLC peak 
area). 
Fragment screening by differential scanning fluorimetry. The used fragment library was 
obtained from Maybridge and stored as 10 mM DMSO solutions at 253°K. The DMSO 
fragments stocks were diluted (1:20) in freshly prepared DSF screening buffer (50 mM Tris-HCl, 
150 mM NaCl, 2 mM MnCl2 10 % (v/v) glycerol, pH = 8.5) to give a final compound 
concentration of 500 µM at 5% (v/v) DMSO. The mastermix contained 4 µM H6PqsE and 8-fold 
concentrated Sypro Orange (Sigma Aldrich). The mastermix was vigorously mixed by pipetting 
and shared into white opaque 96 well PCR plate FrameStar (GeneOn) using 2 or 3 wells per 
fragment. The loaded plate was sealed using PCR sealing foil and centrifuged at 1000 rpm for 1 
min. Each plate contained a protein-only-control (POC) and 1000 µM anthranilic acid as positive 
control. The plate was heated in a StepOnePlus real-time PCR system (Applied Biosystems) 
with 1°K/min starting from 298°K to 368°K. The first derivations of obtained melting curves were 
analysed using the StepOne software and referenced against the POC. Fragments showing a 
shifted TM were screened in a second experiment for validation. Fragment 1 was tested in dose-
depend manner. 
Isothermal Titration Calorimetry. ITC titrations were performed using a ITC200 instrument 
(Microcal Inc.,Malvern). DMSO stock solutions (20 mM) of fragments were diluted 1:20 (v/v) into 
ITC titration buffer (50 mM tricine, 2 mM MnCl2, pH = 8.5) to give 1 mM final compound 
concentration at 5% (v/v) DMSO. Aliquots of the same buffer batch (stored at -253°K) were 
used as for protein storage to avoid buffer-mismatch. H6PqsE was diluted in the same buffer to 
100 µM and DMSO concentration was adjusted to 5% (v/v). Titrations were carried out at 298°K 
using 19 injections of 2 µL every 180s. Areas under the peaks were integrated. Baseline-peaks 
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at the end of a titration accounting for the heat of dilution and mixing were subtracted from the 
measurement. Data were fitted to a 1:1 binding model (MicroCal Origin 7 software). 
Crystallization, Data Collection, Structure Solution, and Refinement. PqsE was crystallized 
in 0.1 M HEPES, 0.2 M MgCl2 and 29-32 % (w/v) PEG400 at 293°K.
21 The crystals were soaked 
with 0.5-10 mM 2-ABA or compounds 1-3 for 6-60 h and flash-cooled in liquid nitrogen. As the 
crystallization condition contained sufficient amounts of PEG400 no further cryoprotection was 
required. Diffraction data were collected at 100 K at beamline X06DA of the SLS synchrotron 
(Swiss Light Source, Paul Scherrer Insititue, Villigen, Switzerland) for PqsE in complex with 2-
ABA, compound 1 or compound 3 and at beamline BL14.2 of the BESSY II synchrotron (Berlin 
Electron Storage Ring Company for Synchrotron Radiation, Helmholtz Zentrum Berlin, Berlin, 
Germany) for PqsE in complex with compound 2. Diffraction data were indexed and integrated 
with XDS
35
 and scaled with AIMLESS.
36
 Rigid-body refinement was performed with REFMAC5 
37,38 using the coordinates of the PDB entry 2Q0I.21 For model building COOT39 was used and 
the structure was refined with phenix.refine40 of the PHENIX software suite.41 
Thioesterase Assay. The effect of compounds on the thioesterase activity of PqsE was 
measured using a procedure described by Yu et al. with slight modifications.21 The assay was 
carried out in 96 well plate (Nunc, clear, U-bottom) with an overall assay volume of 200 µL. The 
photometric measurements were performed on PHERAstar FS plate reader (BMG Labtech). 
H6PqsE (2 µM) in assay buffer (50 mM Tricine, 2 mM MnCl2, 2 mM Ellmanns reagent, 0.1 % 
(v/v) Tween80, pH = 8.5) was incubated for 10 min with different concentrations of test 
compound. Test compounds were added as DMSO stock solutions (5 µL, 1:40 dilution). Two 
controls were used: DMSO as reference control and a blank control without PqsE to monitor 
substrate hydrolysis. The enzymatic reaction was started by addition of the substrate S-(4-
nitrobenzoyl)mercaptoethane (Matrix Scientific) dissolved in DMSO (5 µL; 500 µM final 
concentration) to give a final DMSO concentration of 5% (v/v). After vigorous mixing, the 
enzymatic reaction was followed photometrically at 412 nM using one measurement per minute 
over 15 min. Absorbance values were corrected for the blank controls and plotted over time. 
The derived slope (vx) was used to calculate the residual enzyme activity (Ax) according to 
equation 1: 
Ax = (vx)/(v0) (Equation 1) 
Ax corresponds to the enzyme activity, vx measured slope of the enzymatic reaction in the 
presence of test compound; v0 slope of the DMSO control.For the calculation of IC50 values, Ax 
values were plotted against logarithmic inhibitor concentrations and fitted to the logistic model 
included in Origin 8.6 (Figure S2). The given values emerged from at least two independent 
experiments with n=4. 
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Coupled PqsDE assay. The thioesterase activity towards 2-ABA-CoA, the natural substrate of 
PqsE within the AQ biosynthesis pathway, was tested in a combined assay with PqsD. To this 
end, 0.5 µM PqsD and 0.25 µM PqsE were added to a mixture of 100 µM anthraniloyl-CoA and 
100 µM malonyl-CoA in assay buffer (40 mM HEPES, pH 8.1, 40 mM NaCl and 2 mM MnCl2). 
The total volume was 100 µL. All components of the assay were supplemented with the 
respective inhibitor (in DMSO) prior to starting the reaction by mixing, thereby keeping the 
maximal DMSO concentration below 3% (v/v). Inhibitor concentrations were between 10 and 
600 µM. Reactions were stopped by adding 100 mM NH4OH, 5 % isopropanol and subsequent 
freezing with liquid nitrogen. For analysis of the reaction products 2-ABA and DHQ, samples 
were thawed and centrifuged for 10 minutes at 20,000 × g. Supernatants were analyzed by 
HPLC or HPLC-MS using a VWR LaChrom Elite HPLC system and a Thermo Dionex Ultimate 
3000 UHPLC coupled to an amaZon speed ESI mass spectrometer (Bruker Daltonics), 
respectively. Separation was achieved using a Knauer Eurospher II C18H 150 × 4 mm column 
and a chromatography program with 4 minutes isocratic flow at 5 % isopropanol/15 mM 
NH4HCO3 (pH 8.5) and a 15 minute gradient to 100 % acetonitrile at a flow of 0.6 mL/min. 
Concentrations were calculated from standards of authentic DHQ (Ferak, Berlin, Germany), 2-
AA (Sigma-Aldrich, St. Louis, MO, USA) and 2-ABA, obtained by chemical synthesis.15 Runs 
with authentic 2-ABA verified its stability under the conditions used for HPLC and LC-MS. Data 
analysis and enzyme kinetic calculations were performed with Matlab R2015a optimization 
toolbox (Mathworks, Natick, MA, USA). Time dependent simulation of Michaelis-Menten kinetics 
was performed using the closed solution of Schnell and Medoza.42 
Quantification of HHQ and DHQ. In order to investigate the effects of PqsE ligands on the 
production of extracellular DHQ and HHQ, determination of these metabolites was performed 
according to a procedure modified from previously published methods.43,44 Briefly, cultures of 
Pseudomonas aeruginosa PAO1 or of its isogenic pqsE mutant as a reference were grown for 
17 h in PPGAS medium45 in the presence of inhibitors or DMSO as control. From each culture, 
DHQ and HHQ were worked-up in presence of 1 µM of the internal standard 5,6,7,8-
tetradeutero-2-heptyl-4(1H)-quinolone (HHQ-d4) by addition of methanol and by extraction with 
ethylacetate, respectively. UHPLC-MS/MS analysis was conducted as described by Storz et 
al.43 monitoring the following ions (parent ion [m/z], product ion [m/z], scan time [s], scan width 
[m/z], collision energy [V], tube lens offset [V]): DHQ: 162, 89, 0.4, 0.02, 33, 52; HHQ: 244, 159, 
0.5, 0.01, 30, 106; HHQ-d4: 248, 163, 0.1, 0.01, 32, 113. Xcalibur software was used for data 
acquisition and quantification using a calibration curve based on the peak area ratios of the 
respective analyte and the internal standard. Generally, triplicate samples were analyzed in at 
least two independent experiments. Values were given in percent of the DMSO control (PAO1wt 
control = 100%). 
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Pyocyanin assay. In order to assess the inhibitory potency of PqsE ligands towards the 
formation of virulence factor pyocyanin, we used a protocol adapted to previously reported 
procedures.46,47 In brief, cultures of Pseudomonas aeruginosa PAO1 incubated for 16 h with 
inhibitor or DMSO as control were extracted with chloroform and re-extracted with 0.2 M HCl. 
Pyocyanin was quantified by photometry and values were normalized by OD600. All samples 
were analyzed at least in triplicate in three independent experiments except for PAO1pqsE that 
was analyzed once. Percent inhibition was calculated in relation to the DMSO control. 
PqsE-RhlR reporter gene assay. To investigate the influence of the PqsE thioesterase 
inhibitors on the PqsE-mediated sensitizing effect on C4HSL/RhlR-dependent gene 
transcription, we performed an E. coli-based reporter gene assay according to the protocol by 
Farrow et al.18 with some modifications. Briefly, a two-plasmid system was used consisting of 
one plasmid including tacp-rhlR and a rhlA’-lacZ reporter gene fusion (pECP61.4) and a second 
plasmid, which was either the vector alone (pACYC184) or a plasmid harboring tacp-pqsE 
(pROSE04). Overnight cultures of E. coli DH5α carrying the respective plasmid combinations 
were grown in supplemented A medium with the appropriate antibiotics and then diluted to an 
OD600 of 0.2. After incubation of the subcultures at 310°K and 200 rpm to an OD600 of 0.5, 
aliquots of 1 mL culture were transferred to a 96-deep-well plate containing dried C4-HSL 
and/or test compound in DMSO. The final assay concentrations were: 10 µM C4-HSL, 500 µM 
test compound, and 1% (v/v) DMSO. After 4 h of incubation at 310°K and 180 rpm, 300 µL of 
the culture were transferred into a separate 96-deep-well plate for cell lysis. The lysis solution 
contained 800 µL of chilled Z-buffer (40 mM NaH2PO4, 60 mM Na2HPO4, 10 mM KCl, 1 mM 
MgSO4), 100 µL of chloroform, and 50 µL of 0.1% (m/v) sodium dodecyl sulfate. Cells were 
lysed by rigorous shaking for 30 s. The ß-galactosidase activity was measured photometrically 
at OD420 using PHERAstar Omega (BMG Labtech). Data are expressed as percent ß-
galactosidase induction of controls and represent mean values ± the standard deviation of two 
independent experiments with n = 4. The given ratio was calculated by dividing the ß-
galactosidase activity in the presence of PqsE by the ß-galactosidase activity in the absence of 
PqsE, respectively. 
 
ASSOCIATED CONTENT 
The X-ray structure reported herein have been deposited within the PDB with accession 
numbers: PDB: 5HIO, PqsE in complex with 2-aminobenzoylacetate (2-ABA); PDB: 5HIP PqsE 
in complex with 2-(pyridin-3-yl)benzoic acid (compound 1); PDB: 5HIQ, PqsE in complex with 2-
(1H-pyrrol-1-yl)benzoic acid (compound 2); PDB: 5HIS, PqsE in complex with 3-
methylthiophene-2-carboxylic acid (compound 3).  
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4 Final Discussion 
 
“Großes ensteht immer im Kleinen [big things come from small beginnings]“1 
 
The literal meaning of this advertising slogan aptly summarizes the overall strategy of fragment-
based drug design – the structure of a small, weak but efficient binding fragment is gradually 
extended to generate a bigger lead molecule. The application of such an approach for the 
development of innovative antimicrobials against the virulence of P. aeruginosa was the major 
task of this study (see chapter 2). In more detail, fragment-based methods were utilized for two 
different intentions: for the development of compounds targeting the transcriptional regulator 
PqsR as outlined in the capters 3.1 to 3.3 and the discovery of tool compounds to examine the 
different functions of PqsE as described in chapter 3.4.  
Despite spending many resources and efforts, the application of HTS to antibiotic drug 
discovery was not able to replenish the antibiotic development pipeline.(Payne et al., 2007) 
Mochalkin et al. argued that these negative outcomes can be explained by the use of HTS 
libraries optimized for human drug targets.(Mochalkin et al., 2009) This hypothesis is 
corroborated by the fact that antibiotics cover a clearly different chemical space than other 
drugs.(Payne et al., 2007; O'Shea and Moser, 2008) Until nowadays, natural products have 
been a fruitful source for the discovery of antibiotics (Walsh, 2003) which is emphasized by the 
recent discoveries like the griselimycins (Kling et al., 2015) and teixobactin (Ling et al., 2015). 
However, the size and complexity of these structures hamper a straightforward lead 
optimization by chemical synthesis.(Mochalkin et al., 2009) 
Especially in the context of antibacterial drug discovery, the screening of low molecular weight 
fragments can be an attractive alternative to overcome these drawbacks.(Waldrop, 2009) A 
relatively small fragment library efficiently covers a comparably wide chemical space (Leach et 
al., 2006) and these less complex structures are more likely to form suitable interactions with a 
target protein (Hann et al., 2001). Furthermore, the simplicity of such molecules facilitates 
synthetic accessibility and subsequent generation of drug-like molecules.  
In the interest of convenience, the compound numbering in the following discussion is 
complemented by the addition of a capital letter referring to the corresponding chapter (e.g. 
compound A2 refers to compound 2 shown in chapter A) 
                                                 
1
 slogan of the Saarland marketing campaign 2014 and matching English proverb 
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4.1 Development of PqsR Antagonists 
Chapter A deals with the discovery of PqsR antagonist with a 2-amino-5-phenyl-1,3,4-
oxadiazole scaffold. The thiadiazol A5 was found in an SPR fragment screening and selected 
as starting point for further synthesis based on its high affinity and mixed agonistic/antagonistic 
properties in the E. coli reporter gene assay. Another highly similar hit A9 containing an 
oxadiazole heterocycle was lower ranked according to its affinity but showed pure antagonistic 
activity. This finding gave a hint for the first fragment modifications. The outcome of this study is 
summarized in Figure 11. The combination of an oxadiazole heterocycle (Figure 12, Position A) 
with halogens like Cl and Br or halogen-isosters like CN and CF3 in 3-position (Figure 12, 
Position B) led to antagonists showing potencies in the low micromolar range. Compound A37 
emerged from this activity-guided optimization approach as top candidate and showed 
antivirulence activities in P. aeruginosa. These results nicely demonstrate the value of the E. 
coli test system (Cugini et al., 2007) which allows the unbiased profiling of the functional 
properties even of weak interacting fragments. On the other hand, such a heterologous system 
does not provide any information whether a particular compound class can unfold its activity 
also in the target organism. A lack of activity in P. aeruginosa may have different reasons: Its 
cell envelop can behardly permeable for xenobiotics (Nicas and Hancock, 1983). Furthermore, 
the presence of broad spectrum efflux pumps (Masuda et al., 2000) and enzymatic degradation 
as observed for the quinolone-derived PqsR antagonists (Lu et al., 2014) can result in an 
insufficient concentration at the target site. Therefore, the proof that a compound is active in P. 
aeruginosa should be provided as early as possible during the course of a project. This claim is 
confirmed by the fact that late-stage introduction of in cellulo activity by use of synthetic 
modifications is hardly to achieve as observed during the development of PqsD 
inhibitors.(Sahner et al., 2015) 
 
Figure 12: SAR obtained for the oxadiazole compound class 
At this time, the crystal structure of the PqsR LBD was not published but the two amino acids 
F221 and Q194 were known to be located within the binding pocket.(Klein et al., 2012) Site-
directed mutagenesis in combination with ITC analysis was applied to map the space covered 
by different fragments. This analysis revealed that carboxamide A2 and oxadiazole A37 share 
overlapping space in the pocket but adopted different binding modes. INPHARMA NMR 
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corroborated the competitive binding of both molecules but could not show which parts of both 
molecules overlaid. Notably, the application of such biophysical tools can be an attractive 
alternative in the absence of crystal structure in complex with a ligand. Such a strategy was 
successfully applied for the structure-based optimization of PqsD inhibitors.(Sahner et al., 2013) 
In case of PqsR, the structural knowledge about the LBD comprised only the above mentioned 
amino acids as potential partners for directed interactions. Hence, these efforts led to a rough 
idea about orientation of both compound classes but these insights did not translate into defined 
suggestions for further optimization. Moreover, the subsequently published crystal structure of 
PqsR in complex with NHQ (Introduction, Figure 9) revealed only hydrophobic protein-ligand 
interactions (Ilangovan et al., 2013) which might be hardly traceable in such an approach.  
In the next step, structural modifications of the amino moiety (Figure 12, Position C) in 
combination with ITC analysis were carried out. Comparing the thermodynamic profiles of A37 
and A47 suggested that the amino group does not form directed interactions with the receptor. 
Subsequent replacement or methyllation (A48-A53) led to a complete loss of the antagonistic 
activity. These findings disqualified this moiety as handle for an enlargement of the scaffold. 
 
Figure 13: Bioisosteric replacement of the oxadiazole heterocycle (blue arrows represent 
potential growth vectors). Compounds 12 and 13 were obtained from commercial suppliers and 
antagonistic activities were measured in the E. coli reporter gene assay as described in chapter 
A. 
During fragment optimization, it was not possible to identify a vector to extend the fragment 
structure. The constitution of the oxadiazole heterocycle does not allow the addition of further 
substituents. The bioisosteric replacement of the latter one for five-membered rings offering 
potential growth vectors (12 and 13, Figure 13) resulted in a drop of the antagonistic activity. 
Therefore, the further development of the 2-amino-oxadiazoles class was deprioritized in favor 
of an alternative scaffold as described in Chapter B. 
Whereas the selection of A5 was based on a combination of its functional properties and 
affinity, the 2-amino-pryridine B3 was chosen due to its outstanding EE and LE values. The 
mainly lipophilic nature of the LBD of PqsR (Figure 9) makes the rational design of directed non-
covalent interactions a difficult task. Hence, the enthalpic contribution as an indication of such 
interactions (Ladbury et al., 2010) was utilized as major selection criterion for hit nomination. 
The hit fragment B3 showed a completely enthalpy-driven binding which is reflected in an 
Discussion 125 
 
 
impressive EE of 1.17. This value indicates a good complementary shape between polar groups 
of the ligand and the receptor. (Ladbury et al., 2010) The potential of B3 is also highlighted by 
its LE of 0.85 which significantly exceeded the minimum level (LE > 0.3) for a straightforward 
optimization (Hopkins et al., 2004). Moreover, the compact size of B3 offers several positions 
for a fragment-growing approach.  
 
Figure 14: Fragment-growing strategy for 2-amino-pyridines 
Due to the absence of structural information, close commercial analogs of B3 were screened for 
their affinity to PqsR by ITC to establish a preliminary SAR. In doing so, compounds B5 and B7 
were identified which guided further ligand design (Figure 14). B5 promoted the 4-position of the 
pyridine ring as most promising growth vector and the exchange of Br for a CF3 (B7) led to 
increased affinity and antagonistic activity. Furthermore, B7 showed inhibition of pyocyanin, 
thereby, providing the first proof that the amino-pyridine scaffold is able to permeate into 
P. aeruginosa. 
The next step aimed at the introduction of different moieties into the 4-position of B7. To 
accomplish this, the synthesis of intermediate B4e was pursued. The key step involved the 
introduction of the amino moiety into the 2-position of the pyridine ring. The reaction conditions 
were optimized up to 86:14 regioselectivity making B4e accessible in gram scale. The 
attachment of a flexible benzylamine moiety (B11, Figure 14) by a Buchwald-Hartwig cross 
coupling reaction led to boost in antagonistic activity and affinity.  
The structure of the PqsR LBD in complex with B11 could be solved (Figure 15). Additionally, 
the binding mode of antagonist B11 was investigated by site-directed mutagenesis in 
combination with ITC (Figure 16). The crystal structure revealed that B11 adopts an angled 
conformation in which the amino pyridine headgroup is located in the quinolone pocket and the 
4-fluoro-phenyl moiety points into the alkyl chain pocket.  
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Figure 15: A) Crystal structure of PqsR LBD in complex with B11 (ligand in red, key residues 
highlighted in green). B) 2-D summary of the observed ligand-receptor interactions 
A comparison of the protein- ligand interactions observed in the crystal structure and the results 
obtained by ITC measurements illustrates the difficulty in the interpretation of thermodynamic 
data. A loss in the enthalpic contribution was observed when B11 binds to PqsRF221A (Figure 
15C) indicating a strong interaction with this amino acid side chain. In contrary, the crystal 
structure revealed that F221 is more than 3.5 Å away from the ligand what is a strong argument 
against a direct interaction. This discrepancy might be due to the fact that the omission of this 
phenyl ring (phenylalanine to alanine mutation) has an impact on the overall protein 
conformation (Matthews, 1993) or allows the compound to adopt an alternative binding mode.  
 
Figure 16: A-C) Thermodynamic profiles of B11 binding to PqsRwt compared to T265A, Q194A 
and F221A mutated PqsR, respectively (ΔG in blue, ΔH in green and -TΔS in yellow). D) 
Schematic summary of the ITC-suggested interactions of B11 with PqsR. Data derived from at 
least two independent experiments. 
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The vice versa scenario was observed for T265: The crystal structure clearly showed an H-bond 
interaction (Figure 14) whereas the enthalpy term was not significantly changed (Figure 15A). 
The observation that the formation of H-bond did not necessarily lead to a gain in enthalpy has 
been reported for different other protein-ligand pairs.(Connelly et al., 1994; Winquist et al., 
2013) Moreover, Geschwinder et al. argued in a recent article that enthalpy and entropy are 
influenced by multiple factors e.g. solvation and conformational flexibility.(Geschwindner et al., 
2015) These features are highly sensitive to even small changes on the ligand or the protein 
side what might mask the real contribution of a single protein-ligand interaction.(Geschwindner 
et al., 2015) These findings highlight that the use of thermodynamic data for the 
generation/validation of a hypothetical binding mode should be considered carefully.  
By the use of structure-based methods, the structure of B11 was step-by-step extended to point 
deeper into the alkyl chain pocket. This strategy afforded compound B20 (Figure 13) as top 
candidate showing potent pyocyanin inhibition in P. aeruginosa. In this approach antagonistic 
activity was increased by the introduction of a flexible linker. Hondo et al. described a similar 
approach starting also from a highly efficient binding hit fragment (Hondo et al., 2013). This 
indicates that such a strategy might be applicable for a broader scope of target proteins.  
Chapter C covers the development of hybrid PqsR antagonists by merging of fragment B11 with 
the recently reported HTS hit C2 (Starkey et al., 2014). The quinolone-derived antagonists C1 
(Lu et al., 2014) and C2 share a nitro group as common structural feature. The position of the 
latter within the binding pocket was modeled based on a close HHQ analog. Subsequently, the 
binding mode of C2 was investigated by a pharmacophore-guided docking study with the nitro 
group as an essential feature. A superimposition of the generated docking poses of C2 and the 
crystal structure of B11 (Figure 14) suggested to combine features of both scaffolds. 
The introduction of thioglycolamide-aryl moieties at the 4-position of the amino-pyridine 
headgroup resulted in the most promising hybrid antagonists (Figure 16). The SAR derived from 
this small series of compounds is summarized in Figure 16. The exchange of a chlorine 
substituent for a phenoxy moiety led to tremendous increase in the antagonistic activity in E. coli 
as well as the anti-virulence activity in P. aeruginosa (e.g. C7 vs. C10). This finding is in 
accordance with the SAR reported for the benzamido-benzimidazole scaffold (C2, C3). (Starkey 
et al., 2014) 
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Figure 17: Overview of the SAR of hybrid PqsR antagonists.  
The omission of the amino function at the pyridine head group resulted in a compound with a 
comparable anti-virulence profile; the antagonistic activity was even slightly enhanced (C10 vs. 
C13). Given that during most fragment-growing approaches the initial protein-ligand interactions 
were retained (Hartshorn et al., 2005), this finding was not expected and might be due to the 
unconventional merging approach. Normally, the hit structure is extended gradually, whereas in 
this approach the large thioglycolamide-aryl moiety was added in a single step. As a 
consequence, the geometry of the linker might not be optimal what hinders the formation of an 
H-bond interaction as observed for B11 (Figure 14). The exchange of a pyridine to a pyrimidine 
(C10 to C12) led to ambiguous results: On the one hand, the antagonistic activity and pyocyanin 
inhibition were retained while improving the physico-chemical properties. On the other hand, the 
effect on HHQ and 2-AA was significantly lowered. Overall, the effects on virulence factor 
pyocyanin and HHQ levels differ regarding their response to the antagonization of PqsR 
depending on the compound used. But the finding that small synthetic modifications (as 
described above for C10 to C12) influenced only the biosynthesis of HAQs without affecting 
pyocyanin levels implies that both parameters may be differently regulated by PqsR via a so far 
unknown mechanism. Another explanation would be that the particular compounds hit additional 
targets affecting pyocyanin or HHQ biosynthesis.  
The antagonist C12 showed reduction of eDNA in a P. aeruginosa static biofilm assay and 
inhibited the expression of lectinB. These effects are comparable to a pqsR negative strain. 
Furthermore, these compounds did not affect the viability of eukaryotic cells  
In summary, the thiadiazole/oxadiazole (A5/A9) and the aminopyridine (B3) scaffold were 
selected out of the hits obtained in a SPR fragment screening. A5 was transformed into a 
micromolar antagonist A37 by small synthetic modifications. B3 was developed into the potent 
nanomolar antagonist B20. This development process was initially guided by ITC and later on 
by the use of structure-based design methods. Additionally, B3 was successfully combined with 
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moieties from an HTS hit (Starkey et al., 2014) leading to highly potent hybrid compounds C10 
and C12. 
4.2 Discovery of PqsE Ligands 
Chapter D describes the discovery and biological evaluation of synthetic PqsE ligands. At first, a 
library consisting of 500 fragments was screened using a thermal shift assay. This setup led to 
10 initial hits. ITC was used as secondary screening tool and validated the binding of the 
carboxylic acid derivatives D1-D3. The crystal structures of D1-D3 and enzymatic product 2-
ABA revealed that all these compounds form a complex with the iron center within the active 
site of PqsE and cover an overlapping space in this binding pocket. The discovered hits showed 
inhibition of the thioesterase enzymatic function of PqsE in two different in vitro assays. The 
profiling of these compounds in P. aeruginosa exhibited ambiguous results: One the one hand, 
the DHQ levels were elevated to a similar extent as measured in a pqsE negative strain proving 
that the hits were able to permeate into the bacterial cytoplasm. On the other hand, no effect on 
the major virulence factor pyocyanin was observed. The regulatory role of PqsE is at least 
partially mediated via the transcriptional regulator RhlR.(Farrow et al., 2008; Hazan et al., 2010) 
Farrow et al. showed that this sensitizing effect is also measurable in a heterologous E. coli 
reporter gene system. (Farrow et al., 2008) Hence, the compounds D1-D3 were analyzed in this 
assay and showed no repression of this effect.  
 
Figure 18: Schematic depiction of the different PqsE functions and the discovered screening hit 
D1. 
Our results corroborate and extent the notion that PqsE has two functions which are working 
independently of each other (Figure 17). These insights classify PqsE as a member of the 
growing family of ‘moonlighting proteins’ – proteins performing multiple unrelated 
functions.(Huberts and van der Klei, 2010) Accordingly, the discovered compounds inhibited 
only the enzymatic activity but had no effect on the regulatory function. This is in line with 
knock-out complementation studies showing that PqsE unfolds its gene regulatory activity in 
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absence of a functional pqs system (Farrow et al., 2008). The obtained results allowed the 
hypothesis that the regulatory activity of PqsE is not linked to its enzymatic reaction taking place 
in the active center. Due to the fact that discovered compounds showed inhibition of the enzyme 
reaction in vitro and a similar DHQ/HHQ profile in P. aeruginosa as a pqsE negative strain, a 
not known enzymatic reaction should also be at least partially affected. A second argument for 
this hypothesis is the fact that the effect of PqsE on RhlR is also traceable in E. coli and, 
therefore, in the absence of the specific QS metabolome present in P. aeruginosa.(Farrow et 
al., 2008) Hence, it might be that the regulatory activity relies on a more general mechanism like 
a protein-protein or protein-DNA/RNA interaction. This assumption is further supported by the 
fact that an alanine scan identified amino acids at the protein surface leading to drastically 
reduced pyocyanin levels.(Folch et al., 2013) Notably, this study also found amino acids located 
in the active site which showed decreased pyocyanin production.(Folch et al., 2013) However, 
some of the latter are involved in the complexation of the double iron center. Mutations at this 
site might have a bigger impact on the overall protein structure than the ones at the protein 
surface. 
This study contributes another important piece towards understanding complete ‘PqsE puzzle’. 
In summary, by the use of fragment screening in combination with protein crystallography it was 
possible to discover tool compounds which allowed further insights into the different functions of 
PqsE. At this stage, it is not possible to conclusively evaluate the potential of PqsE as drug 
target. Moreover, it cannot be excluded that a fragment-growing approach would yield 
compounds providing additional features e.g. the interference with the gene regulatory activity 
.  
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4.3 Outlook 
The PqsR antagonists B20 and C10/C12 represent excellent candidates for further medicinal 
chemistry optimization. This optimization process should generate a lead compound suitable for 
the application in acute and chronic animal infection models. A proposal for the further 
optimization of the amino pyridine compound class is outlined in Figure 18. The linker (depicted 
in blue) and the tail part (depicted in red) of the scaffold should be prioritized. The crystal 
structure of B20 suggested that fluorine at the tail part of the molecule could be replaced for 
more bulky substituents. This suggestion is corroborated by the SAR obtained for the hybrid 
antagonists. Here, the exchange of chlorine for phenoxy (compare C7 vs. C10) boosted the 
antagonistic activity. Furthermore, the cocrystal structure of B11/B20 showed that the flexibility 
of the linker allows the scaffold to adopt an angled conformation. In contrast, the hybrid 
antagonists C10/C12 revealed that the linker part can at least partially be rigidified. Hence, the 
design strategy should aim at a reduction of flexibility while replacing the potentially instable 
amide bond. For this purpose, the amide moiety could be exchanged for different 5-membered 
aromatic ring systems either fused to phenyl ring or detached. During this optimization process, 
the head group (depicted in black) should be kept constant and chosen according to the 
synthetic feasibility. At a later stage, the influence of the amino group and the constitution of the 
heterocycle for the activity as well as for the physicochemical properties should be investigated.  
 
 
Figure 19: Proposal for further optimization of the amino pyridine scaffold 
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Different criteria should be considered during this lead generation process: 
 The E. coli assay should be used as primary tool to derive a defined SAR of the 
compounds. This system resembles most closely the conditions in P. aeruginosa because 
it utilizes the native full-length PqsR protein in contrast to the truncated version used for 
ITC and SPR. Suitable compounds should possess an antagonistic activity below 50 nM. 
 The anti-virulence activities regarding reduction of pyocyanin and AHQ levels in 
P. aeruginosa should be retained or even improved compared to C10/C12. The efficacy of 
the compounds should also be evaluated in different clinical isolates and under different 
medium conditions. 
 Experiments should address the question which parameter is most relevant for the 
attenuation of virulent phenotypes – reduction of virulence factor pyocyanin or distinct 
AHQs. Especially, the influence of the antagonists on 2-AA and subsequent persister cell 
formation would be of further interest. 
 Synthetic modifications should be evaluated by weighting the influence on the biological 
activities versus the change of the physicochemical properties. Thus, the LLE metric 
should be used routinely as guidepost during the optimization process. 
 The lead nomination process should also encompass an in vitro pharmacokinetic and 
toxicological profiling like the assessment of the metabolic stability under different 
conditions and the cytotoxicity for relevant cell lines. 
 An ideal lead compound should be applicable for oral administration, but also a local 
treatment in form of an ointment (for infected wound models) or a direct instillation into the 
lung could be an attractive alternative. In this context, modern drug delivery strategies like 
nanoparticles or liposomes should also be considered. 
Besides the development of PqsR antagonists, the screening and biological evaluation of PqsE 
ligands was pursued. The structural information (D1-D3) gathered in this approach could be 
used for the structure-based design of inhibitors showing improved potencies. Whether a gain in 
potency would also lead to an effect on the virulence regulatory function of PqsE remains highly 
questionable. According to the assumption that a protein-protein or DNA-protein interaction is 
the underlying mechanism for this function, it would be of major interest to identify the regulatory 
‘hot-spot’ at the protein surface. Therefore, the PqsE-RhlR reporter-gene assay in E. coli should 
be applied to screen for compounds inhibiting this sensitizing effect of PqsE on RhlR. Weak 
interacting fragments might not be detectable in such a setup. Thus, libraries containing larger 
molecules enriched with natural products might be the better source for such an approach. As 
an alternative, biomolecular NMR studies using PqsE/RhlR or PqsE/DNA could identify the 
interaction area of the particular binding partners. These findings could open the door for the 
structure-based design of PqsE-targeting anti-virulence agents. 
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6 Abbreviations 
2-AA 2.amino-acetophenon 
2-ABA 2-aminobenzoylacetate  
2-ABA-CoA 2-aminobenzoylacetyl coenzyme A 
AHL N-acyl-homoserine lactone  
AHQ  alkyl hydroxy quinolone 
CDCl3 deuterated chloroform 
CF cystic fibrosis 
CFTR cystic fibrosis transmembrane conductance regulator 
CoA coenzyme A 
DHQ 2,4-dihydroxyquinoline 
DMSO dimethyl sulfoxide  
DNA deoxyribonucleic acid 
DSF differential scanning fluorimetry  
eDNA extracellular DNA 
EE enthalpic efficiency  
FBDD fragment-based drug discovery  
HAQ 4-hydroxy-2-akylquinolones  
HHQ 2-heptyl-4(1H)-quinolone 
HQNO  2-heptyl-4-hydroxy quinoline-N-oxide 
HTS high throughput screening 
IC50 half maximal inhibitory effect 
INPHARMA interligand NOE for pharmacophore mapping 
IPA isopropyl alcohol 
ITC  isothermal titration calorimetry 
KA association constant 
KD  dissociation constant 
LBD ligand binding domain 
LE ligand efficiency  
LLE  ligand lipophilicity efficiency 
LTTR LysR-type transcriptional regulator  
MS  mass spectroscopy 
MvfR multiple virulence factor regulator  
NHQ 2-nonyl-4-quinolone 
NMR  nuclear magnetic resonance 
NOE nuclear Overhauser effect 
PQS Pseudomonas Quinolone Signal 
PqsR Pseudomonas quinolone signal receptor 
QS quorum sensing 
RNA ribonucleic acid 
SAR structure activity relationship 
SPR surface plasmon resonance 
SPW surface plasmon wave  
TSA thermal shift assay 
UHPLC ultra high performance liquid chromatography 
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7 Supplementary Material 
7.1 Supplementary Material of Chapter A 
Discovery and Biophysical Characterization of 2-Amino-Oxadiazoles as Novel 
Antagonists of PqsR, an Important Regulator of Pseudomonas aeruginosa Virulence  
1) Surface-Plasmon-Resonance Screening 
a) Protein Expression and Purification. E. coli BL21 (DE3) cells containing the 
pSUMO3_ck4_pqsRC87 plasmid were grown in 2x YT medium containing 50 µg mL-1 kanamycin 
and incubated at 37 °C to an OD600 of approximately 0.5 upon which the shaker temperature 
was gradually reduced to 16 °C. At an OD600 of approximately 0.8 the protein expression was 
induced with 0.2 µM IPTG for 22 h at 16 °C. The cells were harvested by centrifugation (5000 
xg, 10 min, 4 °C) and the cell pellet was resuspended in 100 mL His Trap binding buffer (20 mM 
sodium phosphate, pH 7.4, 500 mM NaCl, 20 mM imidazole, 2 mM MgCl2, 10% glycerol (v/v)). 
To facilitate cellular lysis and to reduce suspension viscosity prior to cell crushing, lysozyme 
(Sigma) and Benzonase Nuclease (Novagen) were added to a final concentration of 0.025 
mg/mL and 0.0025 units/mL, respectively. The bacterial suspension was subsequently passed 
three times through an EmulsiFlex-C5 cell crusher (Avestin; 15,000 psi at 4 ºC). Cell debris 
were removed by centrifugation 20000 xg, 15 min, 4 °C) and the supernatant was filtered 
through a syringe filter (Millipore Millex SV-5μM). The clarified lysate was immediately applied to 
a two-step purification method (ÄKTAxpress instrument, GE Healthcare). This method 
incorporated immobilized metal affinity chromatography (IMAC; HisTrap) and size exclusion 
chromatography column (HiLoad Superdex 200 16/60 Prep Grade). The captured H6SUMO3-
pqsRC87 protein was washed with HisTrap binding buffer (20 mM sodium phosphate pH 7.4, 500 
mM NaCl, 20 mM imidazole, 10% glycerol (v/v)), and eluted with 250 mM imidazole. Eluted 
protein peak (total of 4 mL; A280>50 mAU) was automatically collected and injected onto a 
HiLoad Superdex 200 16/60 Prep Grade column equilibrated in storage buffer (1x PBS, 10% 
glycerol (v/v)). The H6SUMO-tagged protein were stored at –80 °C and used for biophysical 
studies. 
 
b) Minimal biotinylation of H6SUMO-PqsR
C87
. Minimal biotinylation of the H6SUMO-
PqsRC87 was achieved by mixing 48 nmol of H6SUMO-PqsR
C87 (1 eq.) with 24 nmol of EZ-link 
sulfoNHS LC-LC-biotin (0.5 eq.; Thermofisher Scientific) that was freshly dissolved in water. 
Biotinylation reaction mixture was incubated on ice for 2 hours. To remove unreacted biotin 
reagent, the entire biotinylation mixture was subjected to size exclusion chromatography on a 
Superdex200 HR (10/300) column equilibrated in storage buffer (1x PBS, pH 7.4, 10% glycerol 
(v/v)). A protein peak containing biotinylated H6SUMO-PqsR
C87 protein was collected (66 
µg/mL), stored at –80 °C and used for SPR studies.  
 
c) Immobilization of Biotinylated H6SUMO-PqsR
C87. The CM5 sensor chip and amine 
coupling kit were obtained from GE Healthcare. Streptavidin was simultaneously immobilized in 
all four channels of a CM5 sensor chip docked in a Biacore T100 instrument equilibrated with 1x 
HBS-P buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 0.005% Tween-20). Immobilization was 
performed at 37 °C at a constant flow-rate of 10 L/min using standard amide coupling 
chemistry.
1
 Streptavidin was diluted in 10 mM sodium acetate buffer pH 4.5 to a final 
concentration of 100 μg/mL. This approach resulted in immobilization of 8800-10800 response 
units with minimal variation between the four channels on the same chip (SI, Table S1). Freshly 
immobilized surfaces were further conditioned with three consecutive 30 s injections of 
streptavidin surface conditioning solution consisting of 50 mM NaOH and 1 M NaCl. Minimally 
biotinylated H6SUMO-PqsR
C87 protein (66 µg/mL) was captured onto streptavidin chip surfaces 
at 20 °C in 1x HBS-P+ as instrument running buffer. H6Sumo-PqsR
C87 was gradually injected in 
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a single channel at a constant flow-rate of 2 L/min until SPR response increases were no 
longer observed. For negative protein target purposes, minimally biotinylated carbonic 
anhydrase isozyme II (CAII) from bovine erythrocytes was immobilized in one of the flow cells 
on each chip. Overall configurations of biotinylated proteins captured on each chip are 
summarized in Table S1. 
Table S1: Configuration of biotinylated proteins captured on CM5 chips  
Chip Channel Immobilized RU (SA) RU (bt 
proteins) 
purpose 
1 
1 SA + D-biotin 9772 - 
Screening 1
st
 half of 
fragment library + dosage 
experiments 
2 SA + bt-PqsR 9079 6309 
3 SA + SrtA 9401 8573 
4 SA + CAII 8795 7276 
2 
1 SA + D-biotin 10777 - 
Screening 2
nd
 half of 
fragment library + dosage 
experiments 
2 SA + bt-PqsR 10205 5467 
3 SA + CAII 10442 7072 
4 SA + bt-PqsR 10003 5712 
SA (Streptavidin; Sigma), CAII (Bovine Carbonic anhydrase II; Sigma), bt (biotinylated), PqsR 
(H6SUMO-PqsR
C87), SrtA (sortase A enzyme from Staphylococcus aerus; prepared in house) 
d) SUMO protease 2 cleavage of biotinylated H6SUMO-PqsR
C87.H6SUMO tag was 
cleaved from biotinylated H6SUMO-PqsR
C87 using SUMO3 protease 2 according to 
manufacturer’s instructions (LifeSensors). Briefly, a 200 µl (380 µg) sample of bt-H6SUMO-
PqsRC87 in (1x PBS, pH 7.4, 10 % glycerol (v/v)) was mixed with 0.4 µl of 1 M DTT and 2 µl of 
SUMO3 protease 2 (7 units/µl) and incubated at 30 ºC for 2.5 hrs. The mixture was applied onto 
a 1 ml HisTrap FF column at 1 ml/min to remove the H6SUMO tag and His-tagged SUMO3 
protease 2. The flow-through protein (cleaved bt.-PqsRC87) was collected and concentrated 
down to approximately 50 ml using Nanosep Ultrafiltration concentrator (Pall, 3 kDa MW cut-off) 
and subjected to size exclusion chromatography at a constant flow-rate of 0.5 ml/min on a 
Superdex 75 5/150 column equilibrated in 1x PBS, 10 % (v/v) glycerol buffer. Collected cleaved 
bt-PqsRC87 protein (0.4 ml, ~20 µg/ml) was stored frozen in 100 µl aliquots at -80 C and used for 
competition experiments.  
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e) SPR Sensogramms 
 
Figure S1: a – e) Binding affinities for hit compounds 4-8. SPR sensorgrams for fragment hits 
binding to H6SUMO-PqsR
C87 analyzed in duplicate. Insets: fit of the binding responses at 
equilibrium (plotted against fragment concentration) to a simple 1:1 binding isotherm 
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f) SPR Competition Experiments 
 
Figure S2: SPR Competition Experiments.  
SPR sensorgrams obtained with mixtures consisting of PQS ligand and either 4 (left panels) or 
5 (right panels) binding to immobilized pqsRC87 (2,600 RU). Compounds were diluted three-fold 
(4 from 18 µM and 5 from 81 µM) and then mixed 1:1 with 4 different concentrations of PQS. 
Final injected concentration were: Compound 4 at 0 µM (running buffer), 0.11 µM, 0.33 µM, 1 
µM , 3 µM and 9 µM all mixed with PQS at a) 0 µM, b) 1 µM, c) 3 µM and d) 9 µM; Compound 5 
at 0 µM (running buffer), 1 µM, 3 µM, 9 µM, 27 µM and 81 µM all mixed with PQS at f) 0 µM, g) 
1 µM, h) 3 µM and i) 9 µM. Bar charts of SPR responses taken at equilibrium for sensorgrams 
shown in A to D (e) and F to I (j). 
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g) Fragment Library 
Fragments originate from the CSIRO compound collection consistent of approximately 50000 
entities. The screening set is derived from two compound libraries which are described in detail 
in Table S2. 
 
Tabel S2. Physicochemical Properties of Fragment Screening Set 
Property 
  
CSIRO heterocyclic 
chemistry diversity 
CSIRO 
In silico diversity  
Compounds 258 462 
MW 
Min.–Max. 
Mean 
SD 
  
113–363 
220 
49 
  
133–305 
194 
35 
cLogP 
Min.–Max. 
Mean 
SD 
  
-2.2–3.6 
0.79 
1.1 
  
-2.2–5.1 
0.84 
1.03 
tPSA (Å2) 
Min.–Max. 
Mean 
SD 
  
24–137 
65 
21 
  
13–117 
51 
19 
Rotatable bonds 
Min.–Max. 
Mean 
SD 
  
0–9 
3.6 
1.8 
  
0–10 
3.8 
2.1 
HBA 
Min.–Max. 
Mean 
SD 
  
0–7 
3,6 
1.5 
  
0–6 
2.9 
1.2 
HBD 
Min.–Max. 
Mean 
SD 
  
0–3 
0.8 
0.7 
  
0–3 
0.9 
0.7 
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2) Isothermal Titration Calorimetry 
 
a) Protein Expression and Purification. Wild-type, Q194A mutant, and F221A mutant 
H6SUMO-PqsR
C87 were expressed in E. coli and purified using a single nickel affinity 
chromatography step. Briefly, E. coli BL21 (λDE3) cells containing the pSUMO3_ck4_pqsRC87, 
the pSUMO3_ck4_Q194ApqsRC87 or the pSUMO3_ck4_F221ApqsRC87 plasmid2 were grown in 
LB medium containing 50 µg mL-1 kanamycin at 37 °C to an OD600 of approximately 0.8 and 
over-expressed with 0.2 mM IPTG for 16 h at 16 °C. Protein purification was performed as 
described by Klein et al.2 
 
b) Titration Procedure. ITC experiments were carried out using an ITC200 instrument 
(Microcal Inc., GE Healthcare). Concentrations of ligand stock solutions in DMSO were 
determined by the weight of the compound. Final ligand concentrations were achieved by 
diluting 1:20 (v/v) in the experimental buffer resulting in a final DMSO concentration of 5% (v/v). 
Protein concentration was determined by measuring the absorbance at 280 nm using a 
theoretical molarity extinction coefficient of 22900 M-1cm-1. DMSO concentration in the protein 
solution was adjusted to 5% (v/v). ITC measurements were routinely performed at 25 °C in 20 
mM Tris, pH 7.4, 150 mM NaCl, 10% glycerol (v/v), 5% DMSO (v/v) for the wild-type PqsR
C87
 
and in 20 mM Tris, pH 7.8, 300 mM NaCl, 10% glycerol (v/v), 5% DMSO (v/v) for the Q194A 
and the F221A mutants, respectively. The titrations were performed on 43-190 µM H6SUMO-
PqsRC87, H6SUMO-Q194APqsR
C87 or H6SUMO-F221APqsR
C87 in the 200 µL sample cell using 
2-2.6 µL injections of 0.7-2.0 mM ligand solution every 180 s and a maximal syringe volume of 
40 µL. To show competitive binding 43 µM H6SUMO-PqsR
C87 was incubated with 500 µM 
compound 2 for 30 min at 25 °C and a 500 µM solution of 37 was titrated subsequently into the 
preincubated mixture (19 injections of 2 µL). The vice versa experiment was performed 
accordingly. The data were collected and the area under each peak was integrated. To correct 
for heats of dilution and mixing the final base line consisting of small peaks of the same size at 
the end of the experiment was subtracted. The experimental data were fitted to a theoretical 
titration curve (one site binding model) using MicroCal Origin 7 software, with ΔH (enthalpy 
change in kcal/mol), KA (association constant in M
−1), and N (number of binding sites) as 
adjustable parameters. Thermodynamic parameters were calculated from Eq. (1), 
 
ΔG = ΔH – TΔS = RTlnKA = –RTlnKD  (1) 
 
where ΔG, ΔH, and ΔS are the changes in free energy, enthalpy and entropy of binding, 
respectively, T is the absolute temperature, and R = 1.98 cal/mol/K. The LE for each compound 
was calculated from Eq. (2), 
 
LE = –ΔG/(heavy atom count)  (2) 
 
where ΔG is the change in free energy and heavy atom count is the number of non-hydrogen 
atoms of the compound. For each ligand at least two independent experiments were performed 
(Figure S3). 
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c) ITC Titration Curves 
 
Figure S3: Representative ITC titrations  
a) ITC titration of 4 (900 µM) against H6SUMO-PqsR
C87 (86 µM). b) ITC titration of 4 (1 mM) 
against H6SUMO-Q194APqsR
C87 (95 µM). c) ITC titration of 4 (1 mM) against H6SUMO-
F221APqsRC87 (124 µM). d) ITC titration of 37 (500 µM) against H6SUMO-PqsR
C87 (43 µM). e) 
ITC titration of 37 (500 µM) against H6SUMO-Q194APqsR
C87
 (50 µM). f) ITC titration of 37 (500 
µM) against H6SUMO-F221APqsR
C87 (50 µM). The recorded change in heat is shown in units of 
µcal/sec as a function of time for successive injections of the ligand (upper row). Integrated 
heats (black squares) plotted against the molar ratio of the binding reaction. The continuous line 
represents the results of the non-linear least squares fitting of the data to a binding model (lower 
row). 
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d) Investigation of Competitive Binding by ITC  
 
Figure S4: Competitive binding of 2 and 37 to PqsR. Raw ITC data (top) and integrated 
normalized data (bottom) for titrations of 50 µM PqsR with 500 µM 2 in the absence of 37 (■, 
black curve) and in the presence of 500 µM compound 37 (Δ, red curve).  
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3) Functional Evaluation of Compounds  
  
Figure S5: Dose response curve of 41 in E. coli reporter gene assay showing a partial 
antagonistic profile. Compound 41 was tested at 8 concentrations in competition to 50 nM PQS 
to determine the antagonistic activity and 3 different concentrations to show agonistic 
functionality. EC50 was 57.8 µM; values obtained from 2 independent experiments with n = 4. 
Compound 41 tested up to maximum solubility under assay conditions (200 µM). The log 
(inhibitor) vs. response model (Graph Pad Prism 5.04) was used to determine EC50 values. 
 
 
Figure S6: Dose response curve of 37 in E. coli and P. aeruginosa. Compound 37 was tested 
at 11 concentrations in E. coli () and 9 concentrations in P. aeruginosa. EC50 was 7.5 µM in 
E. coli and 38.5 µM in P. aeruginosa; values obtained from 2 independent experiments with n = 
4. The log (inhibitor) vs. response model (Graph Pad Prism 5.04) was used to determine EC50 
values. 
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4) Determination of Antibacterial Activity in P. aeruginosa PA14 
 
Cultures of P. aeruginosa PA14 were inoculated with an overnight culture to obtain a starting 
OD600 = 0.05 and grown in three replicates in 100 ml Erlenmeyer flasks containing 10 ml LB 
medium at 37 °C, 200 rpm and a humidity of 75%. DMSO solutions of compound 37 were 
added to the cultures to a final DMSO concentration of 1%. Bacterial growth was measured as a 
function of OD600 using Spectronic Helios Epsilon spectrophotometer (Thermo Electron 
Corporation). P. aeruginosa PA14 cultures containing 1% DMSO were used as control. 
 
Figure S7. Growth Curves of P. aeruginosa PA14. Strains were grown in the absence () and 
presence of 250 μM compound 37 (). Samples were taken at 0 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 
h and 8 h to measure OD600. Mean value of one experiment with n = 3. 
 
5) Synthesis and Characterization of Intermediates 23-30, 43-46 
 
Benzoic acid derivatives 10-14 and benzoyl chloride derivatives 15-17, 19, 20 were 
obtained from commercial suppliers and used without further purification.  
2-(3-Chlorobenzoyl)hydrazinecarbothioamide (23) was prepared according to General 
Procedure 3 starting from 3-chlorobenzoyl chloride (15, 2.73 g, 15.62 mmol) and 
hydrazinecarbothioamide (1.560 g, 17.12 mmol). The crude product was recrystallized from 
EtOH and obtained as yellow solid (3.724 g, 12.97 mmol, 83% yield).
 1
H NMR (500 MHz, 
DMSO-d6) δ ppm 7.52 (t, J=7.9 Hz, 1 H), 7.63 (dd, J=7.6, 0.9 Hz, 1 H), 7.71 (br. s., 1 H), 7.83 
(d, J=7.6 Hz, 1 H), 7.90 (br. s., 1 H), 7.96 (s, 1 H), 9.36 (br. s., 1 H), 10.49 (s, 1 H); 
13
C NMR 
(126 MHz, DMSO-d6) δ ppm 126.55, 127.73, 130.19, 131.51, 132.96, 134.59, 164.60, 182.00; 
MS(ESI): m/z 229.84 (M+H)+. 
2-(3-Bromobenzoyl)hydrazinecarbothioamide (24) was prepared according to General 
Procedure 3 starting from 3-bromobenzoyl chloride (16, 1.25 g, 5.68 mmol) 
hydrazinecarbothioamide (1.56 g, 17.12 mmol) and obtained as white solid (1.55 g, 5.68 mmol, 
100% yield). 1H NMR (500 MHz, DMSO-d6) δ ppm 7.45 (t, J=7.88 Hz, 1 H), 7.71 (br. s, 1 H), 
7.77 (d, J=8.20 Hz, 1 H), 7.85 (d, J=8.51 Hz, 1 H), 7.90 (br. s, 1 H), 8.09 (s, 1 H), 9.35 (br. s, 1 
H), 10.49 (br. s, 1 H); 13C NMR (126 MHz, DMSO-d6)  ppm 121.4, 126.91, 130.43, 130.57, 
134.39, 134.80, 164.53, 181.98; MS(ESI): m/z 273.71 (M+H) +. 
2-(3-(Trifluoromethyl)benzoyl)hydrazinecarbothioamide  (25) was prepared according to 
General Procedure 3 starting from 3-(trifluoromethyl)benzoyl chloride (17, 10.00 g, 47.9 mmol) 
and hydrazinecarbothioamide (13.11 g, 144 mmol) and obtained as a white solid (10.6 g, 40.3 
mmol, 84% yield). 1H NMR (500 MHz, DMSO-d6) δ ppm 7.69 - 7.80 (m, 2 H), 7.85 - 7.97 (m, 2 
H), 8.16 (d, J=7.9 Hz, 1 H), 8.24 (s, 1 H), 9.39 (br. s, 1 H), 10.64 (br. s, 1 H); 13C NMR (126 
MHz, DMSO-d6) δ ppm 123.93 (d, 
1
J(C,F)=272.2 Hz, 1 C), 124.58 (q, 3J(C,F)=3.7 Hz, 1 C), 
128.23 (q, 3J(C,F)=3.7 Hz, 1 C), 128.94 (d, 2J(C,F)=33.0 Hz, 1 C), 129.50, 131.90, 133.52, 
164.62, 182.00 MS(ESI): m/z 263.92 (M+H) +. 
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2-(3-Cyanobenzoyl)hydrazinecarbothioamide (26) 3-Cyanobenzoic acid (13, 1.5 g, 10.2 
mmol) was suspended in DCM (40 mL). Oxalyl chloride (1.5 mL, 17.14 mmol) and a catalytic 
amount of DMF were added. The solution was refluxed for 2 h. The mixture was concentrated 
under reduced pressure to obtain an orange oil (18). The oil was subsequently dissolved in dry 
THF (10 mL) and added portionwise to a suspension of hydrazinecarbothioamide (3.00 g, 32.9 
mmol) in THF (30 mL). The resulting suspension was stirred over night at RT under nitrogen 
atmosphere. The suspension was quenched with water and alkalized using sat. NaHCO3 
solution. THF was removed under reduced pressure. The aqueous layer was extracted with 
ethyl acetate (2 times). A white solid dispersed between the layers. The aqueous layer was 
filtered to give a solid (S1). The combined ethyl acetate layers were washed with brine, dried 
over MgSO4, filtered and concentrated to dryness to give a solid (S2). Both solids were 
recombined to obtain the expected product (1.14 g, 5.19 mmol, 51% yield). 
1
H NMR (500 MHz, 
DMSO-d6) δ ppm 7.71 (t, J=7.9 Hz, 1 H), 7.76 (br. s, 1 H), 7.95 (br. s, 1 H), 8.04 (d, J=7.6 Hz, 1 
H), 8.17 (d, J=8.2 Hz, 1 H), 8.34 (s, 1 H), 9.41 (br. s, 1 H), 10.61 (br. s, 1 H); 13C NMR (126 
MHz, DMSO-d6) δ ppm 111.24, 118.25, 129.65, 131.64, 132.59, 133.67, 135.11, 164.22, 
181.99; MS (ESI): m/z 220.99 (M+H)
+
. 
2-(3-(Trifluoromethoxy)benzoyl)hydrazinecarbothioamide  (27) was prepared according to 
General Procedure 3 starting from 3-(trifluoromethoxy)benzoyl chloride (19, 0.78 g, 3.48 mmol) 
and hydrazinecarbothioamide (950 mg, 10.43 mmol) and obtained as white solid (0.92 g, 3.34 
mmol, 96% yield) 1H NMR (500 MHz, DMSO-d6) δ ppm 7.58 (d, J=8.8 Hz, 1 H), 7.63 (t, J=8.2 
Hz, 1 H), 7.74 (br. s, 1 H), 7.85 (s, 1 H), 7.87 - 7.96 (m, 2 H), 9.38 (br. s, 1 H), 10.56 (br. s., 1 
H); 13C NMR (126 MHz, DMSO-d6) δ ppm 120.03 (q, 
3J(C,F)=257.5 Hz, 1 C), 120.41, 124.21, 
126.92, 130.38, 134.84, 148.09, 164.33, 181.96; MS (ESI): m/z 279.82 (M+H)+. 
2-(3-Methoxybenzoyl)hydrazinecarbothioamide (28) was prepared according to General 
Procedure 3 starting from 3-methoxybenzoyl chloride (21, 0.55 g, 3.20 mmol) and 
hydrazinecarbothioamide (0.87 g, 9.61 mmol). The aqueous phase was filtered to obtain a 
mixture of product [m/z 225.99 (M+H)+] and an unknown side-product. The crude product was 
used in the next step without further purification.  
2-(3-Methylbenzoyl)hydrazinecarbothioamide (29) was prepared according to General 
Procedure 3 starting from 3-methylbenzoyl chloride (20, 0.58 g, 3.79 mmol) and 
hydrazinecarbothioamide (1.04 g, 11.38 mmol) and obtained as a white solid (0.79 g, 3.79 
mmol, 100 % yield). 1H NMR (500 MHz, DMSO-d6) δ ppm 2.36 (s, 3 H), 7.31 - 7.40 (m, 2 H), 
7.58 (br. s, 1 H), 7.68 (d, J=7.3 Hz, 1 H), 7.73 (s, 1 H), 7.85 (br. s, 1 H), 9.31 (br. s, 1 H), 10.31 
(br. s, 1 H); 13C NMR (126 MHz, DMSO-d6) δ ppm 20.90, 124.94, 128.05, 128.39, 132.26, 
132.48, 137.41, 165.97, 182.01; MS (ESI): m/z 209.96 (M+H)+. 
(3-(Tert-butyl)benzoyl)thiosemiamidecarbazide (30) 3-(Tert-butyl)benzoic acid (14, 1.10 g, 
6.17 mmol) was suspended in DCM (20 mL). Oxalyl chloride (1.1 mL, 12.57 mmol) and a 
catalytic amount of DMF were added. The reaction mixture was refluxed for 2 h under a 
nitrogen atmosphere. The reaction mixture was concentrated under reduced pressure to give a 
yellow oil (22). The oil was dissolved in THF (10 mL) and slowly added to a suspension of 
hydrazinecarbothioamide (1.68 g, 18.43 mmol) in THF (30 mL) at 0 °C. The reaction mixture 
was allowed to warm to RT and was stirred for 24 h at ambient temperature. The reaction was 
quenched with water and alkalized using a saturated aqueous solution of NaHCO 3. THF was 
evaporated and a yellow solid precipitated. The suspension was sonicated and filtered. The 
resulting cake was washed with water and dried in a desiccator to afford the expected product 
(1.36 g, 5.41 mmol, 88% yield). 1H NMR (500 MHz, DMSO-d6) δ ppm 1.31 (s, 9 H), 7.39 (t, 
J=7.7 Hz, 1 H), 7.56 - 7.60 (m, 1 H), 7.63 (br. s, 1 H), 7.70 (dt, J=7.6, 1.4 Hz, 1 H), 7.84 (br. s, 1 
H), 7.91 (t, J=1.7 Hz, 1 H), 9.32 (br. s, 1 H), 10.37 (s, 1 H); 13C NMR (126 MHz, DMSO-d6) δ 
ppm 31.02 (3 C), 34.57, 124.62, 125.08, 127.93, 128.60, 132.21, 150.67, 166.13, 182.04; 
MS(ESI): m/z 252.20 (M+H)+  
3-(Trifluoromethyl)benzohydrazide (43) A sealed reaction vial was charged with MeOH (100 
mL) and triethylamine (10.0 ml, 71.9 mmol). 3-(Trifluoromethyl)benzoyl chloride (7.25 ml, 47.9 
mmol) was added dropwise. The reaction was stirred overnight at RT. The solvent was 
evaporated and the crude product was diluted with water. The aqueous phase was extracted 
with ethyl acetate (3 times). The combined organic layers were concentrated to give a yellow oil. 
The resulting oil was filled into sealed reaction vessel. Water (40 mL) and hydrazine hydrate 
(5.0 mL, 126 mmol) were added. The reaction mixture consisting of two phases was heated for 
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5 h at 120 °C. The reaction was quenched by the addition of water. The resulting suspension 
was filtered to yield the expected product as colorless crystals (7.45 g, 36.5 mmol, 76% yield). 
1H NMR (500 MHz, DMSO-d6) δ ppm 4.65 (br. s., 2 H), 7.70 (t, J=7.88 Hz, 1 H), 7.88 (d, J=7.88 
Hz, 1 H), 8.13 (d, J=7.88 Hz, 1 H), 8.15 (s, 1 H), 10.05 (br. s,1 H); 13C NMR (126 MHz, DMSO-
d6) δ ppm 123.93 (d, 
1J(C,F)=272.18 Hz, 1 C), 123.56 (q, 3J(C,F)=3.67 Hz, 1 C), 127.60 (q, 
3J(C,F)=3.67 Hz, 1 C), 129.15 (q, J=32.1 Hz, 1 C), 129.6, 130.94, 134.16, 164.20; MS (ESI): 
m/z 205.06 (M+H) +. 
Methyl-2-(3-(trifluoromethyl)benzoyl)hydrazinecarboxylate (44) 3-(Trifluoromethyl) 
benzohydrazide (43, 1.00 g, 4.90 mmol) was suspended in water and dioxane (15 mL each). 
NaHCO3 (1.21 g, 14.4 mmol) was added. Methyl chloroformate (0.45 mL, 5.82 mmol) was 
added dropwise at 0 °C (ice bath). The reaction mixture was stirred at bath temperature for 1 h. 
It was then extracted twice with ethyl acetate and the combined organic fractions were washed 
with brine. The organic phase was dried over MgSO4 and concentrated. Heptane was added 
and the solution concentrated to dryness to yield the expected product as a white solid (1.20 g, 
4.58 mmol, 93% yield). 1H NMR (500 MHz, DMSO-d6) δ ppm 3.65 (s, 3 H), 7.77 (t, J=7.7 Hz, 1 
H), 7.97 (d, J=7.9 Hz, 1 H), 8.17 (d, J=8.2 Hz, 1 H), 8.19 (s, 1 H), 9.34 (br. s., 1 H), 10.58 (br. s, 
1 H); 13C NMR (126 MHz, DMSO-d6) δ ppm 52.04, 123.83 (d, 
1J(C,F)=271.3 Hz, 1 C), 123.91, 
128.50, 129.31 (q, 2J(C,F)=33.0 Hz, 1 C), 129.94, 131.46, 133.19, 156.75, 164.66; MS (ESI): 
m/z 262.06 (M+H)+. 
N'-(2,2,2-trifluoroacetyl)-3-(trifluoromethyl)benzohydrazide (45) 3-(Trifluoromethyl)- 
benzohydrazide (43, 1.00 g, 4.90 mmol) and triethylamine (1.20 mL, 8.61 mmol) were dissolved 
in DCM (25 mL). Trifluoroacetic anhydride (0.80 mL, 5.66 mmol) was added slowly at 0 °C. The 
mixture was stirred at RT over night. After 22 h an additional amount of trifluoroacetic anhydride 
(0.10 mL, 0.708 mmol) was added. The reaction mixture was stirred for 2 h at RT. The mixture 
was poured into a saturated aqueous solution of NaHCO3. The aqueous phase was extracted 
twice using DCM. The combined organic layers were washed with brine, dried over MgSO 4 and 
concentrated to afford a yellow oil. The oil was adsorbed on silica gel and purified by flash 
chromatography on silica gel using DCM:THF (95:5) to yield the product as a pale yellow solid 
(0.650 g, 2.16 mmol, 44% yield). 
1
H NMR (500 MHz, DMSO-d6) δ ppm 7.81 (t, J=7.6 Hz, 1 H), 
8.02 (dd, J=7.9, 0.6 Hz, 1 H), 8.20 (d, J=8.2 Hz, 1 H), 8.21 (s, 1 H), 11.10 (s, 1 H), 11.76 (br. s, 
1 H); 13C NMR (126 MHz, DMSO-d6) δ ppm 115.79 (d, 
1J(C,F)=289.6 Hz, 1 C), 123.78 (d, 
1J(C,F)=271.3 Hz, 1 C), 123.98 (d, 3J(C,F)=4.6 Hz, 1 C), 128.94, 129.44 (q, 2J(C,F)=31.2 Hz, 1 
C), 130.16, 131.61, 132.44, 155.83 (q, 2J(C,F)=37.6 Hz, 1 C), 163.84. MS (ESI): m/z (not 
detected) 
Ethyl-5-(3-(trifluoromethyl)phenyl)-1,3,4-oxadiazole-2-carboxylate (46) 3-(Trifluoro 
methyl)benzohydrazide (43, 1.30 g, 6.37 mmol) was dissolved in DCM (50 mL) and 
triethylamine (4.00 mL, 28.7 mmol) was added. Ethyl oxalyl monochloride (1.20 g, 8.79 mmol) 
was added slowly at 0 °C. The mixture was stirred under nitrogen for 1.5 h at bath temperature. 
Tosyl chloride (1.82 g, 9.55 mmol) was added and the reaction was aged at RT for 12 h. The 
mixture was diluted with DCM, washed with NaHCO3 (twice) and brine. The organic layer was 
dried over MgSO4, filtered and concentrated under reduced pressure to yield a brown oil. The oil 
was adsorbed on silica gel and purified by flash chromatography with hexane/acetone (95:5) to 
obtain a colorless oil, which crystallized in the fridge (1.07 g, 3.74 mmol, 59% yield). 1H NMR 
(500 MHz, CHLOROFORM-d) δ ppm 1.51 (t, J=6.9 Hz, 3 H), 4.59 (q, J=7.3 Hz, 2 H), 7.72 (t, 
J=7.9 Hz, 3 H), 7.88 (dd, J=7.9, 0.6 Hz, 6 H), 8.38 (d, J=7.9 Hz, 1 H), 8.45 (s, 1 H); 13C NMR 
(126 MHz, CHLOROFORM-d) δ ppm 14.08, 63.76, 123.32 (q, 1J(C,F)=273.1 Hz, 1 C), 123.66, 
124.52 (q, 3J(C,F)=3.7 Hz, 1 C), 129.32 (q, 3J(C,F)=3.7 Hz, 1 C), 130.00, 130.69, 132.06 (q, 
2J(C,F)=33.9 Hz, 1 C), 154.19, 156.79, 165.19; HRMS: m/z calcd 287.0638 found 287.0649. 
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6) High Resolution Mass Spectroscopy  
All measurements were performed on a Dionex Ultimate 3000 RSLC system using a Waters 
BEH C18, 50 x 2.1 mm, 1.7 µm dp column. Separation of 1 µL sample was achieved by a linear 
gradient with (A) H2O + 0.1% FA to (B) ACN + 0.1% FA at a flow rate of 600 µL/min and 45 °C. 
The gradient was initiated by a 1 min isocratic step at 5% B, followed by an increase to 95% B 
in 6 min to end up with a 1.5 min step at 95% B before reequilibration with initial conditions . UV 
spectra were recorded by a DAD in the range from 200 to 600 nm. The LC flow was split to 75 
µL/min before entering the maXis 4G hr-ToF mass spectrometer (Bruker Daltonics) using the 
standard ESI source. Mass spectra were acquired in centroid mode ranging from 50 – 1000 m/z 
at 2 Hz scan speed. 
 
7) Purity of Final Compounds (LC/MS Determination) 
Purity control was carried out using a SpectraSystems LC system (Thermo Fisher Scientific) 
consisting of a pump, an autosampler, and a VWD detector. Mass spectrometry was performed 
on an MSQ electro spray mass spectrometer (Thermo Fisher Scientific). The system was 
operated by the standard software Xcalibur. An RP-C18 NUCLEODUR 100-5 (125x3 mm) 
column (Macherey-Nagel GmbH) was used as stationary phase. All solvents were HPLC grade. 
For purity determination one of the following methods was used:  
1) Mobil phase, A = water + 0.1% trifluoroacetic acid, B = acetonitrile + 0.1% trifluoroacetic 
acid; gradient, 0.0-15.0 min, 0-100% B, 15.0-20.0 min, 100% B; flow rate 0.8 mL/min; 
injection volume was 10 µL 
2) Mobil phase, A = water, B = acetonitrile; gradient, 0.0-15.0 min, 0-100% B, 15.0-20.0 
min, 100% B; flow rate 0.8 mL/min; injection volume was 10 µL 
Low-resolution mass analysis was carried out at a spray voltage of 3800 V, a capillary 
temperature of 350 °C, and a source CID of 10 V. Spectra were acquired in positive mode from 
100 to 1000 m/z at 254 nm for the UV trace. 
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Cmpd tR (min) Method UV purity  
(%) 
MS (ESI) m/z 
5 7.09 1 98 252.88 (M+H+CH3CN)
+
 
9 7.60 1 98 236.99 (M+H+CH3CN)
+ 
31 8.12 1 96 252.82 (M+H+CH3CN)
+ 
32 7.75 1 95 236.81 (M+H+CH3CN)
+
 
33 6.47 1 98 252.89 (M+H+CH3CN)
+
 
34 6.72 1 97 236.97 (M+H+CH3CN)
+
 
35 5.97 1 99 203.09 (M+H+CH3CN)
+
  
36 8.47 1 98 239.84 (M+H)
+
 
37 8.61 1 99 270.88 (M+H+CH3CN)
+
 
38 6.27 1 99 227.94 (M+H+CH3CN)
+
 
39 8.80 1 97 286.87 (M+H+CH3CN)
+
  
40 6.96 1 99 192.02 (M+H)
+
 
41 7.18 1 95 176.06 (M+H)
+
 
42 9.75 1 96 259.09 (M+H+CH3CN)
+
 
47 10.03 1 97 255.91 (M+H+CH3CN)
+
 
48 10.49 1 99 270.00 (M+H+CH3CN)
+
 
49 10.87 1 99 - 
50 13.06 1 98 - 
51 9.28 1 96 243.89 (M+H)
+
 
52 7.94 1 98 - 
53 9.74 2 99 - 
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7.2 Supplementary Material of Chapter B  
1) Ligand Interaction Studies 
  
Figure S1: 2D schematic representation of compounds 11 (A) and 20 (B) in complex with 
PqsRc91. Protein-ligand interactions after energy minimization using the “Quickprep” application 
included in the MOE software package were indicated as described in the legend.  
 
a) 
b) 
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Figure S2: Modeled binding pose of compound 17.Binding pose of 17 (before energy 
minimization with LigX rose fat line and after grey fat line) was modeled based on the crystal 
structure of PqsRc91 in complex with 11 (thin white line). 
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2) Isothermal Titration Calorimetry  
a) Site-directed Mutagenesis PqsRT265A mutant: The plasmid 
pSUMO3_ck4_T265ApqsRC87 was generated as previously described1 using QuikChange Site-
Directed Mutagenesis Kit (Stratagene) following the manufacturer’s instructions. The following 
primer were used: forward 5' CGAACCGGGCGGCATCGACGCGAAGGTGTATTGC 3‘ and 
reverse 5' GCAATACACCTTCGCGTCGATGCCGCCCGGTTCG 3’. PCR condition to amplify 
the T265A gene: 16 cycles with 35s denaturation at 95 °C, 60 s annealing at 55 °C, and 13 min 
extension. The generated plasmid was transformed via electroporation into E. coli BL21  
b) Expression and Purification of H6SUMOPqsR
c87 H6SUMOPqsR
c87 and T265A mutant 
H6SUMOPqsR
c87 for ITC studies was expressed and purified as previously reported.1,2 Briefly, 
E. coli BL21 (λDE3) transfected with the pSUMO3_ck4_pqsRC87 or 
pSUMO3_ck4_T265ApqsRC87 plasmid2 were grown in LB medium containing 50 µg mL-1 
kanamycin at 37 °C to an OD600 of approximately 0.8 and expression was induced with 0.2 mM 
IPTG for 16 h at 16 °C. The protein was purified using nickel affinity chromatography in a one 
step gradient. 
 
c) Titration Procedure. ITC titrations were performed as described before.1,2 Briefly, ITC 
experiments were carried out using an ITC200 instrument (Microcal Inc., GE Healthcare). The 
titrations were performed on 50-150 µM H6SUMO-PqsR
C87 in the 200 µL sample cell using 19 
injections of 2 µL ligand solution (0.5-1.5 mM) every 180 s. The data were collected and the 
area under each peak was integrated. To correct for heats of dilution and mixing the final base 
line consisting of small peaks of the same size at the end of the titration were substracted. 
Ligand efficiency (LE) was calculated according to formula 1 and enthalpic efficiency (EE) was 
calculated according to formula 2: 
LE = –ΔG/(heavy atom count) (1) 
EE = - ΔH/(heavy atom count) (2) 
ΔG is the change in free energy, ΔH is the enthalpic contribution and heavy atom count is the 
number of non-hydrogen atoms of the compound. 
d) Thermodynamic profiles of 11 binding to PqsRwt and PqsRT265A 
  
Figure S3: Comparison of the thermodynamic profiles of 11 binding to PqsRwt (left part) and 
PqsRT265A (right part). T-test of ∆H values (PqsRwt/PqsRT265A) showed no significant difference 
(P >0.05). T-test of -T∆S elucidated a significant difference (P <0.05).  
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e) Representative ITC titration curves 
 
Figure S4: Representative ITC titrations against H6SUMO-PqsR
C87 (50 µM) a) 7 (500 µM) b) 11 
(500 µM) c) (500 µM) c) 20 (500 µM). The upper row shows the heat change recorded over 
time in µcal/sec for 19-injections of the ligand. The lower row shows the integrated heats (■) 
plotted against the molar ratio of the binding reaction. Data were fitted to a 1:1 binding model 
continuous black line. The continuous line represents the results of the non-linear least squares 
fitting of the 
f) Thermodynamic profiles of selected compounds 
 
Table S1: Thermodynamic evaluation of selected antagonists 
Comp KD (ITC) 
[µM] 
ΔG 
[kcal mol
-1
] 
ΔH 
[kcal mol
-1
] 
-TΔS 
[kcal mol
-1
] 
EE
a
 
[kcal mol
-1
] 
LE
b
 
[kcal mol
-1
] 
9 7.5±0.1 -6.9±0.0 -3.7±0.6 -3.8±0.6 0.23 0.43 
11 0.6±0.2 -8.4±0.2 -9.8±0.8 1.0±0.8 0.49 0.42 
12 1.4±0.5 -8.1±0.3 -11.3±0.3 3.2±0.5 0.57 0.43 
13 1.3±0.3 -8.0±0.1 -11.6±0.9 3.5±0.8 0.55 0.40 
19 4.7±2.3 -7.4±0.3 -13.5±0.6 6.1±0.7 0.64 0.35 
20 2.8±0.5 -7.6±0.1 -11.4±0.9 3.8±1.0 0.50 0.35 
22 1.0±0.0 -8.2±0.2 -12.9±0.1 4.7±0.1 0.56 0.36 
 ITC titrations were performed at 298 K. Data represent mean ± SD from at least two 
independent experiments; aEE = -ΔH/(heavy atom count); bLE = –ΔG/(heavy atom count)  
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3) Protein Crystallography 
 
a) Expression and Purification of PqsR91-319.The ligand binding domain of PqsR 
comprising the residues 91-319 (PqsR91-319) was expressed and purified as reported by Xu et 
al.4 with some modifications. The plasmid pOPIN-His6-SUMO-PqsR91-319 was transformed into 
E.coli BL21-CodonPlus(DE3)-RIL cells and the protein expression was induced with 0.5 mM 
IPTG for 16 h at 20°C, when the culture reached an OD600 of 2.5. After centrifugation, the cells 
were resuspended in buffer A (150 mM Na2HPO4/NaH2PO4, 300 mM NaCl, pH 8.0) 
supplemented with one EDTA-free protease inhibitor cocktail tablet (Roche Life Science). The 
cells were lysed with an Emulsiflex-C3 homogenizer (Avestin) in two cycles and the supernatant 
was applied onto a HisTrap HP column (GE Healthcare). His6-SUMO-PqsR91-319 was eluted 
with a linear gradient of buffer B (150 mM Na2HPO4/NaH2PO4, 300 mM NaCl, 50-200 mM 
imidazole pH 8.0). After cleavage of the His6-SUMO tag by SUMO protease and a second 
nickel affinity chromatography, PqsR91-319 was finally purified by size exclusion chromatography 
in 20 mM HEPES, 150 mM NaCl, 1 mM DTT, pH 8.0. The protein was concentrated to 33 
mg/ml, flash-frozen in liquid nitrogen and stored at -80°C 
 
Table S2: Crystallization conditions of PqsR91-319 in complex with HHQ/11/20 
 
Protein - 
ligand 
complex 
[Protein] 
(mM) 
[Ligand] 
(mM) 
Crystallization condition Cryoprotectant 
PqsR91-319 - 
HHQ 
0.58 5 
0.1 M Tris-HCl (pH 8.5), 50% (v/v) ethylene 
glycol, 0.2 M MgCl2, 0.1 M CsCl 
- 
PqsR91-319 - 
11 
0.78 4 
0.1 M MES (pH 5.7), 0.1 M NaH2PO4,  
0.1 M K2HPO4, 2.4 M NaCl 
20% (v/v) 
glycerol 
PqsR91-319 - 
20 
0.39 2 
0.085 M tri-sodium citrate (pH 5.6), 29.8% (v/v) 
2-methyl-2-propanol, 15% (v/v) glycerol 
- 
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4) E. coli reporter-gene assay: dose-response curves 
 
Figure S3: Antagonistic activity of different compounds measured in the E. coli reporter gene 
assay. Representative dose-response curves of a) compound 7 b) compound 11 and c) 
compound 20. PqsR activity refers to the stimulation of PqsR induced by 50 nM PQS (= 1). 
Black dotes (•) represent the PqsR activity measured in the presence of a single compound 
concentration. The continuous black line is the none-linear regression analysis to determine IC50 
values using a log (inhibitor) vs. response model (Graph Pad Prism 5.04). 
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5) Effects on Pyocyanin in P. aeruginosa 
  
Figure S4: Inhibition of virulence factor pyocyanin was evaluated in the clinical isolate PA14. 
Representative dose-response curves a) compound 11 b) compound 20. Black dotes (•) 
represent the reduction of pyocyanin in presents of a given compound concentration relative to 
DMSO control (= 0 %). The continuous black line is the none-linear regression analysis to 
determine IC50 values using a log (inhibitor) vs. response model with constrains (bottom = 0; top 
=100) (Graph Pad Prism 5.04). 
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6) Synthesis and Characterization of Intermediates 
a) Synthesis of intermediates 4a-4g 
 
 
Ethyl-4-hydroxy-2-oxo-6-(trifluoromethyl)-1,2-dihydropyridine-3-carboxylate (4a)4 (E)-ethyl 
3-amino-4,4,4-trifluorobut-2-enoate (20.1 ml, 137 mmol) and pyridine (13.5 ml, 166 mmol) were 
dissolved in dry DCM (200 ml). Ethyl-3-chloro-3-oxopropanoate (25.0 g, 166 mmol) was added 
slowly via syringe while cooling on a water bath. The reaction was stirred at ambient 
temperature for 4 days. The reaction mixture was diluted with DCM and quenched by addition of 
water. The aqueous layer was acidified by 2 M HCl. The organic layer was washed with 
NaHCO3 saturated solution. Both aqueous layers were re-extracted with DCM. The combined 
organics were washed with brine, dried over MgSO4, filtered and concentrated to yield a brown 
oil (41 g). Crude product was used in the next step. 
The crude (28.2 g, 100 mmol) was dissolved in ethanol (100 ml). Potassium t-butoxide (22.35 g, 
199 mmol) was added portionwise while keeping the temperature below 40°C. Afterwards the 
mixture was heated to 70°C for 2 h and stirred over night at RT. The reaction mixture was 
concentrated to give a brown solid. Saturated aqueous citric acid solution was added and the 
suspension stirred for 20 min. The suspension was filtered and the cake washed intensively 
with water. The resulting solid was dried at vacuum and 50°C to yield ethyl 4-hydroxy-2-oxo-6-
(trifluoromethyl)-1,2-dihydropyridine-3-carboxylate as a white solid (12.6 g, 53.1 mmol, 53% 
yield). 1H NMR (500 MHz, DMSO-d6)  ppm 1.25 (t, J=7.1 Hz, 3 H), 4.25 (q, J=6.9 Hz, 2 H), 
6.80 (s, 1 H), 12.07 (br. s., 2 H); 13C NMR (126 MHz, DMSO-d6)  ppm 13.94, 60.94, 101.97 (q, 
J=2.7 Hz, 1 C), 105.88, 120.83 (q, J=274.9 Hz, 1 C), 162.25, 164.53, 164.56 ( 1C missing).  
 
4-hydroxy-6-(trifluoromethyl)pyridin-2(1H)-one (4c)4 Ethyl-4-hydroxy-2-oxo-6-(trifluoro 
methyl) -1,2-dihydropyridine-3-carboxylate (24.9 g, 102.5 mmol) was added portionwise to a 
stirred solution of 6 M HCl (250 ml) at RT. The suspension was refluxed for 16 h. After cooling 
cooled to RT, the pH of the reaction mixture was adjusted to 4-6 using 10% aqueous ammonia 
solution. The suspension was filtered. The resulting cake was slurried in water and filtered 
again. The solid was dried at high vacuum to give 4-hydroxy-6-(trifluoromethyl)pyridin-2(1H)-
one (16.97 g, 92.5 mmol, 90 % yield) as white solid. 1H NMR (500 MHz, DMSO-d6)  ppm 6.02 
(s, 1 H), 6.59 (s, 1 H); 13C NMR (126 MHz, DMSO-d6)  ppm 97.88, 103.17, 121.55 (q, J=274.9 
Hz, 1 C), 144.23 (q, J=33.0 Hz, 1 C), 165.88, 169.20. 
 
6-(trifluoromethyl)pyridine-2,4-diyl-bis(trifluoromethanesulfonate (4d)5 4-hydroxy-6-
(trifluoromethyl)pyridin-2(1H)-one (15.00 g, 84 mmol) was suspended in Acetonitrile (300 ml). 
Pyridine (14.9 ml, 184 mmol) was added while cooling the mixture on an ice bath. Triflic 
anhydride (31.1 ml, 184 mmol) was added while keeping the temperature below 10°C. An 
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additional amount of triflic anhydride (10 ml, 59.2 mmol) was added and the reaction stirred over 
night. The mixture was poured into saturated Na2CO3 solution and extracted with EA. Combined 
organic extracts were washed with brine, dried (MgSO4), filtered and concentrated. The crude 
was purified by coloumn chromatography using PE:EA 95:5 to give 6-(trifluoromethyl)pyridine-
2,4-diyl bis(trifluoromethanesulfonate) (12 g, 27.1 mmol, 32.3 % yield) a pale yellow solid 1H 
NMR (500 MHz, CHLOROFORM-d)  ppm 7.37 (d, J=1.9 Hz, 1 H), 7.70 (d, J=1.9 Hz, 1 H); 13C 
NMR (126 MHz, CHLOROFORM-d)  ppm 111.46, 114.25 (d, J=2.7 Hz, 1 C), 118.53 (q, 
J=320.8 Hz, 1 C), 118.55 (q, J=320.8 Hz, 1 C), 119.44 (q, J=275.8 Hz, 1 C), 149.70 (q, J=38.5 
Hz, 1 C), 156.58, 159.31; MS (APCI-): m/z 460 (M+OH)-. 
 
 2,4-diiodo-6-(trifluoromethyl)pyridine (4d)
5
 6-(trifluoromethyl)pyridine-2,4-diylbis(trifluoro 
methanesulfonate) (5.00 g, 11.28 mmol) was dissolved in dry acetonitrile (70 ml). KI (11.24 g, 
67.7 mmol) was added. Triflic acid (1.50 ml, 16.9 mmol) was added slowly keeping the 
temperature below 30°C and the reaction was stirred at RT for 24 h under a nitrogen 
atmosphere. The mixture was quenched by addition of water and NaS2SO3 10% (m/V) solution 
was added dropwise untill the brown color changed to light yellow. ACN was evaporated under 
reduced pressure and the resulting suspension filtered. The cake was washed intensively with 
water and dried at high vacuum to give 2,4-diiodo-6-(trifluoromethyl)pyridine (3.6 g, 9.03 mmol, 
80 % yield) as pale yellow solid 1H NMR (500 MHz, CHLOROFORM-d)  ppm 7.98 (s, 1 H), 
8.34 (s, 1 H); 13C NMR (126 MHz, CHLOROFORM-d)  ppm 106.43, 118.49 (q, J=273.1 Hz, 1 
C), 117.69, 129.06 (d, J=2.7 Hz, 1 C), 145.83, 149.13 (q, J=35.7 Hz, 1 C); MS (ESI+): m/z 400 
(M+H)+. 
 
4-iodo-6-(trifluoromethyl)pyridin-2-amine (4e). A crimp vial was charged with 2,4-diiodo-6-
(trifluoromethyl)pyridine (1.00 g, 2.51 mmol) and DMSO (10 ml). The solution was purged with 
argon and stirred under an argon atmosphere. 1,10-phenanthroline (0.059 g, 0.251 mmol) and 
copper(I)oxide (0.018 g, 0.125 mmol) were dissolved in 1 ml DMSO (catalyst solution); this 
mixture was stirred 5 min at RT under an argon atmosphere. The catalyst solution was 
transferred to the reaction mixture while cooling on an ice-bath. NH3(aq) (0.35 ml, 2.69 mmol) 
was slowly added and the reaction stirred at RT for 5 h. An additional amount of NH3(aq) (0.35 
ml, 2.69 mmol) was added. DMSO was evaporated under high vacuum at 40°C. The crude was 
quenched by addition of water and extracted with EA (3 times). The combined organics were 
washed with NH4Cl saturated solution and brine, dried over MgSO4, filtered and concentrated. 
The crude product was purified by chromatography on silica gel (PE:EA 8:2) to give 4-iodo-6-
(trifluoromethyl)pyridin-2-amine (390 mg, 1.35 mmol, 54% yield) as pale yellow solid. 1H NMR 
(500 MHz, CHLOROFORM-d)  ppm 4.93 (br. s., 2 H), 7.07 (d, J=0.6 Hz, 1 H), 7.32 (d, J=0.9 
Hz, 1 H); 13C NMR (126 MHz, CHLOROFORM-d)  ppm 105.25, 119.54 (q, J=274.0 Hz, 1 C), 
118.11 (q, J=3.7 Hz, 1 C), 119.40, 145.79 (q, J=33.9 Hz, 1 C), 157.60; MS (ESI+): m/z 289 
(M+H)+.  
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tert-butyl-4-iodo-6-(trifluoromethyl)pyridin-2-yl)-carbamate (4f) 4-iodo-6-(trifluoromethyl) 
pyridin-2-amine (200 mg, 0.7 mmol), di-tert-butyl dicarbonate (167 mg, 0.76 mmol), 
triethylamine (0.10 ml, 0.76 mmol) and DMAP (5 mg, 0.04 mmol) were dissolved in t-butanol (2 
ml). The mixture was stirred at 35°C over night. The mixture was quenched with brine and 
extracted with EA (3 times). The combined organic extracts were washed with brine, dried 
(MgSO4), filtered and concentrated. The crude was purified by automated flash 
chromatography (Hex:EA 98:2 to 97:3) to give (4-iodo-6-(trifluoromethyl)pyridin-2-yl)carbamic 
acid (110 mg, 0,331 mmol, 48 % yield) as a white solid. 1H NMR (300 MHz, CHLOROFORM-d) 
 ppm 1.53 (s, 9 H), 7.32 (br. s., 1 H), 7.67 (d, J=1.1 Hz, 1 H), 8.62 (s, 1 H); 13C NMR (75 MHz, 
CHLOROFORM-d)  ppm 28.14 (3 c), 82.15, 107.41, 120.24 (d, J=273.4 Hz, 1 C), 123.99, 
146.53 (d, J=33.5 Hz, 1 C), 151.70, 152.09; MS (ESI+) m/z 389 (M+H)+, 333 (M+H-tButyl)+. 
 
2-(2,5-dimethyl-1H-pyrrol-1-yl)-4-iodo-6-(trifluoromethyl)pyridine (4g)6 4-iodo-6-(trifluoro 
methyl)pyridin-2-amine (0.50 g, 1.74 mmol) and hexane-2,5-dione (0.24 g, 2.08 mmol) were 
dissolved in toluol (40 ml). The reaction mixture was heated at reflux using a dean starck trap. 
The reaction mixture was quenched with Na2CO3 saturated solution and the aqueous phase 
was extracted with EA (3 times). The combined organics were washed with brine, dried and 
concentrated to give a brown oil. The crude product was purified by column chromatography 
using hexane:EA 90:10 to yield the 2-(2,5-dimethyl-1H-pyrrol-1-yl)- 4-iodo-6-
(trifluoromethyl)pyridine (0.55 g, 1.50 mmol, 87 % yield) as brown solid. 1H NMR (300 MHz, 
CHLOROFORM-d)  ppm 2.20 (s, 6 H), 5.93 (s, 2 H), 7.79 (s, 1 H), 7.99 (d, J=1.1 Hz, 1 H); MS 
(ESI+) m/z not found.  
 
b) Synthesis of protected precursors 15a and 16a 
 
2-(2,5-dimethyl-1H-pyrrol-1-yl)-4-((4-fluorobenzyl)oxy)-6-(trifluoromethyl)pyridine (15a) (4-
fluorophenyl)methanol (517 mg, 4.10 mmol) was slowly added to a suspension of sodium 
hydride (197 mg, 4.92 mmol) in dry DMF (5 ml). The reaction mixture was heated at 70°C for 10 
min and 2-(2,5-dimethyl-1H-pyrrol-1-yl)- 4-iodo-6-(trifluoromethyl)pyridine (300 mg, 0.82 mmol) 
dissolved in dry DMF (1 ml) was added. The mixture was stirred at 50°C over night. The 
reaction mixture was poured into water and EA was added. After stirring for 10 min at RT, the 
aqueous layer was extracted with EA. The combined organic extracts were washed with NH4Cl 
(2 times) and brine (2 times), dried (MgSO4) and concentrated. The crude was purified by 
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column chromatography (Step gradient 99:1 PE:EA to 95:5 PE:EA) to give 2-(2,5-dimethyl-1H-
pyrrol-1-yl)-4-((4-fluorobenzyl)oxy)- 6-(trifluoromethyl)- pyridine (80 mg, 0.220 mmol, 26.8 % 
yield) as yellow oil. 1H NMR (300 MHz, CHLOROFORM-d)  ppm 2.15 (s, 6 H), 5.17 (s, 2 H), 
5.91 (s, 2 H), 6.87 (d, J=2.0 Hz, 1 H), 7.14 (m, 2 H), 7.27 (s, 1 H), 7.35-7.51 (m, 2 H); 13C NMR 
(75 MHz, CHLOROFORM-d)  ppm 13.32 (2c), 70.20, 106.92, 107.88, 109.79, 115.99 (d, 
J=21.6 Hz, 2 C), 121.01 (d, J=274.9 Hz, 1 C), 128.72, 129.50 (d, J=8.2 Hz, 2 C), 130.37 (d, 
J=3.7 Hz, 1 C), 148.88 (q, J=34.3 Hz, 1 C), 153.81, 162.94 (d, J=250.3 Hz, 1 C), 166.86; MS 
(ESI+) m/z 365 (M+H)+. 
 
 
tert-butyl (4-(4-fluorobenzamido)-6-(trifluoromethyl)pyridin-2-yl)carbamate (16a) A crimp 
reaction vial was charged with tert-butyl-4-iodo-6-(trifluoromethyl)pyridin-2-yl)-carbamate (75 
mg, 0.19 mmol), 4-fluorobenzamide (81 mg, 0.580 mmol) and Cs2CO3 (189 mg, 0.58 mmol). 
Dioxane (6 ml) was added and the solution purged with argon. A solution of Pd2(dba)3 (9 mg, 
0.01 mmol) and xantphos (11 mg, 0.02 mmol) was slowly added and the mixture stirred at 50°C 
for 1 h. An additional amount of Pd2(dba)3 (9 mg, 0.01 mmol) and xantphos (11 mg, 0,02 mmol) 
were and the temperature was increased to 80°C and stirred at this temperature for 3 h. The 
reaction mixture was quenched by addition of ether and filtred through cellite. The crude product 
was adsorbed to silica gel and purified by automated flash chromatography (Hex:EtOAc 100 to 
80:20) to give tert-butyl (4-(4-fluorobenzamido)-6-(trifluoromethyl)pyridin-2-yl)carbamate (46 mg, 
0,115 mmol, 59,6 % yield) as pale yellow oil. 1H NMR (300 MHz, CHLOROFORM-d)  ppm 1.54 
(s, 9 H), 7.15 - 7.26 (m, 2 H), 7.84 - 8.05 (m, 2 H), 8.20 (s, 1 H), 8.27 (s, 1 H); MS (ESI+) m/z 
400 (M+H)+, 344 (M+H-t-butyl)+. 
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c) Synthesis of intermediates 18a, 20a and 21a 
General Procedure for microwave assisted SNAr reactions 2,4-diiodo-6-
(trifluoromethyl)pyridine (0.9 mmol) was dissolved in dry ACN (2 ml). Hunig'sBase (1.8 mmol) 
and amine (1.0 mmol) were added using a MW vial (CEM®). The mixture was heated for 45 min 
at 120°C in the microwave. The mixture was poured into NH4Cl saturated solution and extracted 
with EA (3 times). Combined organics were washed with brine, dried over Na2SO4, filtered and 
concentrated. Regioisomeres and different sideproducts were separated by automated flash 
chromatography. The 4-substituted regioisomere was identified by 2D NOESY NMR. 
 
N-(4-fluorophenethyl)-2-iodo-6-(trifluoromethyl)pyridin-4-amine was synthesized according 
to the general procedure from 2,4-diiodo-6-(trifluoromethyl)pyridine (500 mg, 1.25 mmol) and 2-
(4-fluorophenyl)ethanamine (192 mg, 1.38 mmol). The crude product was purified by automated 
flash chromatography using a gradient (PE to PE:EA 75:25) to give N-(4-fluorophenethyl)-2-
iodo- 6-(trifluoromethyl)pyridin-4-amine (130 mg, 0.32 mmol, 25% yield) as yellow oil. 
1
H NMR 
(500 MHz, CHLOROFORM-d) d ppm 2.91 (t, J=6.9 Hz, 2 H), 3.44 (td, J=6.8, 5.7 Hz, 2 H), 4.42 
(br. s., 1 H), 6.73 (d, J=1.9 Hz, 1 H), 6.96 (d, J=2.2 Hz, 1 H), 7.01 - 7.07 (m, 2 H), 7.14 - 7.19 
(m, 2 H); MS (ESI+) m/z 411 (M+H)+.  
 
N-(2-(4-fluorophenoxy)ethyl)-2-iodo-6-(trifluoromethyl)pyridin-4-amine was synthesized 
according to the general procedure from (2,4-diiodo-6-(trifluoromethyl)pyridine (350 mg, 0.88 
mmol) and 2-(4-fluorophenoxy)ethanamine (150 mg, 0.96 mmol). The crude product was 
purified by automated flash chromatography using a gradient (PE to PE:EA 55:45) to give N-(2-
(4-fluorophenoxy)ethyl)-2-iodo-6-(trifluoromethyl) pyridin-4-amine (60 mg, 0.14 mmol, 16 % 
yield) as yellow oil. 1H NMR (500 MHz, CHLOROFORM-d)  ppm 3.58 (q, J=5.4 Hz, 2 H), 4.14 
(t, J=5.0 Hz, 2 H), 4.88 (br. s., 1 H), 6.81 - 6.90 (m, 3 H), 6.96 - 7.05 (m, 2 H), 7.07 (d, J=2.2 Hz, 
1 H); MS (ESI+) m/z 427 (M+H)+. 
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N-(3-(4-fluorophenyl)propyl)-2-iodo-6-(trifluoromethyl)pyridin-4-amine was synthesized 
according to Method B from 2,4-diiodo-6-(trifluoromethyl)pyridine (500 mg, 1.25 mmol) and 3-(4-
fluorophenyl)propan-1-amine (211 mg, 1.38 mmol). The crude product was purified by 
automated flash chromatography using a gradient (PE to PE:EA 75:25) to give N-(3-(4-
fluorophenyl)propyl)-2-iodo-6-(trifluoromethyl) pyridin-4-amine (140 mg, 0.33 mmol, 26 % yield) 
as yellow oil. 1H NMR (500 MHz, CHLOROFORM-d)  ppm 1.95 (quin, J=7.4 Hz, 2 H), 2.71 (t, 
J=7.4 Hz, 2 H), 3.17 (td, J=7.1, 5.7 Hz, 2 H), 4.40 (br. s., 1 H), 6.70 (d, J=2.2 Hz, 1 H), 6.91 (d, 
J=2.2 Hz, 1 H), 6.99 - 7.05 (m, 2 H), 7.11 - 7.17 (m, 2 H); MS (ESI+) m/z 425 (M+H)+. 
 
d) Synthesis of intermediates 22a and 22b 
 
tert-butyl (2-((4-fluorophenyl)amino)-2-oxoethyl)carbamate (22a): BOC Glycine (1.65 g, 
9.45 mmol), EDC HCl (3.45 g, 18 mmol) and DMAP (0.110 g, 0.90 mmol) were filled into a three 
necked flask and suspended in THF (Volume: 20 ml). Et3N (3,76 ml, 27,0 mmol) and 4-
fluoroaniline (1.00 g, 9.00 mmol) were added and the white suspension stirred under a nitrogen 
atmosphere for 8 h at RT. The mixture was poured into 10% citric acid and stirred for 10 min. 
The white precipitate was filtered off and the resulting cake washed 2 times with water. The 
white solid was dried at high vacuum over night. 1H NMR (300 MHz, CHLOROFORM-d)  ppm 
1.49 (s, 9 H), 3.92 (d, J=6.1 Hz, 2 H), 5.19 (br. s., 1 H), 6.92 - 7.11 (m, 2 H), 7.35 - 7.55 (m, 2 
H), 8.12 (br. s., 1 H); MS (ESI-) m/z 267 (M-H)-. 
 
2-amino-N-(4-fluorophenyl)acetamide (22b): tert-butyl(2-((4-fluorophenyl)amino)-2-oxo- ethyl) 
carbamate (1.60 g, 5.96 mmol) was supended in DCM (20 ml). TFA (2.5 ml, 32.4 mmol) was 
added while cooling on an ice bath. The reaction was stirred at RT for 8 h. The mixture was 
poured into a NaHCO3 saturated solution and extracted with EA (5 times). Combined organics 
were washed with brine, dried (MgSO4), filtered and concentrated. The product was dried at 
high vacuum to give 2-amino-N-(4-fluorophenyl)acetamide (0.6 g, 3.57 mmol, 59.8 % yield) as 
yellow material. 1H NMR (500 MHz, DMSO-d6)  ppm 3.31 (s, 2 H), 7.08 - 7.19 (m, 2 H), 7.59 - 
7.70 (m, 2 H); 13C NMR (126 MHz, DMSO-d6)  ppm 44.78, 115.07 (d, J=22.9 Hz, 2 C), 120.59 
(d, J=7.3 Hz, 2 C), 135.01 (d, J=2.8 Hz, 1 C), 157.76 (d, J=238.3 Hz, 1 C), 171.06; MS (ESI+) 
m/z 169 (M+H)+. 
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7) High Resolution Mass Spectroscopy  
 
All measurements were performed on a Dionex Ultimate 3000 RSLC system using a Waters 
BEH C18, 50 x 2.1 mm, 1.7 µm dp column. Separation of 1 µL sample was achieved by a linear 
gradient with (A) H2O + 0.1% FA to (B) ACN + 0.1% FA at a flow rate of 600 µL/min and 45 °C. 
The gradient was initiated by a 1 min isocratic step at 5% B, followed by an increase to 95% B 
in 6 min to end up with a 1.5 min step at 95% B before reequilibration with initial conditions. UV 
spectra were recorded by a DAD in the range from 200 to 600 nm. The LC flow was split to 75 
µL/min before entering the maXis 4G hr-ToF mass spectrometer (Bruker Daltonics) using the 
standard ESI source. Mass spectra were acquired in centroid mode ranging from 50 – 1000 m/z 
at 2 Hz scan speed. 
8) Purity of Final Compounds (LC/MS Determination) 
Purity control was carried out on two different systems:  
SpectraSystems LC system (Thermo Fisher Scientific) consisting of a pump, an autosampler, 
and a VWD detector. Mass spectrometry was performed on an MSQ electro spray mass 
spectrometer (Thermo Fisher Scientific). The system was operated by the standard software 
Xcalibur. An RP-C18 NUCLEODUR 100-5 (125x3 mm) column (Macherey-Nagel GmbH) was 
used as stationary phase. All solvents were HPLC grade. For purity determination the following 
methods was used: 
Mobil phase, A = water + 0.1% trifluoroacetic acid, B = acetonitrile + 0.1% trifluoroacetic acid; 
gradient, 0.0-15.0 min, 0-100% B, 15.0-20.0 min, 100% B; flow rate 0.8 mL/min. 
LCMS-System (Waters) consisting of a 767 sample Manager, a 2545 binary gradient pump, a 
2998 PDA detector and a 3100 electron spray mass spectrometer equipped with a C-18 column 
(Nucleodur 100-5 C18 ec 150 x 4.6 mm). For purity determination the following methods was 
used: 
Mobil phase, A = water + 0.1% formic acid, B = acetonitrile + 0.1% formic acid; gradient, 0.0-
13.0 min, 0-100% B; flow rate 1 mL/min 
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7.3 Supplementary Material of Chapter C 
1) E. coli reporter-gene assay: dose-response curves 
 
 
Figure S1: Antagonistic activity of different compounds measured in the E. coli reporter gene 
assay. Representative dose-response curves of a) compound 7 b) compound 12. PqsR activity 
refers to the stimulation of PqsR induced by 50 nM PQS (= 1). Black dotes (•) represent the 
PqsR activity measured in the presence of a single compound concentration. The continuous 
black line is the none-linear regression analysis to determine IC50 values using a log (inhibitor) 
vs. response model (Graph Pad Prism 5.04). 
2) Effects on pyocyanin in P. aeruginosa 
 
 
Figure S2: Inhibition of virulence factor pyocyanin was evaluated in the clinical isolate PA14. 
Representative dose-response curves a) compound 7 b) compound 12. Black dotes (•) 
represent the reduction of pyocyanin in presents of a given compound concentration relative to 
DMSO control (= 0 %). The continuous black line is the none-linear regression analysis to 
determine IC50 values using a log (inhibitor) vs. response model with constrains (bottom = 0; top 
=100) (Graph Pad Prism 5.04). 
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3) UPLC-MS/MS quantification of extracellular 2-AA 
The quantification of 2-AA was performed following a modified protocol of Kesarwani et. al.1 The 
analysis was performed on an Accela-HPLC system (Thermo Scientific) coupled with a triple 
quadrupole mass spectrometer TQS Quantum Access Max (Thermo Scientific) using 5,6,7,8-
tetradeutero-2-heptyl-4(1H)-quinolone (d4-HHQ) as internal standard. An NUCLEODUR C18 
Pyramid column (2x125 mm, 3 µm; Macherey-Nagel) was used as stationary phase along with 
a mobile phase consisting of water + 0.1% formic acid (A) and methanol + 0.1% formic acid (B) 
at a flow rate of 0.7 ml/min. The following chromatographic conditions were applied: 0.0-0.5 
isocratic 10% B, 0.5-2.0 linear gradient up to 100 % B, 2.0-3.0 isocratic 100% B, ending 3.0-4.5 
initial conditions. The compounds were ionized using electrospray ionization in positive ion 
mode with the following parameters: spray voltage: 3500 V; vaporizer temperature: 370 °C; 
sheath gas pressure (nitrogen): 35 units; auxiliary gas pressure (nitrogen): 30 units; skimmer 
offset voltage: 0 V; capillary temperature: 270 °C. Selected reaction monitoring was used for 
detecting 2-AA (136.016→91.048 [quantitative], collision energy: 24 V, tube lens: 68 V; 
136.016→117,998 [qualitative], collision energy: 13 V, tube lens: 68 V) and d4-HHQ 
(248.081→162.965 [quantitative], collision energy: 32 V, tube lens: 100 V; 248.081→175.982 
[qualitative], collision energy: 34 V, tube lens: 100 V) employing: scan width: 0.002 m/z; scan 
time: 0.100 s; peak width: 0.70. 
4) Cytotoxicity assay  
HEK 293 cells (2x105 cells per well) were seeded in 24-well, flat-bottomed plates. Culturing of 
cells, incubations and OD measurements were performed as described previously with small 
modifications.2 24 h after seeding the cells the incubation was started by the addition of 
compounds in a final DMSO concentration of 1 % (v/v). The living cell mass was determined 
after 24, 48 and 72 h followed by the calculation of LD50 values. 
Table S1: Cytotoxicity of selected compoundsa 
Number Cyctotoxicity 
HEK293
a 
 
LD50 [µM] 
7 30 
8 >50
b
 
10 > 25
b
 
12 > 50
b
 
aviability of HEK293 cells was quantified in the presence of test compound after 72h using MTT. 
b
no effect on cell viability at solubility maximum. 
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5) LectinB expression in P. aeruginosa 
 
Figure S3: Expression of LecB in P. aeruginosa PAO1. Coomassie-stained 15% SDS-PAGE of 
total cell (TC) fractions of P. aeruginosa cultures grown for 24 h in absence or presence of 
compound 10 or 12 (5 µM or 25 µM). 
6) LLE Calculation (Ligand Lipophilicity Efficiency) 
The ligand lipophilicity efficiency was calculated according to equation 1
3
 
             
           
   
  (1) 
with pIC50 antagonistic activity measured in E.coli, calculated logD (ACD/Percepta 2015) and 
NHA (number of heavy atoms). This equation based on the ones suggested by Mortenson and 
Murray4 and Shultz5.  
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7) Synthesis of Intermediates 
 
 
N-(4-chlorophenyl)-2-mercaptoacetamide (2a) was synthesized according from to general 
procedure A6 from 4-chloroaniline (2.77 g, 21.71 mmol) and 2-mercaptoacetic acid (2.00 g, 21.7 
mmol) and afford the expected product as pale yellow solid (2.99 g, 14.8 mmol, 68 % yield). 
1
H 
NMR (300 MHz, CHLOROFORM-d)  ppm 2.04 (t, J=9.2 Hz, 1 H), 3.41 (d, J=9.3 Hz, 2 H), 7.28 
- 7.37 (m, 2 H), 7.40 - 7.60 (m, 2 H), 8.53 (br. s., 1 H); MS (ESI+) m/z 202 (M+H)+. 
 
 
2-mercapto-N-(4-phenoxyphenyl)acetamide (3a) was synthesized from 4-phenoxyaniline 
(1.00 g, 5.40 mmol) and 2-mercaptoacetic acid (0,547 g, 5,94 mmol) to give the expected 
product as grey solid (1.1 g, 4.24 mmol, 79 % yield). 1H NMR (300 MHz, CHLOROFORM-d)  
ppm 1.96 - 2.13 (m, 1 H), 3.42 (d, J=9.1 Hz, 2 H), 6.97 - 7.05 (m, 4 H), 7.06 - 7.15 (m, 1 H), 7.29 
- 7.40 (m, 2 H), 7.44 - 7.59 (m, 2 H), 8.51 (br. s., 1 H); MS (ESI+) m/z 260 (M+H)+, 282 (M+Na)+. 
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7.4 Supplementary Material of Chapter D 
Dissecting the multiple roles of PqsE in Pseudomonas aeruginosa 
virulence by discovery of small tool compounds 
1) Coupled PqsDE assay 
 
Figure S1. Simulation of the coupled reaction of PqsD and PqsE (A) Schematic representation 
of the enzymatic reaction with the known kinetic parameters (B) The total amount of 2-ABA-CoA 
released by PqsD over time under the given conditions (dashed line). Taking into account the 
intrinsic decomposition of 2-ABA-CoA (rate of at least 0.93 min-1 (Drees and Fetzner, 2015)), the 
concentration accessible for hydrolysis by PqsE is significantly lower (solid line). Models shown 
in B and C incorporate the PqsE reaction into the model shown in A. Calculations are based on 
the assumption that PqsD and PqsE reactions can be described by Michaelis -Menten kinetics 
and both enzymes possess similar apparent KM or vmax values. Blue lines are calculated DHQ, 
red lines are 2-ABA concentrations. C Given PqsD and PqsE possess similar KM values, the 
simulation provides product concentrations as a function of vmax(PqsE) (left: semi-logarithmic, 
right: linear plot; calculations conducted assuming a turnover number of 0.5 s -1 for PqsD and a 
KM of 35 µM for PqsD and PqsE). This model can be used to estimate the effect caused by an 
inhibitor that would act non-competitively on PqsE. D provides a model for competitive 
inhibition, in which KM (PqsE) is affected as function of inhibitor concentration (left: semi-
logarithmic, right: linear plot; calculations conducted assuming a turnover number of 0.5 s -1 for 
both PqsD and PqsE and a KM of 35 µM for PqsD). The model suggests that in the coupled 
reaction, competitive inhibitors are more potent than non-competitive inhibitors.  
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2) Thioesterase Assay 
 
Figure S2. Dose-response curve for hit compounds 1-3. Black squares (■) represent the 
residual enzyme activity (v/v0) in the presence of a given compound concentration. The 
continuous red line represents the non-linear regression analysis (logistic fit) used for IC50 
determination. (a) compound 1 (b) compound 2 (c) compound 3. SD of at least two independent 
experiments with n=3. 
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3) Effects on alkylquinolones in P. aeruginosa 
 
Figure S3. Effects of compounds 1-3 on DHQ levels in PAO1pqsE referenced for DMSO control 
(=100%). SD of at least two independent experiments with n=3.  
 
 
Figure S4. Effects of compounds 1-3 on the level of signalling molecule HHQ in PAO1 
referenced for the DMSO control (=100%). SD of at least two independent experiments 
with n=3. 
  
Supplementary Material 179 
 
 
4) Differential Scanning Fluorimetry 
 
Table S1. DSF derived screening hits 
Category Lib. Name Structure ∆TM1 
[°K] 
∆TM2 
[°K] 
Mean 
[°K] 
 
C
a
rb
o
x
y
li
c
 A
c
id
s
 
 
CC41801 (1) 
 
8.57 8.66 8.62 
CC34301 
(2)  
4.82 3.83 4.33 
AC30341 
(3)  
2.10 2.26 2.18 
AC16433 
 
2.01 1.28 1.65 
CC00901 
 
1.75 0.88 1.32 
 
D
iv
e
rs
e
 
BTB09194 
 
1.96 1.07 1.52 
AC34875 
(4)  
1.94 0.88 1.41 
AC13022 
(5)  
1.37 0.88 1.13 
SB01744 
 
ambiguous 1.07 - 
BTB01373 
 
ambiguous 1.88 - 
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5) Protein Crystallography 
Table S2. Data Collection and Refinement Statistics  
Sample PqsE – 2-ABA PqsE – comp 1 PqsE – comp 2 PqsE – comp 3 
Data collection# 
Beamline+ X06DA, SLS X06DA, SLS BL 14.1, BESSY II X06DA, SLS 
Wavelength (Å) 1.0000 0.9790 0.9184 1.0000 
Resolution range (Å) 
48.66-1.90  
(1.94-1.90) 
49.96-1.99  
(2.04-1.99) 
42.76-2.10  
(2.16-2.10) 
48.76-1.77  
(1.81-1.77) 
Space group P3221 P3221 P3221 P3221 
Cell dimensions 
a, b, c (Å) 
α, β, γ (°) 
 
61.1, 61.1, 146.0 
90.0, 90.0, 120.0 
   
61.3, 61.3, 147.0 60.9, 60.9, 146.2 61.1, 61.1, 146.3 
90.0, 90.0, 120.0 90.0, 90.0, 120.0 90.0, 90.0, 120.0 
Mosaicity (°)§ 0.15 0.18 0.14 0.06 
Total No. of 
measured reflections 
unique reflections 
 
496248 (30421) 
25730 (1596) 
   
439051 (32755) 212632 (17142) 308334 (16459) 
22719 (1674) 19077 (1514) 31806 (1807) 
Mean I/σ(I) 18.8 (2.0) 20.8 (2.0) 10.3 (2.0) 26.4 (2.0) 
Multiplicity 19.3 (19.1) 19.3 (19.6) 11.1 (11.3) 9.7 (9.1) 
Completeness (%) 100.0 (100.0) 100.0 (100.0) 100.0 (100.0) 100.0 (100.0) 
Rmerge (%)
† 12.0 (185.3) 11.0 (169.0) 19.5 (137.6) 5.0 (114.0) 
Rp.i.m. (%)
‡ 2.8 (43.5) 2.6 (39.1) 6.1 (43.0) 1.7 (39.9) 
CC1/2
¥ 99.8 (68.8) 100.0 (69.2) 99.6 (42.5) 100.0 (67.8) 
Solvent content (%) 46.8 47.5 46.4 46.9 
Wilson B-factor  (Å2) 29.6 34.3 29.2 28.6 
Refinement 
Rwork (%) 16.4 (24.2) 16.2 (23.2) 19.3 (28.2) 16.2 (31.9) 
Rfree (%) 19.8 (30.1) 20.6 (26.5) 23.6 (30.4) 20.0 (34.2) 
No. of non H-atoms     
Protein 2606 2585 2580 2325 
Ligand/Ion 15 17 16 11 
Water 195 185 158 145 
R.m.s. deviations     
Bonds (Å) 0.018 0.018 0.011 0.018 
Angles (°) 0.88 1.15 0.46 1.097 
Average B factors (Å2)     
Protein 37 42 37 36 
Ligand/Ion 38 32 31 32 
Water 41 47 40 37 
Ramachandran plot (%)     
Favored regions 97.1 96.7 97.1 97.0 
Outliers 0.0 0.0 0.3 0.3 
MolProbity score¶ 1.16 1.43 1.14 1.34 
PDB code 5HIO 5HIP 5HIQ 5HIS 
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Footnotes of Table S2: 
Values in parentheses refer to the highest resolution shell. The chemical structures of compounds 1-3 are 
depicted in Figure 2B.  
# Data set for each structure was collected from a single crystal.  
+SLS: Swiss Light Source (Paul Scherrer Institute, Villigen, Switzerland). BESSY II: Berlin Electron 
Storage Ring Company for Synchrotron Radiation (Helmholtz-Zentrum Berlin, Berlin, Germany).  
§ Values as reported by AIMLESS.(Evans and Murshudov, 2013)  
† Rmerge= Σhkl Σi |Ii(hkl) - <I(hkl)>| / Σhkl Σi Ii(hkl), where Ii(hkl) is the intensity of the ith measurement of the 
reflection hkl and <I(hkl)> is the mean intensity of multiple observations of the reflection hkl.  
‡ Rp.i.m.= Σhkl [1 / (N - 1)]
1/2
 Σi |Ii(hkl) - <I(hkl)>| / Σhkl Σi Ii(hkl), where N is the multiplicity.(Weiss and 
Hilgenfeld, 1997; Weiss, 2001) 
¥ CC1/2: Correlation coefficient between the intensities of two random half data sets. (Karplus and 
Diederichs, 2012)  
¶ MolProbity score: Quality criterion that includes the clashscore, the Ramachandran and rotamer 
statistics for the respective structure reported by MolProbity.(Chen et al., 2010) 
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6) Expression and Purification of PqsE 
For Crystallization Studies. The DNA sequence encoding PqsE was amplified by PCR from 
genomic Pseudomonas aeruginosa PAO1 DNA and cloned into pET19m, which is a modified 
version of the pET19-b vector (Novagen) and produces the target protein with an N-terminal 
His6 tag followed by a recognition sequence for TEV protease (MGHHHHHHAENLYFQ↑GH; 
arrow indicates the TEV protease cleavage site). E. coli Rosetta 2(DE3) was transformed with 
the plasmid pET19m-pqsE and the cells were grown in Terrific Broth medium supplemented with 
100 µg/ml ampicillin and 33 µg/ml chloramphenicol at 37°C. At OD600 of 1.4 the expression of 
recombinant PqsE was induced with 1 mM IPTG for 3 h at 37°C. The cells were harvested by 
centrifugation at 6.800 g for 10 min at 10°C, resuspended in buffer A (50 mM Tris -HCl, 300 mM 
NaCl, pH 8.0) supplemented with 2 mM MgCl2, 10 nM DNase I (Roche Life Science) and one 
protease inhibitor cocktail tablet (Roche Life Science) followed by cell disruption with an 
Emulsiflex-C3 homogenizer (Avestin) with two cycles. After removal of cellular debris by 
centrifugation the target protein was purified by Ni-NTA affinity chromatography with buffer B (50 
mM Tris-HCl, 300 mM NaCl, 100 mM imidazole, pH 8.0) and the N-terminal His6-tag was 
cleaved off with His6-tagged TEV protease (1 mg protease per 25 mg His6-TEV-PqsE) at 4°C for 
16 h. During tag removal the buffer was exchanged to buffer C (20 mM Tris-HCl, 150 mM NaCl, 
pH 8.0) by dialysis. Untagged PqsE was separated from uncleaved PqsE and TEV protease by 
a second Ni-NTA affinity chromatography with buffer D (20 mM Tris-HCl, 150 mM NaCl, 50-200 
mM imidazole). As a final purification step PqsE was loaded on a Superdex 75 26/60 size 
exclusion chromatography column (GE Healthcare) and eluted with buffer C. Afterwards, the 
protein was concentrated to ~34 mg/ml and stored at 4 °C for up to 6 months, as protein that 
was flash-frozen in liquid nitrogen and stored at - 80 °C only yielded poorly diffracting crystals. 
 
For DSF Screening / ITC Experiments /Biological Assays. PqsE was expressed as reported 
by Yu et al. (Yu et al., 2009) with slight modifications. Escherichia coli Rosetta(DE3)pLysS 
containing the plasmid pET28a-pqsE were grown in TB medium supplemented with 50 µg/mL 
kanamycin and 25 µg/mL chloramphenicol. Protein expression was induced using IPTG (0.6 
mM) at OD600 of 0.8 and the temperature was reduced to 20°C. For use in DSF screening, ITC 
studies and thioesterase assay, PqsE was purified by Ni-NTA affinity chromatography using 
binding buffer (50 mM Tris-HCl, 150 mM NaCl, 20 mM imidazole pH 8.0) and one step elution 
(50 mM Tris-HCl, 150 mM NaCl, 500 mM imidazole pH 8.0). For DSF screening and 
thioesterase assays H6PqsE was buffer exchanged to (50 mM Tris-HCl, 150 mM NaCl, 10 % 
(v/v) glycerol, pH 8.5) and stored at -80°C. For ITC studies H6PqsE was concentrated and buffer 
exchanged to (50 mM Tricine, 2 mM MnCl2) and stored at -80°C. 
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